

=> d bib abs hitstr

L8 ANSWER 1 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1999:487274 CAPLUS
 DN 131:116520
 TI Preparation of phenylalanine derivatives as pharmaceutical agents
 IN Head, John Clifford; Archibald, Sarah Catherine; Warrellow, Graham John;
 Porter, John Robert
 PA Celltech Therapeutics Limited, UK
 SO PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

Not prior art.


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9937618	A1	19990729	WO 1999-GB279	19990127
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9924320	A1	19990809	AU 1999-24320	19990127
PRAI	GB 1998-1674		19980127		
	GB 1998-26669		19981203		
	WO 1999-GB279		19990127		
OS	MARPAT 131:116520				
AB	Phenylalanine derivs. 4-[R1(Alk1)rL1s]C6H2RaRb(Alk2)mCHRR2NR3COHet [R is				
a	carboxylic acid or deriv.; R1 = H, OH, alkoxy or optionally substituted cycloaliph., polycycloaliph., heterocycloaliph., polyheterocycloaliph., arom, or heteroarom. group; Alk1 = optionally substituted aliph. or heteroaliph. chain; L1 is a linker atom or group; r, s = 0, 1; Ra, Rb = -L2(CH2)pL3Rcq, where L2, L3 = a covalent bond or linker atom or group; p = 0, 1; q = 1-3; Rc = H, halo, alkyl, OH, alkoxy, etc.; Alk2 = alkylene;				
m	= 0, 1; R2 = H, Me; R3 = H, alkyl; Het is an optionally substituted heteroarom. group] and their salts, solvates, hydrates and N-oxides were prepd. as pharmaceutical agents. Thus, N-(2-chloronicotinoyl)-N'-(3,5-dichloro-4-picolyl)-L-4-aminophenylalanine was prepd. by coupling				
reaction	of N-(3,5-dichloro-4-picolyl)-L-4-aminophenylalanine Me ester with 2-chloronicotinoyl chloride followed by ester hydrolysis. Title compds. were tested for inhibition of integrin-dependent cell adhesion and generally have IC50 values in the .alpha.4.beta.1 and .alpha.4.beta.7 assays of 1.mu.M and below.				
IT	232618-01-8P				
	RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of phenylalanine derivs. as pharmaceutical agents)				

Searched by John Dantzman 308-4488

RN 232618-01-8 CAPLUS

CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)sulfonyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 2

L8 ANSWER 2 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1999:354479 CAPLUS

DN 130:352551

TI Preparation of substituted pyrrole derivatives as cell adhesion inhibitors

IN Chang, Linda; Hagmann, William K.; MacCoss, Malcolm

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 61 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9926922	A1	19990603	WO 1998-US24635	19981118
	W:				
	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9914634	A1	19990615	AU 1999-14634	19981118
PRAI	US 1997-66366		19971121		
	GB 1998-4400		19980302		
	US 1997-PV66366		19971121		
	WO 1998-US24635		19981118		
OS	MARPAT 130:352551				
GI					

not printed

AB Pyrrole derivs. I [X = CO₂H or esters or amides, PO₃H₂, PH(O)OH, SO₂H, SO₃H or their esters, 5-tetrazolyl; Y = CO, OCO, NHCO or substituted iminocarbonyl, SO₂, PO₂H or esters, COCO; Z = a bond, CH₂ or substituted methylene; R₁ = (un)substituted alkyl, alkenyl, alkynyl, Cy (Cy = cycloalkyl, heterocyclyl, aryl, heteroaryl), Cy-alkyl, -alkenyl, or -alkynyl; R₂ = H, (un)substituted alkyl, Cy, Cy-alkyl; R₃ = H, alkyl, alkenyl, alkynyl, Cy-(Cy)_p (p = 0 or 1), Cy-(Cy)_p-alkyl, -alkenyl, or -alkynyl; R₄ = H, (un)substituted alkyl, alkenyl, alkynyl, Cy, Cy-alkyl; R₅, R₆, R₇ = H, CF₃, NO₂, halo, CN, etc. or R₅ and R₆ or R₆ and R₇ form a ring optionally contg. N, O, or S] were prepd. as antagonists of VLA-4 and/or .alpha.4.beta.7 and as such are useful in the inhibition or prevention of cell adhesion and cell adhesion-mediated pathologies.

Thus,

Searched by John Dantzman

308-4488

N-[N-(3,5-dichlorobenzenesulfonyl)pyrrole-2-carbonyl]-L-phenylalanine was prepd. by coupling of N-(3,5-dichlorobenzenesulfonyl)pyrrole-2-carboxylic acid with L-phenylalanine tert-Bu ester, followed by sapon.


IT 225244-28-0P 225244-29-1P 225244-30-4P
 225244-31-5P 225244-32-6P 225244-33-7P
 225244-34-8P 225244-36-0P 225244-38-2P
 225244-40-6P 225244-42-8P 225244-44-0P
 225244-46-2P 225244-48-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of substituted pyrrole derivs. as cell adhesion inhibitors)

RN 225244-28-0 CAPLUS

CN L-Phenylalanine, N-[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225244-29-1 CAPLUS

CN Benzenebutanoic acid, .alpha.-[[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225244-30-4 CAPLUS

CN L-Norleucine, N-[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 225244-31-5 CAPLUS

CN L-Tyrosine,

N-[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]-
O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 225244-32-6 CAPLUS

CN L-Tyrosine,

N-[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]-
O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225244-33-7 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, .alpha.-[[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]amino]-2'-methoxy-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225244-34-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, .alpha.-[[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]amino]-3'-methoxy-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225244-36-0 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 2'-cyano-.alpha.-[[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]amino]-, (.alpha.S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225244-38-2 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 3'-cyano-.alpha.-[[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]amino]-, (.alpha.S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225244-40-6 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, .alpha.-[[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]amino]-2'-propoxy-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225244-42-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, .alpha.-[[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]amino]-2'-(1H-tetrazol-5-yl)-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225244-44-0 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, .alpha.-[[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]amino]-2'-(methylthio)-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225244-46-2 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, .alpha.-[[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]amino]-2'-(methylsulfonyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 225244-48-4 CAPLUS

CN L-Tyrosine,

N-[[1-[(3,5-dichlorophenyl)sulfonyl]-1H-pyrrol-2-yl]carbonyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



=> d bib abs hitstr 3

L8 ANSWER 3 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1999:354478 CAPLUS
 DN 131:5529
 TI Preparation of substituted .beta.-alanine derivatives as cell adhesion inhibitors
 IN Durette, Philippe L.; Hagmann, William K.; Kopka, Ihor E.; MacCoss, Malcolm; Mills, Sander G.; Mumford, Richard A.; Magriotis, Plato A.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 109 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9926921	A1	19990603	WO 1998-US24898	19981124
	W:		AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	AU 9915327	A1	19990615	AU 1999-15327	19981124
PRAI	US 1997-66484	19971124	←		
	GB 1997-27215	19971223			
	US 1997-PV66484	19971124			
	WO 1998-US24898	19981124			
OS	MARPAT 131:5529				
GI					



AB .beta.-Alanine derivs. I [A, Z = C, C:C, C-C; B = a bond, C, C-C, C:C, N, O, S, S(O), SO₂, N-Y-R₁; X = CO₂H, PO₃H₂, PH(O)OH, SO₂H, SO₃H or their esters or amides, 5-tetrazolyl; Y = CO, OCO, NHCO, SO₂, etc.; R₁ = (un)substituted alkyl, alkenyl, alkynyl, Cy (Cy = cycloalkyl, heterocycloalkyl, aryl, heteroaryl), Cy-alkyl, -alkenyl, or -alkynyl; R₂

= H, (un)substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; R₃ = H, (un)substituted alkyl, Cy, Cy-alkyl; R₄-R₁₀ = H, alkyl, alkenyl, alkynyl, etc.] were prepd. as antagonists of VLA-4 and/or .alpha.4.beta.7 and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. Thus,

Searched by John Dantzman 308-4488

N-[(3,4-dimethoxybenzenesulfonyl)-1,2,3,4-tetrahydroisoquinoline-3(S)-carbonyl]-3(S)-(3,4-methylenedioxyphenyl)-3-aminopropionic acid was
prepd.

by amidation of N-(tert-butoxycarbonyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid with Me (S)-3-amino-3-(3,4-methylenedioxyphenyl)propanoate, deblocking, sulfonylation with 3,4-dimethoxybenzenesulfonyl chloride, and sapon.


IT 217450-90-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted .beta.-alanine derivs. as cell adhesion inhibitors)

RN 217450-90-3 CAPLUS

CN L-Aspartic acid, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




=> d bib abs hitstr 4

L8 ANSWER 4 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1999:350649 CAPLUS
 DN 130:352550
 TI Synthesis of 4-substituted 4-piperidinecarboxamide derivatives as cell adhesion inhibitors
 IN Delaszlo, Stephen E.; Hagmann, William K.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9925685	A1	19990527	WO 1998-US24513	19981116
	W: AL, AM, AU, AZ, BA, BE, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9914150	A1	19990607	AU 1999-14150	19981116
PRAI	US 1997-65917		19971118		
	GB 1997-27214		19971223		
	US 1997-PV65917		19971118		
	WO 1998-US24513		19981116		
OS	MARPAT 130:352550				
GI					

not prior art.



AB 4-Substituted 4-piperidinecarboxamides I [L = CO, OCO, NHCO or substituted iminocarbonyl, SO₂, P(O)OR₄, COCO; X is a bond, CH₂ or substituted methylene; Z = CO₂H, PO₃H₂, PH(O)OH, SOH, SO₂H, SO₃H or their esters, CONH₂ or substituted carboxamido, 5-tetrazolyl; R₁, R₂ = (un)substituted alkyl, alkenyl, alkynyl, Cy (cycloalkyl, heterocycloalkyl, aryl, heteroaryl); Cy-alkyl, Cy-alkenyl, or Cy-alkynyl; R₃ = H, (un)substituted alkyl or Cy; R₄ = H or (un)substituted alkyl, alkenyl, alkynyl, Cy, or Cy-alkyl; R₅ = H, (un)substituted alkyl, alkenyl, alkynyl, Cy-(Cyl)_p (Cyl same definition as Cy, p = 0, 1), Cy-(Cyl)_p-alkyl, -alkenyl, or -alkynyl] were prepd. as antagonists of VLA-4 and/or .alpha.4.beta.7 and as such are

useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. Thus, N-[4-methyl-1-[4-(N'-2-

Searched by John Dantzman 308-4488

methylphenylureido)phenylacetyl]piperidiny-4-carbonyl]-L-4-fluorophenylalanine was prepd. from L-4-fluorophenylalanine tert-Bu ester via 2-step N-acylation in soln.


IT 225239-84-9P 225239-85-0P 225239-86-1P
 225239-87-2P 225239-93-0P 225239-94-1P
 225239-95-2P 225239-96-3P 225239-97-4P
 225239-98-5P 225239-99-6P 225240-00-6P
 225240-01-7P 225240-02-8P 225240-03-9P
 225240-04-0P 225240-05-1P 225240-42-6P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis of piperidinecarboxamide derivs. as cell adhesion inhibitors)

RN 225239-84-9 CAPLUS

CN L-Norleucine, N-[[1-[(3,5-dichlorophenyl)sulfonyl]-4-phenyl-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225239-85-0 CAPLUS


CN L-Phenylalanine, N-[[1-[(3,5-dichlorophenyl)sulfonyl]-4-phenyl-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 225239-86-1 CAPLUS


CN Benzeneacetic acid, .alpha.-[[[1-[(3,5-dichlorophenyl)sulfonyl]-4-phenyl-4-piperidiny]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 225239-87-2 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, .alpha.-[[[1-[(3,5-dichlorophenyl)sulfonyl]-4-phenyl-4-piperidinyloxycarbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225239-93-0 CAPLUS

CN L-Phenylalanine, N-[[[1-(butylsulfonyl)-4-phenyl-4-piperidinyloxycarbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225239-94-1 CAPLUS

CN L-Phenylalanine, N-[[[1-(octylsulfonyl)-4-phenyl-4-piperidinyloxycarbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225239-95-2 CAPLUS

CN L-Phenylalanine, N-[[4-phenyl-1-(phenylsulfonyl)-4-piperidinyl]carbonyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225239-96-3 CAPLUS

CN L-Phenylalanine, N-[[1-[(4-fluorophenyl)sulfonyl]-4-phenyl-4-
piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225239-97-4 CAPLUS

CN L-Phenylalanine, N-[[1-[(4-methoxyphenyl)sulfonyl]-4-phenyl-4-
piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225239-98-5 CAPLUS

CN L-Phenylalanine, N-[[1-[[4-(acetalamino)phenyl]sulfonyl]-4-phenyl-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225239-99-6 CAPLUS

CN L-Phenylalanine, N-[[4-phenyl-1-[[4-(trifluoromethoxy)phenyl]sulfonyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225240-00-6 CAPLUS

CN L-Phenylalanine, N-[[4-phenyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 225240-01-7 CAPLUS

CN L-Phenylalanine,

N-[[1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-4-phenyl-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225240-02-8 CAPLUS

CN L-Phenylalanine, N-[[1-[(3-methylphenyl)sulfonyl]-4-phenyl-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225240-03-9 CAPLUS

CN L-Phenylalanine, N-[[1-[(3-cyanophenyl)sulfonyl]-4-phenyl-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225240-04-0 CAPLUS

CN L-Phenylalanine, N-[[1-[(3-chlorophenyl)sulfonyl]-4-phenyl-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225240-05-1 CAPLUS

CN L-Phenylalanine, N-[[1-[(3-fluorophenyl)sulfonyl]-4-phenyl-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 225240-42-6 CAPLUS


CN [1,1'-Biphenyl]-4-propanoic acid, .alpha.-[[[1-[(3,5-dichlorophenyl)sulfonyl]-4-methyl-4-piperidinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 5

L8 ANSWER 5 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1999:348263 CAPLUS
 DN 131:116490
 TI Metallopeptide approach to the design of biologically active ligands:
 design of specific human neutrophil elastase inhibitors
 AU Shi, Yiqun; Sharma, Shubh
 CS Edison Corporate Center, Palatin Technologies Inc., Edison, NJ, 08837,
 USA
 SO Bioorg. Med. Chem. Lett. (1999), 9(10), 1469-1474
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 GI




AB A series of metallopeptides I (R = C₆H₅, SO₂C₆H₄Me-4; R₁ = H, OH, NH₂; Ad = 1-adamantyl) was designed to inhibit human neutrophil elastase utilizing a modified metallopeptide scheme, developed by the authors and termed metal-ion induced distinctive array of structures (MIDAS). These metallopeptides, synthesized by soln. and solid-phase methods, exhibited excellent structural diversity and specificity in inhibiting human neutrophil elastase.

IT **232259-21-1P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (design and prepn. of metallopeptides as inhibitors of specific human neutrophil elastase)

RN 232259-21-1 CAPLUS
 CN Rhenate(2-), [N-[(4-methylphenyl)sulfonyl]-L-isoleucyl-.kappa.N-N6-(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)-L-lysyl-.kappa.N2-L-cysteinyl-.kappa.N,.kappa.S-L-valinato(5-)]oxo-, monohydrogen, (SP-5-35)- (9CI)

(CA INDEX NAME)




=> d bib abs hitstr 6

L8 ANSWER 6 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1999:282093 CAPLUS
 DN 130:282371
 TI Preparation of azapeptide acids as cell adhesion inhibitors
 IN Delaszlo, Stephen E.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 94 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9920272	A1	19990429	WO 1998-US22008	19981019
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9913614	A1	19990510	AU 1999-13614	19981019
PRAI	US 1997-62874		19971021		
	US 1997-65763		19971117		
	GB 1997-24874		19971126		
	WO 1998-US22008		19981019		
OS	MARPAT 130:282371				
GI					

Not printed



AB Azapeptide acids I [(un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, Cy, Cy-C1-10 alkyl, Cy-C2-10 alkenyl, Cy-C2-10 alkynyl; R2, R3 = independently H, any group R1; R2R3 form (un)substituted, optionally benzo-fused 4-7-membered heterocyclic ring; R5 = H, (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, aryl-C1-10 alkyl, heteroaryl, heteroaryl-C1-10 alkyl; R6 = H, (un)substituted Ar1-Ar2-C1-10 alkyl, Ar1-Ar2-C2-10 alkenyl, Ar1-Ar2-C2-10 alkynyl, Ar1-C.tplbond.C-Ar2-C1-10 alkyl, Ar1-C2 alkenyl-Ar2-C1-10 alkyl, Ar1-Ar2, any group R1; X = CO2R8, P(O)(OR8)(OR9), SOMOR8, CONR9R10, 5-tetrazolyl, CONHSO2R11; R8, R9 =

Searched by John Dantzman 308-4488


independently H, (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, Cy, Cy-C1-10 alkyl; R10 = H, (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, CN, aryl, , aryl-C1-10 alkyl, heteroaryl, heteroaryl-C1-10 alkyl, SO2R11; R11 = (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl; Y = CO, O2C, NR9CO, SO2, P(O)(OR8), COCO;

Cy = cycloalkyl, heterocyclyl, aryl, heteroaryl; m = 0-2; n = 0-2], and pharmaceutically acceptable salts thereof, are antagonists of VLA-4 and/or .alpha.4.beta.7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compds. may be formulated into pharmaceutical compns. and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders. Thus, sequential coupling of 1-(benzyloxycarbonyl)pyrazolidine (prepn. given) with triphosgene and L-leucine tert-Bu ester, followed by hydrogenolysis, sulfonylation with PhSO2Cl, and acidic deesterification, gave desired free azapeptide II.

IT 222853-76-1P 222853-77-2P 222853-78-3P
 222853-79-4P 222853-80-7P 222853-81-8P
 222853-82-9P 222853-83-0P 222853-85-2P
 222853-86-3P 222853-88-5P 222853-98-7P
 222854-02-6P 222854-04-8P 222854-06-0P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of azapeptide acids as cell adhesion inhibitors)


RN 222853-76-1 CAPLUS
 CN L-Leucine, N-[[2-(phenylsulfonyl)-1-pyrazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 222853-77-2 CAPLUS
 CN 2-Naphthalenepropanoic acid, .alpha.-[[[2-[(3,5-dichlorophenyl)sulfonyl]-1-pyrazolidinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 222853-78-3 CAPLUS

CN L-Phenylalanine, N-[[(5R)-2-[(3,5-dichlorophenyl)sulfonyl]-5-methyl-1-pyrazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 222853-79-4 CAPLUS

CN L-Phenylalanine, N-[[(5S)-2-[(3,5-dichlorophenyl)sulfonyl]-5-methyl-1-pyrazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 222853-80-7 CAPLUS

CN L-Phenylalanine, N-[[2-[(3,5-dichlorophenyl)sulfonyl]-3-methyl-1-pyrazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 222853-81-8 CAPLUS

CN L-Phenylalanine, N-[[2-[(3,5-dichlorophenyl)sulfonyl]tetrahydro-1(2H)-pyridazinyl]carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 222853-82-9 CAPLUS

CN L-Phenylalanine, 4-fluoro-N-[[2-[(3-fluorophenyl)sulfonyl]tetrahydro-1(2H)-pyridazinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 222853-83-0 CAPLUS


CN L-Phenylalanine, N-[[2-[(3,5-dichlorophenyl)sulfonyl]-1-

Searched by John Dantzman

308-4488

pyrazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 222853-85-2 CAPLUS


CN L-Norleucine, N-[[2-[(4-fluorophenyl)sulfonyl]-1-pyrazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 222853-86-3 CAPLUS


CN Benzeneacetic acid, .alpha.-[[[2-[(4-fluorophenyl)sulfonyl]-1-pyrazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 222853-88-5 CAPLUS


CN [1,1'-Biphenyl]-4-propanoic acid, .alpha.-[[[2-[(4-fluorophenyl)sulfonyl]-1-pyrazolidinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 222853-98-7 CAPLUS
 CN L-Phenylalanine, N-[[2-[(4-fluorophenyl)sulfonyl]-1-pyrazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 222854-02-6 CAPLUS
 CN L-Phenylalanine, 4-fluoro-N-[[2-[(3-fluorophenyl)sulfonyl]-1-pyrazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 222854-04-8 CAPLUS
 CN [1,1'-Biphenyl]-4-propanoic acid, 2'-cyano-.alpha.-[[[2-[(3-fluorophenyl)sulfonyl]-1-pyrazolidinyl]carbonyl]amino]-, (.alpha.S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 222854-06-0 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, .alpha.-[[[2-[(3,5-dichlorophenyl)sulfonyl]-1-pyrazolidinyl]carbonyl]amino]-2'-methoxy-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



=> d bib abs hitstr 7

L8 ANSWER 7 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1999:222915 CAPLUS
 DN 130:267342
 TI Preparation of phenylsulfonylindolines as immunophilin ligands useful as antiasthmatic, antiallergic, antirheumatic, immunosuppressive, antipsoriatic and neuroprotective agents.
 IN Reichert, Dietmar; Kutscher, Bernhard; Szelenyi, Stefan; Poppe, Hildegard;
 Quinkert, Gerhard; Brune, Kay; Bang, Holger; Deppe, Holger
 PA Asta Medica Aktiengesellschaft, Germany
 SO PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9915501	A1	19990401	WO 1998-EP5300	19980820
	W: AU, BR, CA, HU, IL, JP, KR, MX, NO, NZ, RU				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 19742263	A1	19990401	DE 1997-19742263	19970925
	AU 9893450	A1	19990412	AU 1998-93450	19980820
PRAI	DE 1997-19742263		19970925		
	WO 1998-EP5300		19980820		
OS	MARPAT 130:267342				
GI					



Not prior art

AB Title compds. [I; R1 = H, (substituted) alkyl, alkoxy, amino acid Me ester

residue; R2 = H, (substituted) alkyl, alkoxy; R3 = H, F, OR4, Br, NHR4;

R4

= H, cycloalkyl, (substituted) alkyl, carboxyalkyl; B = CH2; D = CH; BD = CH:C; X = O, S, H2; Z = S, O, NR5; R5 = H, (substituted) alkyl, alkoxy; A = without ring, nonarom., arom., heteroaryl, nonarom. heterocyclic ring], were prepd. Thus,

(2S)-1-[[(2S)-1-(4-aminophenylsulfonyl)pipecolyl]carbon
 yl]-N-(2-methoxyethyl)indolin-2-carboxamide (general prepn given) gave
 40-60% inhibition of peptidyl prolyl isomerase activity.

IT **221900-70-5P**


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenylsulfonylindolines as immunophilin ligands useful as

Searched by John Dantzman 308-4488

drugs)
RN 221900-70-5 CAPLUS
CN L-Leucine, N-[[[(2S)-1-[[4-(acetylamino)phenyl]sulfonyl]-2,3-dihydro-1H-indol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 8

L8 ANSWER 8 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1999:113712 CAPLUS

DN 130:168662

TI Preparation of N-sulfonylproline dipeptide derivatives and analogs as inhibitors of leukocyte adhesion mediated by VLA-4

IN Thorsett, Eugene D.; Semko, Christopher M.; Pleiss, Michael A.; Kreft, Anthony; Konradi, Andrei W.; Grant, Francine S.; Baudy, Reinhardt Bernhard; Sarantakis, Dimitrios

PA Athena Neurosciences, Inc., USA; American Home Products Corporation

SO PCT Int. Appl., 294 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906437	A1	19990211	WO 1998-US16070	19980731
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG.			

AU 9888234 A1 19990222 AU 1998-88234 19980731

PRAI US 1997-904423 19970731

WO 1998-US16070 19980731

OS MARPAT 130:168662

AB Disclosed are title compds. R1SO2NR2CHR3QCHR5COR6 [R1 = (un)substituted alkyl, (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; R2 = H, any group R1; R1R2 may form (un)substituted heterocyclic ring; R3 = H, any group R1; R2R3 may form (un)substituted heterocyclic ring; R5 = CH2X1; X1 = H, OH, acylamino, (un)substituted alkyl, alkoxy, aryloxy, aryl, aryloxyaryl, CO2H, carboxyalkyl, carboxyaryl, carboxyheteroaryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; Q = C(X)NR7; R7 = H, alkyl; X = O, S; R6 = NH2, (un)substituted alkoxy, (un)substituted cycloalkoxy,

succinimidyl,oxo,

adamantylamino, .beta.-cholest-5-en-3-yloxy, NHOY, NH(CH2)pCO2Y,

OCH2NR9R10; Y = H, (un)substituted alkyl, (un)substituted aryl; p = 1-8;

R9 = (un)substituted CO-aryl; R10 = H, CH2CO2R11, NHSO2Z'; R11 = alkyl;

Z'

= (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted

aryl,

(un)substituted heteroaryl, (un)substituted heterocyclyl; and

pharmaceutically acceptable salts thereof, with provisos] which bind

VLA-4

(also referred to as integrin .alpha.4.beta.1 and CD49d/CD29). Certain

of

these compds. also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compds. are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human,

Searched by John Dantzman 308-4488

} Different
Inventive
entity.

← Appears to be provisional of present case.
Prov. 60/104,592

wherein the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compds. can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. Thus, BOP-mediated peptide coupling of Ts-Pro-OH (Ts = tosyl) with H-Tyr-OMe gave 75% of the corresponding ester, which underwent sapon. in quant. yield to give desired dipeptide Ts-Pro-Tyr-OH. All prepd. compds. have IC50 .ltoreq. 15 .mu.M in a VLA-4 binding assay.

IT 220302-20-5P 220302-23-8P 220302-24-9P
 220302-25-0P 220302-26-1P 220302-27-2P
 220302-28-3P 220302-29-4P 220302-30-7P
 220302-31-8P 220302-32-9P 220302-33-0P
 220302-34-1P 220302-35-2P 220302-36-3P
 220302-37-4P 220302-38-5P 220302-39-6P
 220302-40-9P 220302-41-0P 220302-42-1P
 220302-44-3P 220302-45-4P 220302-46-5P
 220302-47-6P 220302-48-7P 220302-49-8P
 220302-50-1P 220302-51-2P 220302-52-3P
 220302-53-4P 220302-54-5P 220302-60-3P
 220302-64-7P 220302-65-8P 220302-68-1P
 220302-70-5P 220302-71-6P 220302-73-8P
 220302-74-9P 220302-75-0P 220302-76-1P
 220302-78-3P 220302-79-4P 220302-81-8P
 220302-83-0P 220302-84-1P 220302-87-4P
 220302-88-5P 220302-95-4P 220302-97-6P
 220303-05-9P 220303-06-0P 220303-08-2P
 220303-09-3P 220303-16-2P 220303-23-1P
 220303-31-1P 220303-32-2P 220303-33-3P
 220303-41-3P 220303-55-9P 220303-58-2P
 220303-61-7P 220303-62-8P 220303-63-9P
 220365-30-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of N-sulfonylproline dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220302-20-5 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(1-phenylethyl)-(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 220302-23-8 CAPLUS

Searched by John Dantzman

308-4488

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-24-9 CAPLUS

CN Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-carboxy- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220302-25-0 CAPLUS

CN Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-carboxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 220302-26-1 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(2-carboxyphenyl)-
(9CI) (CA INDEX NAME)

Searched by John Dantzman

308-4488


Absolute stereochemistry.



RN 220302-27-2 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(phenylmethyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220302-28-3 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-iodo- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 220302-29-4 CAPLUS


CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-methyl- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 220302-30-7 CAPLUS
 CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-nitro- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 220302-31-8 CAPLUS
 CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220302-32-9 CAPLUS
 CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3,5-diiodo- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 220302-33-0 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-(benzoylamino)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-34-1 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-iodo- (9CI) (CA
INDEX
NAME)


Absolute stereochemistry.



RN 220302-35-2 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-chloro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220302-36-3 CAPLUS

CN L-Leucine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-37-4 CAPLUS

CN L-Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-38-5 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-(acetylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-39-6 CAPLUS

CN L-Isoleucine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-40-9 CAPLUS

CN L-Aspartic acid, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-41-0 CAPLUS

CN L-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-42-1 CAPLUS

CN L-Glutamic acid, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-44-3 CAPLUS

CN L-Histidine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-1-(phenylmethyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220302-45-4 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-bis(phenylmethyl)amino- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-46-5 CAPLUS

CN L-Methionine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-47-6 CAPLUS

CN L-Serine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-48-7 CAPLUS

CN L-Histidine, N-[[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-49-8 CAPLUS

CN L-Histidine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-1-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-50-1 CAPLUS

CN D-Histidine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220302-51-2 CAPLUS

CN L-Histidine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman


308-4488



RN 220302-52-3 CAPLUS

CN Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-(2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-53-4 CAPLUS

CN Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-(1,3-benzodioxol-5-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-54-5 CAPLUS

CN L-Valine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-60-3 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(3-methylphenyl)sulfonyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-64-7 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-bis(phenylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-65-8 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-(pentylamino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-68-1 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(4-cyanophenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-70-5 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-(1,1-dimethylethoxy)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-71-6 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(3S)-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-73-8 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(3-methoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-74-9 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[(4,5-dihydro-1H-imidazol-2-yl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-75-0 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(propylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-76-1 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-78-3 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[4-(chloromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-79-4 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(chloromethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-81-8 CAPLUS

CN L-Phenylalanine, 4-(benzoylamino)-N-[[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-83-0 CAPLUS

CN L-Tyrosine, N-[[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-84-1 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-87-4 CAPLUS

CN L-Phenylalanine, N-[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-4-[(3-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220302-88-5 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220302-95-4 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(2-methoxybenzoyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman


308-4488



RN 220302-97-6 CAPLUS

CN L-Phenylalanine, 4-(acetylamino)-N-[[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220303-05-9 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(2-bromobenzoyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220303-06-0 CAPLUS

CN L-Phenylalanine, 1-[(phenylmethyl)sulfonyl]-L-prolyl-4-[(4-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220303-08-2 CAPLUS

CN L-Phenylalanine, 4-[(2-bromobenzoyl)amino]-N-[(3R)-4-[(4-methylphenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl]- (9CI)

(CA
INDEX NAME)


Absolute stereochemistry.



RN 220303-09-3 CAPLUS

CN L-Phenylalanine, N-[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-4-[(4-pyridinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220303-16-2 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[2-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220303-23-1 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-(3,4-dihydro-3-methyl-2-oxo-1(2H)-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220303-31-1 CAPLUS

CN L-Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220303-32-2 CAPLUS

CN L-Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-[5-
[[(dimethylamino)carbonyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220303-33-3 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-
[(dimethylamino)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220303-41-3 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[2-
(dimethylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220303-55-9 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-
[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220303-58-2 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-(dimethylamino)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220303-61-7 CAPLUS

CN D-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-D-prolyl- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 220303-62-8 CAPLUS

CN D-Aspartic acid, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220303-63-9 CAPLUS

CN D-Glutamic acid, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220365-30-0 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[(2,3,3a,7a-tetrahydro-1H-indol-2-yl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220149-81-5

RL: RCT (Reactant)


(prepn. of N-sulfonylproline dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220149-81-5 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-amino- (9CI)
(CA

INDEX NAME)

Absolute stereochemistry.




IT 220176-17-0P 220176-20-5P 220176-95-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of N-sulfonylproline dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220176-17-0 CAPLUS

CN L-Aspartic acid, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-,
24-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-20-5 CAPLUS

CN L-Glutamic acid, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-,
25-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-95-4 CAPLUS

CN D-Glutamic acid, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-,
25-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 9

L8 ANSWER 9 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1999:113711 CAPLUS

DN 130:153985

TI Preparation of N-sulfonylprolylphenylalanine derivatives and analogs as inhibitors of leukocyte adhesion mediated by VLA-4

IN Thorsett, Eugene D.; Semko, Christopher M.; Pleiss, Michael A.; Lombardo, Louis John; Konradi, Andrei W.; Grant, Francine S.; Dressen, Darren B.; Dappen, Michael S.

PA Athena Neurosciences, Inc., USA; American Home Products Corporation

SO PCT Int. Appl., 172 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906436	A1	19990211	WO 1998-US15327	19980731
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9885851	A1	19990222	AU 1998-85851	19980731
PRAI	US 1997-903585	19970731	09/127,601 (P. Sullivan).		
	WO 1998-US15327	19980731			

OS MARPAT 130:153985

AB Disclosed are title compds. R1SO2NR2CHR3QCHR5COR6 [R1 = (un)substituted alkyl, (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; R2NCHR3 form satd. heterocyclic group with the proviso that when monosubstituted, the substituent on the satd. heterocyclic group is not CO2H; R5 = (CH2)n-aryl, (CH2)n-heteroaryl; n = 1-4; Q = C(X)NR7; R7 = H, alkyl; X = O, S; R6 = NH2, (un)substituted alkoxy, (un)substituted cycloalkoxy, succinimidyl, adamantylamino, .beta.-cholest-5-en-3-yloxy,

NHOY, NH(CH2)pCO2Y, OCH2NR9R10; Y = H, (un)substituted alkyl, (un)substituted aryl; p = 1-8; R9 = (un)substituted CO-aryl; R10 = H, CH2CO2R11, NHSO2Z; R11 = alkyl; Z = (un)substituted alkyl,

(un)substituted

cycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted heterocyclyl; and pharmaceutically acceptable salts thereof, with the proviso that when R1 = 2,4,6-Me3C6H2, R2NCHR3 = pyrrolidinyl ring and Q = C(O)NH, then R5 .noteq. benzyl; with the

further

proviso that when R1 = 4-MeC6H4, R2NCHR3 = pyrrolidinyl derived from D-proline, and Q = C(O)NH, then R5 .noteq. benzyl derived from D-phenylalanine] which bind VLA-4 (also referred to as integrin .alpha.4.beta.1 and CD49d/CD29). Certain of these compds. also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compds. are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, wherein the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia,

Searched by John Dantzman 308-4488

diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compds. can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. Thus, BOP-mediated coupling of Boc-L-Pro-OH with L-phenylalanine benzyl ester hydrochloride in the presence of N-methylmorpholine, followed by acidic deprotection, sulfonylation with MeSO₂Cl, and catalytic deprotection to give desired dipeptide MeSO₂-L-Pro-L-Phe-OH.

IT 220187-04-2P 220187-13-3P 220187-54-2P

RL: BAC (Biological activity or effector, except adverse); RCT

(Reactant);


SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonylprolylphenylalanine derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220187-04-2 CAPLUS

CN L-Phenylalanine, 1-[[2-(methoxycarbonyl)phenyl]sulfonyl]-L-prolyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220187-13-3 CAPLUS

CN L-Phenylalanine, 1-[(4-cyanophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220187-54-2 CAPLUS

CN L-Phenylalanine, N-[[[(3R)-4-[(4-methylphenyl)sulfonyl]-3-thiomorpholinyl]carbonyl]- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488

Absolute stereochemistry.



IT 217450-71-0P 220186-85-6P 220186-87-8P
 220186-88-9P 220186-89-0P 220186-90-3P
 220186-91-4P 220186-92-5P 220186-94-7P
 220186-95-8P 220186-96-9P 220186-97-0P
 220186-98-1P 220186-99-2P 220187-00-8P
 220187-01-9P 220187-02-0P 220187-03-1P
 220187-05-3P 220187-06-4P 220187-07-5P
 220187-08-6P 220187-09-7P 220187-10-0P
 220187-11-1P 220187-12-2P 220187-14-4P
 220187-15-5P 220187-16-6P 220187-17-7P
 220187-18-8P 220187-19-9P 220187-20-2P
 220187-21-3P 220187-22-4P 220187-23-5P
 220187-24-6P 220187-32-6P 220187-40-6P
 220187-41-7P 220187-42-8P 220187-44-0P
 220187-46-2P 220187-49-5P 220187-50-8P
 220187-51-9P 220187-55-3P 220187-58-6P
 220187-63-3P 220187-68-8P 220187-69-9P
 220187-70-2P 220187-71-3P 220187-76-8P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonylprolylphenylalanine derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 217450-71-0 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488

RN 220186-85-6 CAPLUS

CN L-Phenylalanine, 1-(methylsulfonyl)-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220186-87-8 CAPLUS

CN L-Phenylalanine, 1-[(phenylmethyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220186-88-9 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220186-89-0 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220186-90-3 CAPLUS

CN L-Phenylalanine, N-[[[(2S)-1-[(4-methylphenyl)sulfonyl]-2-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220186-91-4 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-D-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220186-92-5 CAPLUS

CN L-Phenylalanine, (4R)-4-hydroxy-1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220186-94-7 CAPLUS

CN L-Phenylalanine, N-[[(2S)-1-[(4-methylphenyl)sulfonyl]-2-azetidiny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220186-95-8 CAPLUS

CN Benzenebutanoic acid, .alpha.-[[[(2S)-1-[(4-methylphenyl)sulfonyl]-2-pyrrolidiny]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220186-96-9 CAPLUS

CN L-Phenylalanine, 1-[(4-chlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220186-97-0 CAPLUS

CN L-Phenylalanine, 1-(1-naphthalenylsulfonyl)-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220186-98-1 CAPLUS

CN L-Phenylalanine, 1-(2-naphthalenylsulfonyl)-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220186-99-2 CAPLUS

CN L-Phenylalanine, 1-[(4-methoxyphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220187-00-8 CAPLUS

CN L-Phenylalanine, 1-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-L-prolyl-
(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 220187-01-9 CAPLUS

CN L-Phenylalanine, (4R)-4-fluoro-1-[(4-methylphenyl)sulfonyl]-L-prolyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220187-02-0 CAPLUS

CN L-Phenylalanine, (4S)-4-fluoro-1-[(4-methylphenyl)sulfonyl]-L-prolyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman


308-4488



RN 220187-03-1 CAPLUS

CN L-Phenylalanine, N-[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-05-3 CAPLUS

CN L-Phenylalanine, 1-[(2-carboxyphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220187-06-4 CAPLUS

CN L-Phenylalanine, N-[[(4R)-3-[(4-methylphenyl)sulfonyl]-4-
Searched by John Dantzman 308-4488

thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-07-5 CAPLUS

CN L-Phenylalanine, 1-[[4-(trifluoromethoxy)phenyl]sulfonyl]-L-prolyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220187-08-6 CAPLUS

CN L-Phenylalanine, 1-[(3,4-dichlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 220187-09-7 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-3-phenylprolyl- (9CI) (CA
Searched by John Dantzman 308-4488)

INDEX NAME)


Absolute stereochemistry.



RN 220187-10-0 CAPLUS

CN L-Phenylalanine, 1-[(3,4-dimethoxyphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-11-1 CAPLUS

CN L-Phenylalanine, 1-[(4-nitrophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220187-12-2 CAPLUS

Searched by John Dantzman

308-4488

CN L-Phenylalanine, 1-[[4-(acetamino)phenyl]sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-14-4 CAPLUS

CN L-Tryptophan, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-15-5 CAPLUS

CN L-Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 220187-16-6 CAPLUS

CN L-Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-(2-naphthalenyl)-
(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 220187-17-7 CAPLUS

CN L-Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-(2-thienyl)- (9CI)
(CA

INDEX NAME)


Absolute stereochemistry.



RN 220187-18-8 CAPLUS

CN L-Phenylalanine, 1-[(1-methylethyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 220187-19-9 CAPLUS

CN L-Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-(3-pyridinyl)- (9CI)

Searched by John Dantzman 308-4488

(CA INDEX NAME)

Absolute stereochemistry.




RN 220187-20-2 CAPLUS

CN L-Phenylalanine,

(4S)-1-[(4-methylphenyl)sulfonyl]-4-(phenylthio)-L-prolyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220187-21-3 CAPLUS

CN L-Phenylalanine,

(4S)-1-[(4-methylphenyl)sulfonyl]-4-[(phenylmethyl)thio]-
L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488

RN 220187-22-4 CAPLUS

CN L-Histidine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-23-5 CAPLUS

CN L-Phenylalanine, (4S)-4-amino-1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220187-24-6 CAPLUS

CN L-Phenylalanine, (4R)-4-amino-1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220187-32-6 CAPLUS

CN L-Phenylalanine, (4S)-4-hydroxy-1-[(4-methylphenyl)sulfonyl]-L-prolyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-40-6 CAPLUS

CN L-Phenylalanine, 1-(2-thienylsulfonyl)-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-41-7 CAPLUS

CN L-Phenylalanine, 1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-42-8 CAPLUS

CN L-Phenylalanine, 1-[(2-phenylethyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-44-0 CAPLUS

CN L-Phenylalanine, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-46-2 CAPLUS

CN L-Phenylalanine, 1-[[4-(aminoiminomethyl)phenyl]sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-49-5 CAPLUS

CN Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-(1H-1,2,4-triazol-3-yl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-50-8 CAPLUS

CN Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-(2-thiazolyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220187-51-9 CAPLUS

CN L-Phenylalanine,
1-[[4-[3-(dimethylamino)propoxy]phenyl]sulfonyl]-L-prolyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-55-3 CAPLUS

CN L-Phenylalanine, N-[[(3R)-4-[(4-methylphenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-58-6 CAPLUS

CN L-Phenylalanine, 1-(butylsulfonyl)-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-63-3 CAPLUS

CN L-Phenylalanine, 4-methoxy-1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-68-8 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]thio-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-69-9 CAPLUS

CN D-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220187-70-2 CAPLUS

CN L-Phenylalanine, 3,3-dimethyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman


308-4488



RN 220187-71-3 CAPLUS

CN L-Phenylalanine, N-[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-1,1-dioxido-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220187-76-8 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-5-oxo-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220149-81-5 220187-82-6

RL: RCT (Reactant)

Searched by John Dantzman

308-4488

(prepn. of N-sulfonylprolylphenylalanine derivs. and analogs as
inhibitors of leukocyte adhesion mediated by VLA-4)


RN 220149-81-5 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-amino- (9CI)

(CA

INDEX NAME)

Absolute stereochemistry.




RN 220187-82-6 CAPLUS

CN L-Histidine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-(phenylmethyl)-
(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



=> d bib abs hitstr 11

L8 ANSWER 11 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1999:113709 CAPLUS
 DN 130:153983
 TI Preparation of N-sulfonylated aminophenylalanine dipeptide derivatives and
 analogs as inhibitors of leukocyte adhesion mediated by VLA-4
 IN Ashwell, Susan; Grant, Francine S.; Konradi, Andrei W.; Kreft, Anthony; Lombardo, Louis John; Pleiss, Michael A.; Sarantakis, Dimitrios; Semko, Christopher M.; Thorsett, Eugene D.
 PA Athena Neurosciences, Inc., USA; American Home Products Corporation
 SO PCT Int. Appl., 164 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906434	A1	19990211	WO 1998-US15312	19980730
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9885846	A1	19990222	AU 1998-85846	19980730
PRAI	US 1997-920353	19970731	← Prev. 60/112,019 ← no corresp.		
	WO 1998-US15312	19980730			us case.
OS	MARPAT 130:153983				
GI					



I

AB Disclosed are title compds. R1SO2NR2CHR3QCHR5COR6 [R1 = (un)substituted alkyl, (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; R2 = H, any group R1; R1R2 may form (un)substituted heterocyclic ring; R3 = H, any group R1; R2R3 may form (un)substituted heterocyclic ring; R5 = (CH2)x-Ar-R5'; R5' = NR12C(Z)NR8R8', NR12C(Z)R13; R12 = H, alkyl, aryl; R8, R8' = independently H, any group R1; R8R8' may form heterocyclic ring; R13 = satd. heterocycle; Z = O, S, NR13; x = 1-4;
 Searched by John Dantzman 308-4488

, (CH₂)_n-heteroaryl; n = 1-4; Q = C(X)NR₇; R₇ = H, alkyl; X = O, S; R₆ = NH₂, (un)substituted alkoxy, (un)substituted cycloalkoxy, succinimidyl, adamantylamino, .beta.-cholest-5-en-3-yl, NHOY, NH(CH₂)_pCO₂Y, OCH₂NR₉R₁₀; Y = H, (un)substituted alkyl, (un)substituted aryl; p = 1-8; R₉ = (un)substituted CO-aryl; R₁₀ = H, CH₂CO₂R₁₁, NHSO₂Z; R₁₁ = alkyl; Z = (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted heterocyclyl; and pharmaceutically acceptable salts thereof, with provisos] which bind

VLA-4

(also referred to as integrin .alpha.4.beta.1 and CD49d/CD29). Certain of

these compds. also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compds. are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, wherein the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compds. can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. Thus, condensation of N-tosyl-L-prolyl-4-amino-L-phenylalanine Me ester with 3-phenylpropyl isothiocyanate gave the corresponding urea I.

IT 220149-02-0P

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);


SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonylated aminophenylalanine dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220149-02-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(2S)-2-carboxy-2-[[[(3R)-4-[(4-methylphenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl]amino]ethyl]phenyl]amino]carbonyl]-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220148-90-3P 220148-92-5P 220148-93-6P
 220148-94-7P 220148-96-9P 220148-97-0P
 220148-99-2P 220149-00-8P 220149-03-1P
 220149-04-2P 220149-05-3P 220149-14-4P
 220149-16-6P 220149-18-8P 220149-19-9P
 220149-22-4P 220149-24-6P 220149-27-9P
 220149-30-4P 220149-31-5P 220149-33-7P
 220149-34-8P 220149-35-9P 220149-37-1P
 220149-38-2P 220149-42-8P 220149-43-9P
 220149-44-0P 220149-45-1P 220149-47-3P
 220149-48-4P 220149-50-8P 220149-51-9P
 220149-52-0P 220149-55-3P 220149-64-4P
 220149-65-5P 220149-66-6P 220149-67-7P
 220149-69-9P 220150-60-7P 220150-61-8P
 220202-29-9P 220202-30-2P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonylated aminophenylalanine dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220148-90-3 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[1-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-1H-indol-2-yl]carbonyl]amino]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 220148-92-5 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(4-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220148-93-6 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(3S)-2-[(1,1-dimethylethoxy)carbonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220148-94-7 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[2-(4-morpholinyl)ethyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220148-96-9 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[2-(1-piperidinyl)ethyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220148-97-0 CAPLUS

Searched by John Dantzman

308-4488

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[3-(4-morpholinyl)propyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220148-99-2 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(2S)-1-[(4-methylphenyl)sulfonyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-00-8 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(2-phenylethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-03-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(2S)-2-carboxy-2-[[[(3R)-4-[(4-methylphenyl)sulfonyl]-3-thiomorpholinyl]carbonyl]amino]ethyl]phenyl]amino]carbonyl]-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-04-2 CAPLUS

CN L-Phenylalanine, N-[[[(3R)-4-[(4-methylphenyl)sulfonyl]-3-thiomorpholinyl]carbonyl]-4-[(4-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-05-3 CAPLUS

CN L-Phenylalanine, N-[[(3R)-4-[(4-methylphenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl]-4-[(4-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-14-4 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[1-[(1,1-dimethylethoxy)carbonyl]-3-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-16-6 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-18-8 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-[[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-19-9 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-[(4-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-22-4 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-[[[1-[(1,1-dimethylethoxy)carbonyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-24-6 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(2S)-1-[(1,1-dimethylethoxy)carbonyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-27-9 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(3-phenylpropyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-30-4 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(2S,4R)-1-[(1,1-dimethylethoxy)carbonyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-31-5 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[3-(diethylamino)propyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-33-7 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-[[[1-[(1,1-dimethylethoxy)carbonyl]-2-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-34-8 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-[(2-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220149-35-9 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(4R)-3-[(1,1-dimethylethoxy)carbonyl]-4-thiazolidinyl]carbonyl]amino]- (9CI) (CA

INDEX
NAME)


Absolute stereochemistry.



RN 220149-37-1 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(methylamino)thioxomethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220149-38-2 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(phenylmethyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488


Absolute stereochemistry.



RN 220149-42-8 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[1,4-bis[(1,1-dimethylethoxy)carbonyl]-2-piperazinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-43-9 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(2-piperazinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-44-0 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[1-[(1,1-dimethylethoxy)carbonyl]-2-piperidiny]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-45-1 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(2-piperidiny]carbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-47-3 CAPLUS

CN D-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[1-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-1H-indol-2-yl]carbonyl]amino]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220149-48-4 CAPLUS

CN D-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[1-(phenylmethoxy)carbonyl]-4-piperidiny]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220149-50-8 CAPLUS

CN L-Phenylalanine,

3,3-dimethyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(4-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-51-9 CAPLUS

CN L-Phenylalanine, 3,3-dimethyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(3S)-2-[(1,1-dimethylethoxy)carbonyl]-1,2,3,4-tetrahydro-3-isoquinoliny]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-52-0 CAPLUS

CN L-Phenylalanine, 1-[(4-bromophenyl)sulfonyl]-L-prolyl-4-[(4-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-55-3 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(2S,4R)-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488

RN 220149-64-4 CAPLUS

CN L-Phenylalanine, 1-[(phenylmethyl)sulfonyl]-L-prolyl-4-[(4-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-65-5 CAPLUS

CN L-Phenylalanine, 1-[(phenylmethyl)sulfonyl]-L-prolyl-4-[[[1-[(1,1-dimethylethoxy)carbonyl]-1,2,3,4-tetrahydro-2-quinolinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-66-6 CAPLUS

CN L-Phenylalanine, 1-[(phenylmethyl)sulfonyl]-L-prolyl-4-[[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220149-67-7 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[1-[(1,1-dimethylethoxy)carbonyl]-4-phenyl-4-piperidyl]carbonyl]amino]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220149-69-9 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(2S)-2-pyrrolidinylcarbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220150-60-7 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(3-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220150-61-8 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(2-phenylethyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220202-29-9 CAPLUS


CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(octahydro-1H-indol-2-yl)carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220202-30-2 CAPLUS
 CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[1-[(1,1-dimethylethoxy)carbonyl]octahydro-1H-indol-2-yl]carbonyl]amino]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



IT 220149-81-5
 RL: RCT (Reactant)
 (prepn. of N-sulfonylated aminophenylalanine dipeptide derivs. and
 analogs as inhibitors of leukocyte adhesion mediated by VLA-4)
 RN 220149-81-5 CAPLUS
 CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-amino- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 12

L8 ANSWER 12 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1999:113708 CAPLUS

DN 130:153982

TI Preparation of N-sulfonyl phenylalanine dipeptide derivatives and analogs as inhibitors of leukocyte adhesion mediated by VLA-4

IN Dappen, Michael S.; Dressen, Darren B.; Grant, Francine S.; Pleiss, Michael A.; Robinson, Cynthia Y.; Sarantakis, Dimitrios; Thorsett, Eugene D.

PA Athena Neurosciences, Inc., USA; American Home Products Corporation

SO PCT Int. Appl., 190 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906433	A1	19990211	WO 1998-US15952	19980731
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9886786	A1	19990222	AU 1998-86786	19980731
PRAI	US 1997-904416	19970731	← 60/112,010 ← us non prov. us case		
	WO 1998-US15952	19980731			
OS	MARPAT 130:153982				
AB	Disclosed are title compds. R1SO2NR2CHR3QCHR5COR6 [R1 = (un)substituted alkyl, (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; R2 = H, any group R1; R1R2 may form (un)substituted heterocyclic ring; R3 = H, any group R1; R2R3 may form (un)substituted unsatd. heterocyclic ring; R5 = CH2X1; X1 = H, OH, optionally substituted acylamino, alkyl, aryloxy, aryl, aryloxyaryl, CO2H, carboxyalkyl, carboxyheteroaryl, etc.; Q = C(X)NR7; R7 = H, alkyl; X = O, S; R6 = NH2, (un)substituted alkoxy, (un)substituted cycloalkoxy, succinimidyl, adamantylamino, .beta.-cholest-5-en-3-yloxy, NHOY, NH(CH2)pCO2Y, OCH2NR9R10; Y = H, (un)substituted alkyl, (un)substituted aryl; p = 1-8; R9 = (un)substituted CO-aryl; R10 = H, CH2CO2R11, NHSO2Z; R11 = alkyl; Z				

(un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted heterocyclyl; and pharmaceutically acceptable salts thereof, with provisos] which bind

VLA-4 (also referred to as integrin .alpha.4.beta.1 and CD49d/CD29). Certain of

these compds. also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compds. are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, wherein the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compds. can also be administered for the

Searched by John Dantzman 308-4488

treatment of inflammatory brain diseases such as multiple sclerosis. Thus, reaction of Ts-Gly-OH (Ts = tosyl) with oxalyl chloride in CH₂Cl₂, followed by peptide coupling with L-phenylalanine benzyl ester tosylate and catalytic hydrogenolysis, gave desired title compd. Ts-Gly-Phe-OH. All prepd. compds. have IC₅₀ .1 to req. 15 .mu.M in a VLA-4 binding assay.

IT 220185-84-2P 220185-85-3P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonyl phenylalanine dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220185-84-2 CAPLUS

CN L-Phenylalanine, N-[[(2S)-2,3-dihydro-1-[(4-methylphenyl)sulfonyl]-1H-indol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220185-85-3 CAPLUS

CN L-Phenylalanine, N-[[(3S)-1,2,3,4-tetrahydro-2-[(4-methylphenyl)sulfonyl]-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220176-98-7


RL: RCT (Reactant)

(prepn. of N-sulfonyl phenylalanine dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220176-98-7 CAPLUS

CN Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 13

L8 ANSWER 13 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1999:113707 CAPLUS

DN 130:153981

TI Preparation of N-sulfonyl dipeptide derivatives and analogs as inhibitors of leukocyte adhesion mediated by VLA-4

IN Thorsett, Eugene D.; Semko, Christopher M.; Pleiss, Michael A.; Lombardo, Louis John; Grant, Francine S.; Dressen, Darren B.; Dappen, Michael S.

PA Athena Neurosciences, Inc., USA; American Home Products Corporation

SO PCT Int. Appl., 155 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906432	A1	19990211	WO 1998-US15325	19980731
	W:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	AU 9885850	A1	19990222	AU 1998-85850	19980731
PRAI	US 1997-904417	19970731	← 60/100,429 (no non prov. US case)		
	WO 1998-US15325	19980731			
OS	MARPAT 130:153981				
AB	Disclosed are title compds. R1SO2NR2CHR3QCHR5COR6 [R1 = (un)substituted alkyl, (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; R2 = H, any group R1; R1R2 may form (un)substituted heterocyclic ring; R3 = H, any group R1; R2R3 may form (un)substituted heterocyclic ring; R5 = Alk-X1, :CHY; Alk = alkyl chain of 1-10 carbon atoms; X1 = halo, CN, NO2, optionally substituted sulfonyl, sulfonyloxy, amino, alkyl, aryloxy, aryl, aryloxyaryl, carboxyalkyl, carboxyheteroaryl, etc.; Q = C(X)NR7; R7 = H, alkyl; X = O, S; R6 = NH2, (un)substituted alkoxy, (un)substituted cycloalkoxy, succinimidyloxy, adamantylamino, .beta.-cholest-5-en-3-yloxy, NHOY, NH(CH2)pCO2Y, OCH2NR9R10; Y = H, (un)substituted alkyl, (un)substituted aryl; p = 1-8; R9 = (un)substituted CO-aryl; R10 = H, CH2CO2R11, NHSO2Z; R11 = alkyl; Z = (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted heterocyclyl; and pharmaceutically acceptable salts thereof, with provisos] which bind VLA-4 (also referred to as integrin .alpha.4.beta.1 and CD49d/CD29). Certain of these compds. also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compds. are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, wherein the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compds.				

Searched by John Dantzman 308-4488

can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. Thus, BOP-mediated peptide coupling of Ts-Pro-OH (Ts = tosyl) with H-Asp(OCMe₃)-OMe.HCl, followed by .alpha.-ester sapon., gave desired title compd.

Ts-Pro-Asp(OCMe₃)-OH.

All prepd. compds. have IC₅₀ .1 to req. 15 .mu.M in a VLA-4 binding assay.

IT 220176-17-0P 220176-18-1P 220176-19-2P
 220176-20-5P 220176-21-6P 220176-22-7P
 220176-23-8P 220176-24-9P 220176-28-3P
 220176-31-8P 220176-32-9P 220176-33-0P
 220176-34-1P 220176-38-5P 220176-40-9P
 220176-41-0P 220176-42-1P 220176-43-2P
 220176-44-3P 220176-45-4P 220176-46-5P
 220176-47-6P 220176-48-7P 220176-49-8P
 220176-50-1P 220176-51-2P 220176-52-3P
 220176-72-7P 220176-73-8P 220176-74-9P
 220176-75-0P 220176-76-1P 220176-77-2P
 220176-78-3P 220176-79-4P 220176-80-7P
 220176-81-8P 220176-82-9P 220176-83-0P
 220176-85-2P 220176-86-3P 220176-87-4P
 220176-88-5P 220176-89-6P 220176-90-9P
 220176-91-0P 220176-93-2P 220176-94-3P
 220176-95-4P 220176-96-5P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonyl dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220176-17-0 CAPLUS

CN L-Aspartic acid, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 24-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-18-1 CAPLUS

CN L-Asparagine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-19-2 CAPLUS

CN L-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-[(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-20-5 CAPLUS

CN L-Glutamic acid, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-, 25-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-21-6 CAPLUS

CN L-Glutamine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-22-7 CAPLUS

CN L-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-
[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-23-8 CAPLUS

CN L-Serine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(phenylmethyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220176-24-9 CAPLUS

CN L-Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-cyclohexyl- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 220176-28-3 CAPLUS

CN D-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-[(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-31-8 CAPLUS

CN L-Lysine, N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-32-9 CAPLUS

CN L-Asparagine, N2-[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-33-0 CAPLUS

CN L-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-[(2-propenyloxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-34-1 CAPLUS

CN L-Lysine, 1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-N6-[(2-propenyloxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488

RN 220176-38-5 CAPLUS

Butanoic acid, 2-[[[(2S)-1-[(4-methylphenyl)sulfonyl]-2-pyrrolidinyl]carbonyl]amino]-4-[[(2-propenyloxy)carbonyl]amino]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220176-40-9 CAPLUS

L-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-[N-methyl-N-(4-methylphenyl)sulfonyl]glycyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-41-0 CAPLUS

CN L-Asparagine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-(4-phenylbutyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-42-1 CAPLUS

CN L-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-(1H-indol-3-ylacetyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-43-2 CAPLUS

CN L-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-[3-(1H-indol-3-yl)-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-44-3 CAPLUS

CN L-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-[(4-fluorophenoxy)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220176-45-4 CAPLUS

Searched by John Dantzman

308-4488


CN L-Asparagine,
1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-[(1R)-1-phenylethyl]-,
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220176-46-5 CAPLUS
CN L-Asparagine,
1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-[(1S)-1-phenylethyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220176-47-6 CAPLUS
CN L-Asparagine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-[[4-(dimethylamino)phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-48-7 CAPLUS
Searched by John Dantzman 308-4488

CN L-Asparagine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-49-8 CAPLUS

CN L-Glutamine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-50-1 CAPLUS

CN L-Glutamine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-51-2 CAPLUS

CN L-Glutamine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-butyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-52-3 CAPLUS

CN L-Glutamine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488


RN 220176-72-7 CAPLUS
CN L-Asparagine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-[4-(acetylamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220176-73-8 CAPLUS
CN L-Asparagine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-4-pyridinyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 220176-74-9 CAPLUS
CN L-Asparagine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-75-0 CAPLUS
CN L-Asparagine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-(3-methoxyphenyl)-
Searched by John Dantzman 308-4488

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-76-1 CAPLUS

CN L-Glutamine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-77-2 CAPLUS

CN L-Glutamine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-2-pyridinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220176-78-3 CAPLUS

CN L-Glutamine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-79-4 CAPLUS

CN L-Glutamine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-3-pyridinyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220176-80-7 CAPLUS

CN L-Ornithine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N5-[imino[(4-methylphenyl)sulfonyl]amino]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-81-8 CAPLUS

CN L-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-[(ethylamino)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220176-82-9 CAPLUS

CN L-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-[(ethylamino)carbonyl]- (9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-83-0 CAPLUS

CN L-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-[[4-methoxyphenyl]amino]carbonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-85-2 CAPLUS

CN L-Asparagine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-86-3 CAPLUS

CN L-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-[N-[(1,1-dimethylethoxy)carbonyl]glycyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-87-4 CAPLUS

CN L-Lysine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-[[1-(phenylmethoxy)carbonyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-88-5 CAPLUS

CN L-Lysine, N2,N6-bis[1-[(4-methylphenyl)sulfonyl]-L-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220176-89-6 CAPLUS

CN L-Lysine,

1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-(4-piperidinylcarbonyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220176-90-9 CAPLUS

CN Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-

[[[(phenylmethoxy)carbonyl]amino]-L-alanine]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220176-91-0 CAPLUS

Searched by John Dantzman 308-4488

CN L-Asparagine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-N,N-dimethyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220176-93-2 CAPLUS

CN L-Asparagine, 1-[(4-methylphenyl)sulfonyl]-5-oxo-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220176-94-3 CAPLUS

CN L-Lysine,
1-[(4-methylphenyl)sulfonyl]-L-prolyl-N6-[(5-methoxy-1H-indol-3-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220176-95-4 CAPLUS

CN D-Glutamic acid, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-,
25-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488


Absolute stereochemistry.



RN 220176-96-5 CAPLUS

CN D-Aspartic acid, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-,
24-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220176-98-7


RL: RCT (Reactant)

(prepn. of N-sulfonyl dipeptide derivs. and analogs as inhibitors of
leukocyte adhesion mediated by VLA-4)

RN 220176-98-7 CAPLUS

CN Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-amino- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 14

L8 ANSWER 14 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1999:113706 CAPLUS

DN 130:168661

TI Preparation of N-sulfonyl phenylalanine dipeptide derivatives and analogs as inhibitors of leukocyte adhesion mediated by VLA-4

IN Thorsett, Eugene D.; Semko, Christopher M.; Sarantakis, Dimitrios; Pleiss,

Michael A.; Lombardo, Louis John; Kreft, Anthony; Konradi, Andrei W.; Grant, Francine S.; Dressen, Darren B.; Dappen, Michael S.; Baudy, Reinhardt Bernhard; Ashwell, Susan

PA Athena Neurosciences, Inc., USA; American Home Products Corporation

SO PCT Int. Appl., 254 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9906431	A1	19990211	WO 1998-US15313	19980730
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9886611	A1	19990222	AU 1998-86611	19980730
PRAI	US 1997-920394	19970731	60/104,599 (no other appls)		
	WO 1998-US15313	19980730			
OS	MARPAT 130:168661				
AB	Disclosed are title compds. R1SO2NR2CHR3QCHR5COR6 [R1 = (un)substituted alkyl, (un)substituted aryl, (un)substituted cycloalkyl, (un)substituted heterocyclyl; R2 = H, any group R1; R1R2 may form (un)substituted heterocyclic ring; R3 = H, any group R1; R2R3 may form (un)substituted heterocyclic ring; R5 = (CH2)x-Ar-R5'; R5' = substituted alkylcarbonylamino, alkoxyaryl, aryl, heteroaryl, NR2, alkoxy-NR2, alkenyl, alkynyl, aryloxy, heteroaryloxy, tetrazolyl, etc.; each R = H, any group R1; Ar = (un)substituted aryl or heteroaryl; x = 1-4; Q = C(X)NR7; R7 = H, alkyl; X = O, S; R6 = NH2, (un)substituted alkoxy, (un)substituted cycloalkoxy, succinimidyl, adamantylamino, .beta.-cholest-5-en-3-yloxy, NHOY, NH(CH2)pCO2Y, OCH2NR9R10; Y = H, (un)substituted alkyl, (un)substituted aryl; p = 1-8; R9 = (un)substituted CO-aryl; R10 = H, CH2CO2R11, NHSO2Z; R11 = alkyl; Z = (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted heterocyclyl; and pharmaceutically acceptable salts thereof, with provisos] which bind VLA-4 (also referred to as integrin .alpha.4.beta.1 and CD49d/CD29). Certain of these compds. also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compds. are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, wherein the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia,				

Searched by John Dantzman 308-4488

diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compds. can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. Thus, BOP-mediated peptide coupling of Ts-Pro-Phe(4-NH₂)-OMe (Ts = tosyl) with Boc-Gly-OH, followed by sapon., gave desired title compd. Ts-Pro-Phe(4-Boc-Gly-NH)-OH. All prepd.

compds.

have IC₅₀ .1 to req. 15 .mu.M in a VLA-4 binding assay.

IT 220396-90-7P

RL: BAC (Biological activity or effector, except adverse); RCT

(Reactant);


SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonyl phenylalanine dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220396-90-7 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220396-92-9P 220396-93-0P 220396-94-1P
 220396-95-2P 220396-96-3P 220396-97-4P
 220396-99-6P 220397-01-3P 220397-03-5P
 220397-04-6P 220397-06-8P 220397-09-1P
 220397-10-4P 220397-12-6P 220397-13-7P
 220397-15-9P 220397-16-0P 220397-17-1P
 220397-18-2P 220397-19-3P 220397-20-6P
 220397-22-8P 220397-23-9P 220397-24-0P
 220397-26-2P 220397-27-3P 220397-28-4P
 220397-31-9P 220397-33-1P 220397-34-2P
 220397-35-3P 220397-36-4P 220397-38-6P
 220397-39-7P 220397-41-1P 220397-44-4P
 220397-46-6P 220397-48-8P 220397-49-9P
 220397-51-3P 220397-52-4P 220397-56-8P
 220397-58-0P 220397-59-1P 220397-60-4P
 220397-61-5P 220397-62-6P 220397-63-7P
 220397-64-8P 220397-65-9P 220397-66-0P
 220397-67-1P 220397-69-3P 220397-70-6P
 220397-71-7P 220397-72-8P 220397-74-0P
 220397-76-2P 220397-77-3P 220397-86-4P
 220397-88-6P 220397-90-0P 220397-92-2P
 220397-94-4P 220397-96-6P 220397-99-9P
 220398-01-6P 220398-03-8P 220398-04-9P
 220398-07-2P 220398-08-3P 220398-13-0P

Searched by John Dantzman

308-4488

220398-15-2P 220398-17-4P 220398-19-6P

220398-24-3P 220398-30-1P 220398-31-2P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonyl phenylalanine dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220396-92-9 CAPLUS


CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(aminoacetyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 220396-91-8

CMF C23 H28 N4 O6 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 220396-93-0 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(3-carboxy-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220396-94-1 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[(2S)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220396-95-2 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[(2R)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220396-96-3 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[(2R)-2-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-3-phenylpropyl]amino]- (9CI) (CA INDEX NAME)

Searched by John Dantzman

308-4488

Absolute stereochemistry.




RN 220396-97-4 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen)-5-yl)amino]thioxomethyl]amino]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A

HO



PAGE 1-B




RN 220396-99-6 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(3-methylphenyl)amino]carbonyl]amino]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Me

RN 220397-01-3 CAPLUS

CN L-Phenylalanine,
1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(3S)-3-amino-3-carboxy-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220397-03-5 CAPLUS

CN L-Tyrosine,

1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(carboxyphenylmethyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-04-6 CAPLUS

CN L-Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-(2'-carboxy[1,1'-
biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-06-8 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[2-
[[(phenylmethoxy)carbonyl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-09-1 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[bis[[4-(dimethylamino)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-10-4 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220397-12-6 CAPLUS

CN L-Tyrosine, O-[3-(dimethylamino)propyl]-N-[[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman


308-4488



RN 220397-13-7 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-15-9 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-[bis(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-16-0 CAPLUS

CN L-Tyrosine, 1-(2-thienylsulfonyl)-L-prolyl-O-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-17-1 CAPLUS

CN L-Tyrosine, 1-[(5-chloro-2-thienyl)sulfonyl]-L-prolyl-O-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-18-2 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-19-3 CAPLUS

CN L-Tyrosine, 1-[(2,5-dichloro-3-thienyl)sulfonyl]-L-prolyl-O-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-20-6 CAPLUS

CN L-Tyrosine, 1-[(1-methyl-1H-pyrazol-4-yl)sulfonyl]-L-prolyl-O-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-22-8 CAPLUS

CN L-Tyrosine, 1-(2-thiazolylsulfonyl)-L-prolyl-O-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-23-9 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[3-methyl(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-24-0 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[3-(diethylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-26-2 CAPLUS

CN L-Tyrosine, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-L-prolyl-O-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-27-3 CAPLUS

CN L-Tyrosine, 1-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfonyl]-L-prolyl-O-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-28-4 CAPLUS

CN L-Tyrosine, O-[3-(dimethylamino)propyl]-N-[[4-(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-31-9 CAPLUS

CN L-Tyrosine, O-[3-(dimethylamino)propyl]-N-[[3-(4-methylphenyl)sulfonyl]-3-thiomorpholinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220397-33-1 CAPLUS


CN L-Tyrosine, 1-[[4-(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 220397-34-2 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-35-3 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220397-36-4 CAPLUS

CN L-Tyrosine,


1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[3-[4-(3-chlorophenyl)-
1-piperazinyl]propyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 220397-38-6 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-(4-
morpholinyl)ethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-39-7 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-41-1 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-(hexahydro-1H-azepin-1-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-44-4 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-46-6 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-
[[trifluoromethyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-48-8 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-oxo-2-
(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-49-9 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(carboxymethyl)-
(9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 220397-51-3 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(2-amino-2-oxoethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-52-4 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-[(1,1-dimethylethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220397-56-8 CAPLUS


CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(2S)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxo-6-[[[(phenylmethoxy)carbonyl]amino]hexyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 220397-58-0 CAPLUS

CN L-Phenylalanine,

1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[(2S)-6-amino-2-
 [[(1,1-dimethylethoxy)carbonyl]amino]-1-oxohexyl]amino]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 220397-59-1 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(4-amino-1-
 oxobutyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220397-60-4 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[4-[(1,1-dimethylethoxy)carbonyl]amino]-1-oxobutyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 220397-61-5 CAPLUS

CN L-Phenylalanine,
1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[4-(methylamino)-
1-oxobutyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220397-62-6 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-1-oxobutyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 220397-63-7 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(2S)-2-amino-1-oxo-3-(phenylmethoxy)propyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220397-64-8 CAPLUS

CN L-Phenylalanine,

1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[4-carboxy-1-oxo-4-[(phenylmethoxy)carbonyl]amino]butyl]amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— Ph

RN 220397-65-9 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(4-amino-4-carboxy-1-oxobutyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-66-0 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-67-1 CAPLUS

CN L-Phenylalanine, 4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]amino]-N-[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-69-3 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[[(methylamino)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-70-6 CAPLUS

CN L-Phenylalanine, N-[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-4-[[(methylethylamino)acetyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-71-7 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[(dimethylamino)acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220397-72-8 CAPLUS

CN L-Phenylalanine, 4-[[(dimethylamino)acetyl]amino]-N-[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488

NAME)


Absolute stereochemistry.



RN 220397-74-0 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[2-formyl-1,2,3,4-tetrahydro-3-isoquinolinyl)methyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-76-2 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-[3-(dimethylamino)propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220397-77-3 CAPLUS

CN L-Tyrosine, 3,3-dimethyl-1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488


Absolute stereochemistry.



RN 220397-86-4 CAPLUS

CN Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-(3-phenoxy-1-propynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-88-6 CAPLUS

CN Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-(3-methoxy-1-propynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220397-90-0 CAPLUS

CN Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[3-[4-(ethoxycarbonyl)phenoxy]-1-propynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OEt

RN 220397-92-2 CAPLUS

CN Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[5-methoxy-4-(methoxycarbonyl)-5-oxo-1-pentynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-94-4 CAPLUS

CN Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[4-(acetylamino)-4-carboxy-1-butynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220397-96-6 CAPLUS

CN Phenylalanine,

1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[3-[(4,5-dihydro-4-oxo-5-phenyl-2-oxazolyl)amino]-1-propynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220397-99-9 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-[2-(1-phenyl-1,2,4-oxadiazol-5-yl)ethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220398-01-6 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[[1-[(1,1-dimethylethoxy)carbonyl]-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220398-03-8 CAPLUS

CN Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-[(1-methyl-4-piperidinyl)oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220398-04-9 CAPLUS

CN Tyrosine,
1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-(1-methyl-4-piperidinyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220398-07-2 CAPLUS

CN L-Tyrosine, N-[[[(3R)-4-[(4-methylphenyl)sulfonyl]-1,1-dioxido-3-thiomorpholinyl]carbonyl]-O-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220398-08-3 CAPLUS

CN L-Tyrosine, N-[[(4R)-5,5-dimethyl-3-[(4-methylphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-O-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220398-13-0 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[(ethenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220398-15-2 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-oxo-2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220398-17-4 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-[bis(1-methylethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220398-19-6 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-(acetylmethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220398-24-3 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-[[4-
Searched by John Dantzman 308-4488

methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220398-30-1 CAPLUS

CN L-Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220398-31-2 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220149-81-5

RL: RCT (Reactant)

(prepn. of N-sulfonyl phenylalanine dipeptide derivs. and analogs as inhibitors of leukocyte adhesion mediated by VLA-4)


RN 220149-81-5 CAPLUS

CN L-Phenylalanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-4-amino- (9CI) (CA

Searched by John Dantzman 308-4488

INDEX NAME)

Absolute stereochemistry.




IT 220302-70-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of N-sulfonyl phenylalanine dipeptide derivs. and analogs as
inhibitors of leukocyte adhesion mediated by VLA-4)

RN 220302-70-5 CAPLUS

CN L-Tyrosine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-O-[2-(1,1-
dimethylethoxy)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 17

L8 ANSWER 17 OF 61 CAPLUS COPYRIGHT 2000 ACS
AN 1999:104519 CAPLUS
DN 130:153971
TI Preparation of tryptophan ureas as neurokinin antagonists
IN Shah, Shrenik K.; Qi, Hongbo; Maccoss, Malcolm
PA Merck and Co., Inc., USA
SO U.S., 14 pp.
CODEN: USXXAM

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5869489	A	19990209	US 1997-814387	19970311
OS	MARPAT 130:153971				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed are substituted azacycles I [ring G = spirocycle Q1 or Q2, piperazine Q3, piperidine Q4; X = CH₂, NSO₂Me, NAc; R = Ph, 2-MeOC₆H₄, 2-MeC₆H₄, CH₂Ph; R1 = Ph, R11 = NOME [sic] (NHAc intended); R1 = H, R11 = CH₂Ph, 1,2,3,4-tetrahydroquinazolin-2-on-1-yl; R2 = OCH₂Ph wherein the Ph is optionally substituted with 1-3 substituents halo, Me, or CF₃; N(R3)-C1-4 alkylphenyl, wherein the C1-4 alkyl may be linear or branched, the Ph is optionally substituted with 1-3 substituents halo, Me, MeO, or CF₃; R3 = H, Me, Et] as tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma. In particular compds. I are neurokinin antagonists. Thus, amidation of

1.967 g Boc-Trp-OH (Boc = Me₃CO₂C) with 0.87 mL MeNHCH₂Ph gave 2.56 g of the corresponding amide, which underwent deprotection with CF₃CO₂H, condensation with carbonyldiimidazole, and urea formation with spiro[1H-indene-1,4'-piperidine] hydrochloride to give title compd. II (L-743,516). II and related Trp derivs. showed IC₅₀ values of >1000 to 1 nM for human neurokinin 1 (NK1) antagonist activity.


IT 199110-55-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of tryptophan ureas as neurokinin antagonists)

RN 199110-55-9 CAPLUS

CN L-Tryptophan, N-[[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indol-3,4'-piperidin]-1'-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



A handwritten mark, possibly a signature or initials, consisting of a large, stylized 'X' or 'Z' shape.

=> d bib abs hitstr 18

L8 ANSWER 18 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1998:799995 CAPLUS

DN 130:52736

TI Preparation of biarylalkanoic acids as cell adhesion inhibitors

IN Durette, Philippe L.; Hagmann, William K.; Maccoss, Malcolm; Mills, Sander

G.; Mumford, Richard A.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9853817	A1	19981203	WO 1998-US10951	19980529
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9877031	A1	19981230	AU 1998-77031	19980529
PRAI	US 1997-47856		19970529		
	GB 1997-14316		19970707		
	US 1997-66831		19971125		
	GB 1998-680		19980114		
	WO 1998-US10951		19980529		
OS	MARPAT 130:52736				
AB	Compds. R1YNR2CR3R4CONR5CR6R7X [R1 = (un)substituted alkyl, alkenyl, alkynyl, a cyclic group Cy, Cy-alkyl, Cy-alkenyl, Cy-alkynyl; R2, R3 independently are H or R1; or R2 and R3 together form a ring; R4, R7 independently are H, (un)substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; or R3 and R4 together form a ring; R5 = H or (un)substituted alkyl or Cy; R6 = diarylalkyl, -alkenyl, or -alkynyl; X = CO2H, PO3H2, PH(O)OH, SO2H, SO3H or ester derivs., carbamoyl group, or 5-tetrazolyl; Y = CO, OCO, NHCO or iminocarbonyl group, SO2, P(O)(ORi) (Ri =alkyl, alkenyl, alkynyl, aryl), COCO] were prepd. as cell adhesion inhibitors. Pharmaceutical compns. are described.				
	Thus, N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-L-4-(4-fluorophenyl)phenylalanine was prepd. by coupling of N-(3,5-dichlorobenzenesulfonyl)-L-proline with 4-iodo-L-phenylalanine and reaction with 4-fluorobenzeneboronic acid.				
IT	217326-67-5				
	RL: RCT (Reactant)				
	(prepn. of peptidyl biarylalkanoic acids as cell adhesion inhibitors)				
RN	217326-67-5 CAPLUS				
CN	L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(trimethylstannyl)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

Searched by John Dantzman

308-4488




IT 217325-45-6P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of peptidyl biarylalkanoic acids as cell adhesion inhibitors)

RN 217325-45-6 CAPLUS

CN L-Alanine, (4R)-4-amino-1-(phenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-
 biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 217325-07-0P 217325-08-1P 217325-09-2P
 217325-10-5P 217325-11-6P 217325-12-7P
 217325-13-8P 217325-14-9P 217325-15-0P
 217325-16-1P 217325-17-2P 217325-18-3P
 217325-19-4P 217325-20-7P 217325-21-8P
 217325-22-9P 217325-23-0P 217325-24-1P
 217325-25-2P 217325-26-3P 217325-27-4P
 217325-29-6P 217325-31-0P 217325-32-1P
 217325-33-2P 217325-34-3P 217325-35-4P
 217325-36-5P 217325-37-6P 217325-38-7P
 217325-39-8P 217325-40-1P 217325-41-2P
 217325-42-3P 217325-43-4P 217325-46-7P
 217325-47-8P 217325-48-9P 217325-49-0P
 217325-50-3P 217325-51-4P 217325-52-5P
 217325-53-6P 217325-54-7P 217325-55-8P
 217325-56-9P 217325-58-1P 217325-59-2P
 217325-60-5P 217325-61-6P 217325-62-7P
 217325-63-8P 217325-64-9P 217325-65-0P
 217325-66-1P 217325-67-2P 217325-68-3P

Searched by John Dantzman

308-4488

217325-69-4P 217325-70-7P 217325-71-8P
 217325-72-9P 217325-73-0P 217325-74-1P
 217325-75-2P 217325-76-3P 217325-77-4P
 217325-78-5P 217325-79-6P 217325-80-9P
 217325-81-0P 217325-82-1P 217325-83-2P
 217325-84-3P 217325-85-4P 217325-86-5P
 217325-87-6P 217325-88-7P 217325-89-8P
 217325-90-1P 217325-91-2P 217325-92-3P
 217325-93-4P 217325-94-5P 217325-95-6P
 217325-96-7P 217325-97-8P 217325-98-9P
 217325-99-0P 217326-00-6P 217326-01-7P
 217326-02-8P 217326-03-9P 217326-04-0P
 217326-05-1P 217326-06-2P 217326-08-4P
 217326-09-5P 217326-12-0P 217326-13-1P
 217326-14-2P 217326-15-3P 217326-16-4P
 217326-17-5P 217326-18-6P 217326-19-7P
 217326-20-0P 217326-21-1P 217326-22-2P
 217326-25-5P 217326-26-6P 217326-27-7P
 217326-28-8P 217326-29-9P 217326-30-2P
 217326-31-3P 217326-32-4P 217326-34-6P
 217326-36-8P 217326-38-0P 217326-39-1P
 217326-40-4P 217326-41-5P 217326-42-6P
 217326-43-7P 217326-44-8P 217326-45-9P
 217326-46-0P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptidyl biarylalkanoic acids as cell adhesion inhibitors)

RN 217325-07-0 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, .alpha.-[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-08-1 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman


308-4488



RN 217325-09-2 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(4'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-10-5 CAPLUS


CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-11-6 CAPLUS
CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-(3-thienyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-12-7 CAPLUS
CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217325-13-8 CAPLUS
CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-14-9 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(2'-formyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-15-0 CAPLUS

CN L-Phenylalanine, 1-[(3-fluorophenyl)sulfonyl]-L-prolyl-4-(3-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-16-1 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(2',6'-difluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488


Absolute stereochemistry.



RN 217325-17-2 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[2'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-18-3 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(4'-methyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-19-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(2'-carboxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-20-7 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[2'-(methoxycarbonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488

RN 217325-21-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(3'-formyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-22-9 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(3'-amino[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-23-0 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(2'-methyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-24-1 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[3'-(acetylamino)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-25-2 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(1'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-26-3 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(3'-carboxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-27-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[3'-(methoxycarbonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-29-6 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(2',4'-dichloro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-31-0 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-(2-formyl-3-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-32-1 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(4'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488

RN 217325-33-2 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-formyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-34-3 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-35-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-36-5 CAPLUS

CN L-Alanine, 2-methyl-1-(phenylsulfonyl)-L-prolyl-3-(2'-formyl[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-37-6 CAPLUS

CN L-Alanine, 2-methyl-1-(phenylsulfonyl)-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-38-7 CAPLUS

CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylthio)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-39-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[4-(2-methoxyphenyl)-2-thienyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-40-1 CAPLUS

CN D-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-D-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-41-2 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-D-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-42-3 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-43-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylthio)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-46-7 CAPLUS

CN L-Alanine, (4S)-4-amino-1-(phenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-47-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-48-9 CAPLUS

Searched by John Dantzman

308-4488

CN L-Alanine, (4R)-4-(benzoylamino)-1-(phenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-49-0 CAPLUS

CN L-Alanine, (4S)-4-(benzoylamino)-1-(phenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-50-3 CAPLUS

CN L-Alanine, (4R)-4-[(phenylacetyl)amino]-1-(phenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-51-4 CAPLUS

CN L-Alanine,

(4S)-4-[(phenylacetyl)amino]-1-(phenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-52-5 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-53-6 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-(3S)-3-methyl-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-54-7 CAPLUS

CN L-Alanine, 1-[(3-fluorophenyl)sulfonyl]-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-55-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(4'-fluoro-2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-56-9 CAPLUS

Searched by John Dantzman

308-4488

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-58-1 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[2'-(methylthio)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-59-2 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[2'-(5-methyl-1,3,4-oxadiazol-2-yl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-60-5 CAPLUS


CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-[2-methyl-5-(trifluoromethyl)-7-benzoxazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 217325-61-6 CAPLUS


CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-[2-methyl-6-[5-(trifluoromethyl)-1H-tetrazol-1-yl]-4-benzoxazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 217325-62-7 CAPLUS
CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-[2-methyl-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]-7-benzoxazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 217325-63-8 CAPLUS

CN L-Phenylalanine,

1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-(3-pyridinyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-64-9 CAPLUS

CN L-Phenylalanine,

1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-(2-pyridinyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488

RN 217325-65-0 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-(5-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-66-1 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(3'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-67-2 CAPLUS


CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-(2-methyl-4-benzoxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 217325-68-3 CAPLUS


CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-[6-(acetylamino)-2-methyl-4-benzoxazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 217325-69-4 CAPLUS

CN L-Phenylalanine, 1-(phenylsulfonyl)-L-prolyl-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488


RN 217325-70-7 CAPLUS
 CN L-Alanine, (3S)-1-[(3,5-dichlorophenyl)sulfonyl]-3-methyl-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-71-8 CAPLUS
 CN L-Alanine,
 2-methyl-1-(phenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217325-72-9 CAPLUS
 CN L-Alanine,
 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-73-0 CAPLUS

CN L-Phenylalanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(5-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-74-1 CAPLUS

CN L-Alanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-75-2 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-76-3 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(5-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-77-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(3'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-78-5 CAPLUS

Searched by John Dantzman

308-4488

CN L-Alanine,
1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(5'-fluoro-
2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-79-6 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-
methoxy-5'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-80-9 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(2-
pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-81-0 CAPLUS

CN L-Alanine,

1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano-3'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-82-1 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-((trifluoromethyl)sulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-83-2 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(2-thiazolyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-84-3 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-85-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-alanyl-4-(2-cyano-2H-pyrimidin-5-yl)- (9CI) (CA INDEX NAME)

4'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-86-5 CAPLUS

CN L-Alanine,

1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(5'-cyano-2'-fluoro[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-87-6 CAPLUS


CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1-methyl-1H-indol-7-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 217325-88-7 CAPLUS

CN L-Phenylalanine,


1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1H-indol-7-yl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 217325-89-8 CAPLUS
CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-
benzo[b]thien-4-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 217325-90-1 CAPLUS


CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(4-benzoxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 217325-91-2 CAPLUS
CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(2-methyl-4-benzoxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 217325-92-3 CAPLUS


CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-[2-(trifluoromethyl)-4-benzoxazolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 217325-93-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(1-methylethoxy)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217325-94-5 CAPLUS

CN L-Alanine,

1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-95-6 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[2'-(2-methyl-2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-96-7 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[2'-(aminocarbonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-97-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[2'-(methyamino)carbonyl][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-98-9 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[2'-((dimethylamino)carbonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217325-99-0 CAPLUS

CN L-Alanine, 2-methyl-1-(phenylsulfonyl)-L-prolyl-3-(2'-carboxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217326-00-6 CAPLUS

CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-((dimethylamino)carbonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488


Absolute stereochemistry.



RN 217326-01-7 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylamino)carbonyl]-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-02-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(dimethylamino)carbonyl]-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217326-03-9 CAPLUS

Searched by John Dantzman

308-4488

CN L-Alanine, 1-(butylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-04-0 CAPLUS

CN L-Alanine,
1-[(3-bromophenyl)sulfonyl]-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-
4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-05-1 CAPLUS

CN L-Alanine, 1-(phenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-06-2 CAPLUS

CN L-Alanine, 1-[(4-methylphenyl)sulfonyl]-L-prolyl-3-(2'-cyano[1,1'-
biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-08-4 CAPLUS

CN L-Alanine, 1-(3-pyridinylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-09-5 CAPLUS

CN L-Alanine, 1-(2-thienylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-12-0 CAPLUS

CN L-Alanine, 1-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfonyl]-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-13-1 CAPLUS

CN L-Alanine, 1-(2-benzothiazolylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-14-2 CAPLUS

CN L-Alanine, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-15-3 CAPLUS

CN L-Alanine,
1-[(3-iodophenyl)sulfonyl]-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-
4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-16-4 CAPLUS

CN L-Alanine, 1-(methylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-17-5 CAPLUS

CN L-Alanine, 1-[(trifluoromethyl)sulfonyl]-L-prolyl-3-(2'-cyano[1,1'-
biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-18-6 CAPLUS

CN L-Alanine,
1-[(3-bromophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano[1,1'-
biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217326-19-7 CAPLUS

CN L-Alanine,

1-[(3,5-dichlorophenyl)sulfonyl]-2-(2-propenyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217326-20-0 CAPLUS

CN L-Alanine,

1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-2-methyl-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-21-1 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-propyl-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME) ,


Absolute stereochemistry.



RN 217326-22-2 CAPLUS

CN L-Alanine,
2-methyl-1-(methylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217326-25-5 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 2'-cyano-.alpha.-[[[(2S)-1-[(3,5-

Searched by John Dantzman 308-4488

dichlorophenyl)sulfonyl]-2-methyl-2-piperidiny]carbonyl]amino]-,
(.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-26-6 CAPLUS

CN L-Alanine, 2-methyl-1-(2-naphthalenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-27-7 CAPLUS

CN L-Alanine, (4R)-4-amino-1-(methylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-28-8 CAPLUS

CN L-Alanine, (4R)-4-amino-1-[(1-methylethyl)sulfonyl]-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-29-9 CAPLUS

CN L-Alanine, 1-[(1,1-dimethylethyl)sulfonyl]-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-30-2 CAPLUS

CN L-Alanine, 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-31-3 CAPLUS

CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2'-methoxy[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-32-4 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1-oxido-2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-34-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-36-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[2'-(methanesulfinyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-38-0 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[2'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-39-1 CAPLUS

CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-40-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-41-5 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-42-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-43-7 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 2'-cyano-.beta.-methyl-.alpha.-[[[(2S)-1-(phenylsulfonyl)-2-pyrrolidinyl]carbonyl]amino]-, (.beta.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-44-8 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 2'-cyano-.beta.-methyl-.alpha.-[[[(2S)-1-(phenylsulfonyl)-2-pyrrolidinyl]carbonyl]amino]-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217326-45-9 CAPLUS

CN L-Alanine,

(4R)-4-[(dimethylamino)iminomethyl]-1-(phenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217326-46-0 CAPLUS

CN L-Alanine, (4R)-4-(dimethylamino)-1-(phenylsulfonyl)-L-prolyl-3-(2'-cyano[1,1'-biphenyl]-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 19

L8 ANSWER 19 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1998:799992 CAPLUS

DN 130:52724

TI Preparation of heterocyclic dipeptide derivatives as cell adhesion inhibitors

IN Durette, Philippe L.; Hagmann, William K.; Maccoss, Malcolm; Mills, Sander

G.; Mumford, Richard A.; Van Riper, Gail M.; Schmidt, Jack A.; Kevin, Nancy J.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 129 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9853814	A1	19981203	WO 1998-US10940	19980529
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	WO 9964395	A1	19991216	WO 1998-US11623	19980611
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRAI	US 1997-48017		19970529	← 09/424,825	
	GB 1997-14314		19970707		
	US 1997-66525		19971125		
	GB 1998-686		19980114		
OS	MARPAT 130:52724				
GI					



AB Title compds. I [R1 = (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, Cy, Cy-C1-10 alkyl, Cy-C2-10 alkenyl, Cy-C2-10 alkynyl; R2, R5 = independently (un)substituted H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, aryl-C1-10 alkyl, heteroaryl, heteroaryl-C1-10 alkyl; R3 = H, (un)substituted C1-10 alkyl, Cy, Cy-C1-10 alkyl; R4 = H, any group R1; R3R4 form mono- or bicyclic ring contg. 0-2 heteroatoms N, O, S; R4R5 form

3-7 membered mono- or bicyclic ring contg. 0-2 heteroatoms N, O, S; R10,

Searched by John Dantzman 308-4488

R11 = independently = any group R3, (un)substituted C2-10 alkenyl, C2-10 alkynyl; R10R11 may form 5-7 membered heterocyclic ring contg. 0-2 addnl. heteroatoms N, O, S; R6-R8 = independently any group R10, OR10, NO2,

halo,

CF3,

S(O)mR10, SR10, SO3R10, NR10R11, COR10, CO2R10, O2R10, CN, CONR10R11,

oxo, NR10S(O)mR11, etc.; two of R6-R8 may form 5-7 membered (un)satd. monocyclic ring contg. 0-3 heteroatoms N, O, S; Cy = cycloalkyl, heterocyclyl, aryl, heteroaryl; A, Z = independently C, C-C; B = bond, C, C-C, N, O, S, S(O)m; X = CO2R10, P(O)(OR10)(OR11), P(O)(R10)(OR11), S(O)mOR10, CONR10R11, 5-tetrazolyl; Y = CO, O2C, NR11CO, SO2, P(O)(OR4), COCO; m = 1-2] = are antagonists of VLA-4 and/or .alpha.4.beta.7, and are useful for inhibition or prevention of cell adhesion and cell adhesion mediated pathologies. These compds. may be formulated into

pharmaceutical

compns. and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders. Thus, coupling of L-2-naphthylalanine tert-Bu ester (H-Nal-OtBu) (prepn. given) with Cbz-Pro-OH (Cbz = PhCH2O2C), followed by catalytic deprotection, sulfonylation with 3,5-Cl2C6H3SO2Cl, and acidic deesterification gave desired N-sulfonyldipeptide Cl2C6H3SO2-Nal-Pro-OH. Procedures for inhibition of VLA-4 dependent adhesion to a CS-1 conjugate and VCAM-IG fusion protein are given.

IT 217449-98-4P 217449-99-5P 217450-00-5P

217450-01-6P 217450-02-7P 217450-03-8P

217450-04-9P 217450-05-0P 217450-06-1P

217450-08-3P 217450-09-4P 217450-12-9P

217450-13-0P 217450-14-1P 217450-16-3P

217450-17-4P 217450-18-5P 217450-19-6P

217450-20-9P 217450-21-0P 217450-22-1P

217450-23-2P 217450-24-3P 217450-25-4P

217450-26-5P 217450-27-6P 217450-28-7P

217450-29-8P 217450-30-1P 217450-31-2P

217450-32-3P 217450-33-4P 217450-34-5P

217450-35-6P 217450-36-7P 217450-37-8P

217450-38-9P 217450-39-0P 217450-40-3P

217450-41-4P 217450-42-5P 217450-43-6P

217450-44-7P 217450-46-9P 217450-47-0P

217450-48-1P 217450-49-2P 217450-50-5P

217450-51-6P 217450-52-7P 217450-53-8P

217450-54-9P 217450-55-0P 217450-56-1P

217450-59-4P 217450-61-8P 217450-62-9P

217450-63-0P 217450-64-1P 217450-65-2P

217450-66-3P 217450-67-4P 217450-68-5P

217450-69-6P 217450-70-9P 217450-71-0P

217450-72-1P 217450-73-2P 217450-75-4P

217450-77-6P 217450-78-7P 217450-79-8P

217450-80-1P 217450-81-2P 217450-83-4P

217450-85-6P 217450-87-8P 217450-88-9P

217450-90-3P 217450-91-4P 217450-92-5P

217450-93-6P 217450-94-7P 217450-95-8P

217450-96-9P 217450-98-1P 217450-99-2P

217451-01-9P 217451-02-0P 217451-03-1P

217451-05-3P 217451-07-5P 217451-08-6P

217451-09-7P 217451-10-0P 217451-11-1P

217451-12-2P 217451-13-3P 217451-14-4P

217451-15-5P 217451-16-6P 217451-17-7P

Searched by John Dantzman

308-4488

217451-18-8P 217451-19-9P 217451-20-2P
217451-21-3P 217451-22-4P 217451-23-5P
217451-24-6P 217451-25-7P 217451-26-8P
217451-28-0P 217451-30-4P 217451-31-5P
217451-33-7P 217451-35-9P 217451-36-0P
217451-38-2P 217451-39-3P 217451-40-6P
217451-42-8P 217451-44-0P 217451-45-1P
217451-46-2P 217451-47-3P 217451-48-4P
217451-49-5P 217451-50-8P 217451-51-9P
217451-52-0P 217451-54-2P 217451-57-5P
217451-59-7P 217451-61-1P 217451-63-3P
217451-64-4P 217451-66-6P 217451-67-7P
217451-68-8P 217451-69-9P 217451-70-2P
217451-71-3P 217451-72-4P 217451-73-5P
217451-74-6P 217451-75-7P 217451-76-8P
217451-77-9P 217451-78-0P 217451-79-1P
217451-80-4P 217451-81-5P 217451-82-6P
217451-83-7P 217451-84-8P 217451-85-9P
217451-86-0P 217451-87-1P 217451-88-2P
217451-89-3P 217451-90-6P 217451-91-7P
217451-92-8P 217451-93-9P 217451-94-0P
217451-95-1P 217451-96-2P 217451-97-3P
217451-98-4P 217451-99-5P 217452-01-2P
217452-02-3P 217452-03-4P 217452-04-5P
217452-06-7P 217452-08-9P 217452-09-0P
217452-10-3P 217452-11-4P 217452-12-5P
217452-13-6P 217452-14-7P 217452-16-9P
217452-17-0P 217452-18-1P 217452-19-2P
217452-20-5P 217452-21-6P 217452-22-7P
217452-23-8P 217452-24-9P 217452-25-0P
217452-26-1P 217452-27-2P 217452-28-3P
217452-29-4P 217452-30-7P 217452-31-8P
217452-32-9P 217452-33-0P 217452-34-1P
217452-35-2P 217452-36-3P 217452-37-4P
217452-40-9P 217452-41-0P 217452-42-1P
217452-44-3P 217452-46-5P 217452-47-6P
217452-48-7P 217452-49-8P 217452-50-1P
217452-51-2P 217452-52-3P 217452-53-4P
217452-54-5P 217452-55-6P 217452-56-7P
217452-60-3P 217452-61-4P 217452-62-5P
217452-63-6P 217452-64-7P 217452-65-8P
217452-66-9P 217452-69-2P 217452-70-5P
217452-72-7P 217452-73-8P 217452-74-9P
217452-75-0P 217452-76-1P 217452-77-2P
217452-78-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of heterocyclic dipeptide derivs. as cell adhesion inhibitors)

RN 217449-98-4 CAPLUS

CN L-Leucine,

N-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinoliny]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217449-99-5 CAPLUS

CN L-Arginine,

N2-[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-00-5 CAPLUS

CN L-Glutamic acid, N-[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-01-6 CAPLUS

CN Glycine, N-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinoliny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-02-7 CAPLUS

CN 1-Naphthalenepropanoic acid, .alpha.-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinoliny]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217450-03-8 CAPLUS

CN L-Valine,

N-[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-04-9 CAPLUS

CN 2-Thiophenepropanoic acid, .alpha.-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-05-0 CAPLUS

CN Cyclohexanepropanoic acid, .alpha.-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-06-1 CAPLUS

CN 2-Naphthalenepropanoic acid, .alpha.-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217450-08-3 CAPLUS

CN L-Norleucine,

N-[(3S)-2-[(2,4-dinitrophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-09-4 CAPLUS

CN L-Phenylalanine, N-[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl-.beta.-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-12-9 CAPLUS

CN L-Norleucine, N-[[(3S)-2-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-13-0 CAPLUS

CN L-Norleucine, N-[[(3S)-1,2,3,4-tetrahydro-2-(2-naphthalenylsulfonyl)-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217450-14-1 CAPLUS

CN L-Norleucine,

N-[(3S)-1,2,3,4-tetrahydro-2-[(4-methoxyphenyl)sulfonyl]-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217450-16-3 CAPLUS

CN L-Cysteine,

N-[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-17-4 CAPLUS

CN L-Norleucine, N-[[[(3S)-2-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-18-5 CAPLUS

CN L-Norleucine,
N-[[[(3S)-2-[(2,5-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-19-6 CAPLUS

CN L-Norleucine, N-[[(3S)-1,2,3,4-tetrahydro-2-[(2,4,6-trimethylphenyl)sulfonyl]-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-20-9 CAPLUS

CN L-Norleucine, N-[[(3S)-1,2,3,4-tetrahydro-2-[(4-methylphenyl)sulfonyl]-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-23-2 CAPLUS

CN L-Norleucine, N-[[[(3S)-2-[(4-fluorophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-24-3 CAPLUS

CN L-Norleucine, N-[[[(3S)-1,2,3,4-tetrahydro-2-(1-naphthalenylsulfonyl)-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-25-4 CAPLUS

CN L-Norleucine, N-[(3S)-1,2,3,4-tetrahydro-2-[(phenylmethyl)sulfonyl]-3-isoquinolinyl]carbamate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-26-5 CAPLUS

CN L-Norleucine, N-[(3S)-1,2,3,4-tetrahydro-2-[(4-nitrophenyl)sulfonyl]-3-isoquinolinyl]carbamate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217450-27-6 CAPLUS

Searched by John Dantzman

308-4488

CN L-Phenylalanine, N-[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-28-7 CAPLUS

CN L-Glutamine, N2-[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-29-8 CAPLUS

CN L-Phenylalanine, N-[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]-4-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-30-1 CAPLUS

CN L-Asparagine, N2-[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-31-2 CAPLUS

CN L-Methionine, N-[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-32-3 CAPLUS

CN Benzenebutanoic acid, .alpha.-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]amino]-, (.alpha.S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 217450-33-4 CAPLUS

CN D-Norleucine, N-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-34-5 CAPLUS

CN L-Phenylalanine, N-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-35-6 CAPLUS

CN L-Norleucine, N-[[[(3S)-1,2,3,4-tetrahydro-2-[(3-methylphenyl)sulfonyl]-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-36-7 CAPLUS

CN L-Norleucine, N-[[[(3S)-1,2,3,4-tetrahydro-2-[[4-(trifluoromethyl)phenyl]sulfonyl]-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-37-8 CAPLUS

CN L-Norleucine, N-[[[(3S)-1,2,3,4-tetrahydro-2-[(4-propylphenyl)sulfonyl]-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-38-9 CAPLUS

CN L-Norleucine, N-[[[(3S)-1,2,3,4-tetrahydro-2-[[4-(1-methylethyl)phenyl]sulfonyl]-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-39-0 CAPLUS

CN L-Norleucine,
N-[[[(3S)-2-[(2,6-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-40-3 CAPLUS

CN L-Norleucine, N-[[[(3S)-2-[(4-ethylphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-41-4 CAPLUS

CN L-Norleucine,
N-[[[(3S)-2-[(2,4-difluorophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-42-5 CAPLUS

CN L-Norleucine, N-[[[(3S)-2-[(2-cyanophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-43-6 CAPLUS

CN L-Norleucine,
N-[[[(3S)-2-[[4-(1,1-dimethylpropyl)phenyl]sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-44-7 CAPLUS

CN L-Norleucine, N-[[[(3S)-2-[(4-chloro-3-nitrophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-46-9 CAPLUS

CN L-Norleucine,
N-[[[(3S)-2-[(3,5-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217450-47-0 CAPLUS

CN L-Norleucine,

N-[[(3S)-2-[(3,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217450-48-1 CAPLUS

CN L-Norleucine, N-[[(3S)-1,2,3,4-tetrahydro-2-[[2-


(trifluoromethyl)phenyl]sulfonyl]-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217450-49-2 CAPLUS
 CN L-Norleucine,
 N-[[(3S)-2-[(2,3-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-
 3-isoquinoliny]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217450-50-5 CAPLUS
 CN L-Norleucine,
 N-[[(3S)-2-[(2,4-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-
 3-isoquinoliny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-51-6 CAPLUS

CN L-Norleucine, N-[[[(3S)-2-[(2,5-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-52-7 CAPLUS

CN L-Serine,
N-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-53-8 CAPLUS

CN L-Isoleucine, N-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-54-9 CAPLUS

CN L-Tryptophan, N-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-55-0 CAPLUS

CN L-Tryptophan, N-[[[(3S)-2-(2,1,3-benzothiadiazol-4-ylsulfonyl)-1,2,3,4-tetrahydro-3-isoquinolinylnyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-56-1 CAPLUS

CN 3-Pyridinepropanoic acid, .alpha.-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinylnyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-59-4 CAPLUS

CN D-Norleucine, N-[[(3R)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-61-8 CAPLUS

CN L-Norleucine, N-[[(3S)-2-[(4-cyanophenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-62-9 CAPLUS

CN L-Norleucine, N-[[[(3S)-1,2,3,4-tetrahydro-2-(phenylsulfonyl)-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-63-0 CAPLUS

CN L-Norleucine, N-[[[(3S)-1,2,3,4-tetrahydro-2-[(3-nitrophenyl)sulfonyl]-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217450-64-1 CAPLUS

Searched by John Dantzman

308-4488

CN L-Norleucine, N-[[[(3S)-1,2,3,4-tetrahydro-2-[[3-(trifluoromethyl)phenyl]sulfonyl]-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-65-2 CAPLUS

CN L-Norleucine, N-[[[(3S)-1,2,3,4-tetrahydro-2-(2-thienylsulfonyl)-3-isoquinolinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-66-3 CAPLUS

CN L-Leucine, N-[[[(3S)-2-[[3,4-dimethoxyphenyl]sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-67-4 CAPLUS

CN L-Ornithine, N5-(aminocarbonyl)-N2-[[[(3S)-2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-3-isoquinolinyl]carbonyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-68-5 CAPLUS

CN L-Norleucine, N-[[[(3S)-1,2,3,4-tetrahydro-2-[(4-iodophenyl)sulfonyl]-3-isoquinolinyl]carbonyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-69-6 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-70-9 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488


RN 217450-71-0 CAPLUS
CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 217450-72-1 CAPLUS
CN L-Glutamic acid, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 217450-73-2 CAPLUS
CN L-Arginine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 217450-75-4 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3,4-dichloro-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-77-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-bromo- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 217450-78-7 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-nitro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 217450-79-8 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(4-thiazolyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-80-1 CAPLUS


CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-2-chloro- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 217450-81-2 CAPLUS
 CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-chloro-
 (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 217450-83-4 CAPLUS
 CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-cyano- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-85-6 CAPLUS
 Searched by John Dantzman 308-4488

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-, hydrogen sulfate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-87-8 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3,5-diiodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-88-9 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-90-3 CAPLUS

CN L-Aspartic acid, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-91-4 CAPLUS

CN L-Tryptophan, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217450-92-5 CAPLUS

Searched by John Dantzman

308-4488

CN L-Methionine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-93-6 CAPLUS

CN L-Norleucine, 1-[(3,4-dimethoxyphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-94-7 CAPLUS

CN L-Alanine, 1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-95-8 CAPLUS

CN 2-Naphthalenepropanoic acid, .alpha.-[[[(4R)-3-[(3,4-dimethoxyphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217450-96-9 CAPLUS


CN L-Norleucine, N-[[[(4R)-3-[(3,4-dimethoxyphenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217450-98-1 CAPLUS
CN 2-Naphthalenepropanoic acid, .alpha.-[[[(4R)-3-[(3,5-dichlorophenyl)sulfonyl]-4-thiazolidinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217450-99-2 CAPLUS
CN L-Norleucine, N-[[[(2S)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217451-01-9 CAPLUS
CN Benzenebutanoic acid, .alpha.-[[[(2S)-1-[(3,5-dichlorophenyl)sulfonyl]-2-piperidinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-02-0 CAPLUS

CN L-Tyrosine, N-[[[(2S)-1-[(3,5-dichlorophenyl)sulfonyl]-2-piperidinyl]carbonyl]-3-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-03-1 CAPLUS

CN 2-Naphthalenepropanoic acid, .alpha.-[[[(2S)-1-[(3,5-dichlorophenyl)sulfonyl]-2-piperidinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-05-3 CAPLUS

CN 2-Naphthalenepropanoic acid, .alpha.-[[[(2S)-1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-2-piperidiny]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-07-5 CAPLUS

CN L-Norleucine, N-[[[(2S)-1-[(3,4-dimethoxyphenyl)sulfonyl]octahydro-1H-indol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-08-6 CAPLUS

CN L-Norleucine, N-[[[1-[(3,4-dimethoxyphenyl)sulfonyl]-2-azetidiny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-09-7 CAPLUS

CN L-Alanine, (4S)-1-[(3,5-dichlorophenyl)sulfonyl]-4-hydroxy-L-prolyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-10-0 CAPLUS

CN L-Norleucine, (4S)-1-[(3,4-dimethoxyphenyl)sulfonyl]-4-hydroxy-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-11-1 CAPLUS

Searched by John Dantzman

308-4488

CN L-Norleucine, 3,4-didehydro-1-[(3,4-dimethoxyphenyl)sulfonyl]-L-prolyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-12-2 CAPLUS

CN L-Norleucine, 1-[[3-[bis(phenylsulfonyl)amino]phenyl]sulfonyl]-L-prolyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-13-3 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(4-pyridinyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-14-4 CAPLUS

CN L-Alanine, (4R)-4-amino-1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-15-5 CAPLUS

CN L-Phenylalanine, 3,4-didehydro-1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488

RN 217451-16-6 CAPLUS

CN L-Phenylalanine, 1-[(3-chlorophenyl)sulfonyl]-L-prolyl-4-fluoro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 217451-17-7 CAPLUS

CN L-Phenylalanine,
(4R)-1-[(3,5-dichlorophenyl)sulfonyl]-4-hydroxy-L-prolyl-
4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-18-8 CAPLUS

CN L-Tyrosine, N-[[[(4R)-3-[(3,5-dichlorophenyl)sulfonyl]-4-
thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-19-9 CAPLUS

CN L-Tyrosine, N-[[[(4R)-3-[(3,5-dichlorophenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-3-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-20-2 CAPLUS

CN 2-Naphthalenepropanoic acid, .alpha.-[[[(4R)-3-[(3-fluorophenyl)sulfonyl]-4-thiazolidinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217451-21-3 CAPLUS


CN 2-Naphthalenepropanoic acid, .alpha.-[[[(2S)-1-[(3-fluorophenyl)sulfonyl]-

Searched by John Dantzman

308-4488

2-piperidiny]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-22-4 CAPLUS

CN L-Phenylalanine, 4-fluoro-N-[[(4R)-3-[(3-fluorophenyl)sulfonyl]-4-thiazolidiny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-23-5 CAPLUS

CN L-Phenylalanine, 1-[(3-fluorophenyl)sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-24-6 CAPLUS

Searched by John Dantzman

308-4488

CN L-Phenylalanine, 1-[(3-chlorophenyl)sulfonyl]-3,4-didehydro-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-25-7 CAPLUS

CN L-Phenylalanine, (4R)-1-[(3-fluorophenyl)sulfonyl]-4-hydroxy-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-26-8 CAPLUS


CN L-Phenylalanine, (4R)-1-[(3-chlorophenyl)sulfonyl]-4-hydroxy-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-28-0 CAPLUS
CN L-Phenylalanine, N-[[(2S)-1-[(3,5-dichlorophenyl)sulfonyl]-2-piperidiny]carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-30-4 CAPLUS
CN L-Tyrosine, 3,4-didehydro-1-[(3-fluorophenyl)sulfonyl]-L-prolyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 217451-31-5 CAPLUS
CN L-Tyrosine, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-33-7 CAPLUS
CN L-Tyrosine, (4R)-1-[(3-fluorophenyl)sulfonyl]-4-hydroxy-L-prolyl- (9CI)
Searched by John Dantzman 308-4488

(CA INDEX NAME)


Absolute stereochemistry.



RN 217451-35-9 CAPLUS

CN L-Tyrosine, (4R)-1-[(3-chlorophenyl)sulfonyl]-4-hydroxy-L-prolyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 217451-36-0 CAPLUS

CN L-Phenylalanine, 4-fluoro-N-[[(2S)-1-[(3-fluorophenyl)sulfonyl]-2-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-38-2 CAPLUS

CN L-Tyrosine, (4R)-1-[(3-fluorophenyl)sulfonyl]-4-hydroxy-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488


Absolute stereochemistry.



RN 217451-39-3 CAPLUS

CN L-Tyrosine, (4R)-1-[(3-chlorophenyl)sulfonyl]-4-hydroxy-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-40-6 CAPLUS

CN L-Tyrosine, 3,4-didehydro-1-[(4,5-dichloro-2-thienyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-42-8 CAPLUS

CN L-Phenylalanine, (3S)-1-[(3,5-dichlorophenyl)sulfonyl]-3-methyl-L-prolyl-4-

Searched by John Dantzman 308-4488

fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-44-0 CAPLUS

CN L-Tyrosine, 3,4-didehydro-1-[(3-fluorophenyl)sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-45-1 CAPLUS

CN L-Tyrosine, 1-[(3-chlorophenyl)sulfonyl]-3,4-didehydro-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-46-2 CAPLUS

Searched by John Dantzman

308-4488

CN L-Phenylalanine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-fluoro-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-47-3 CAPLUS

CN L-Tyrosine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 217451-48-4 CAPLUS

CN L-Tyrosine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(1,1-
dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-49-5 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl- (9CI)
(CA INDEX NAME)

Searched by John Dantzman


308-4488

Absolute stereochemistry.




RN 217451-50-8 CAPLUS
 CN L-Tyrosine, 1-[(3-fluorophenyl)sulfonyl]-L-prolyl-3-iodo- (9CI) (CA
 INDEX
 NAME)

Absolute stereochemistry.



RN 217451-51-9 CAPLUS
 CN L-Tyrosine, 1-[(3-chlorophenyl)sulfonyl]-L-prolyl-3-iodo- (9CI) (CA
 INDEX
 NAME)


Absolute stereochemistry.



RN 217451-52-0 CAPLUS
 CN L-Phenylalanine, 1-[(3-fluorophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX
 Searched by John Dantzman 308-4488

NAME)


Absolute stereochemistry.



RN 217451-54-2 CAPLUS

CN L-Phenylalanine, 1-[(3-chlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-57-5 CAPLUS


CN L-Phenylalanine, (4R)-1-[(3-fluorophenyl)sulfonyl]-4-hydroxy-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-59-7 CAPLUS
 CN L-Phenylalanine, (4R)-1-[(3-chlorophenyl)sulfonyl]-4-hydroxy-L-prolyl-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-61-1 CAPLUS
 CN L-Alanine, 3,4-didehydro-1-[(4,5-dichloro-2-thienyl)sulfonyl]-L-prolyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217451-63-3 CAPLUS
 CN 4-Pyridinepropanoic acid, .alpha.-[[[(4R)-3-[(4,5-dichloro-2-thienyl)sulfonyl]-4-thiazolidinyl]carbonyl]amino]-, (.alpha.S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-64-4 CAPLUS

CN L-Phenylalanine, 3,4-didehydro-1-[(4,5-dichloro-2-thienyl)sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-66-6 CAPLUS

CN L-Phenylalanine, (4R)-1-[(3,5-dichlorophenyl)sulfonyl]-4-hydroxy-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-67-7 CAPLUS

Searched by John Dantzman

308-4488


CN L-Phenylalanine,
1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-fluoro-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-68-8 CAPLUS
CN L-Phenylalanine,
4-fluoro-N-[[[(4R)-3-[[3-(trifluoromethyl)phenyl]sulfonyl]-
4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217451-69-9 CAPLUS
CN L-Phenylalanine, 3,4-didehydro-1-[(3-fluorophenyl)sulfonyl]-L-prolyl-4-
fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-70-2 CAPLUS
CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-, dihydrogen
Searched by John Dantzman 308-4488

phosphate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-71-3 CAPLUS

CN L-Tyrosine, (4R)-4-amino-1-[(3-chlorophenyl)sulfonyl]-L-prolyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 217451-72-4 CAPLUS

CN L-Tyrosine, N-[[[(4R)-3-[(4,5-dichloro-2-thienyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-73-5 CAPLUS

CN L-Phenylalanine,

1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-L-prolyl-4-fluoro-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-74-6 CAPLUS

CN D-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-D-prolyl-4-fluoro-
(9CI)

(CA INDEX NAME)

Absolute stereochemistry.




RN 217451-75-7 CAPLUS

Searched by John Dantzman

308-4488


CN L-Alanine,
(4R)-4-amino-1-[(4,5-dichloro-2-thienyl)sulfonyl]-L-prolyl-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-76-8 CAPLUS
CN L-Phenylalanine, 1-[[5-[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl]-2-thienyl]sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217451-77-9 CAPLUS
CN L-Phenylalanine, 1-[[5-[[[4-chlorobenzoyl]amino]methyl]-2-thienyl]sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-78-0 CAPLUS
CN L-Phenylalanine, 1-[[5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl]sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488


Absolute stereochemistry.



RN 217451-79-1 CAPLUS

CN L-Tyrosine, 1-[(3-fluorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-80-4 CAPLUS

CN L-Phenylalanine, (4R)-4-amino-1-[(3-fluorophenyl)sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-81-5 CAPLUS

CN L-Phenylalanine, (4R)-4-amino-1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman


308-4488



RN 217451-82-6 CAPLUS

CN L-Phenylalanine, (4R)-4-amino-1-[(3-chlorophenyl)sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-83-7 CAPLUS

CN L-Phenylalanine,
(4S)-4-amino-1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-84-8 CAPLUS

CN L-Phenylalanine, N-[[(4R)-3-[(3-chlorophenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-85-9 CAPLUS

CN L-Phenylalanine, 1-[(4-bromo-5-chloro-2-thienyl)sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-86-0 CAPLUS

CN L-Phenylalanine, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Searched by John Dantzman

308-4488




RN 217451-87-1 CAPLUS
 CN L-Tyrosine, N-[[[(4R)-3-[(3,5-dichlorophenyl)sulfonyl]-4-thiazolidinyl]carbonyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-88-2 CAPLUS
 CN L-Phenylalanine,
 1-[[5-[(benzoylamino)methyl]-2-thienyl]sulfonyl]-L-prolyl-
 4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217451-89-3 CAPLUS
 CN L-Tyrosine, 1-[(3-chlorophenyl)sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-90-6 CAPLUS

CN L-Phenylalanine, 1-[[5-(phenylsulfonyl)-2-thienyl]sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-91-7 CAPLUS

CN L-Phenylalanine, 1-[(3-bromo-5-chloro-2-thienyl)sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-92-8 CAPLUS

CN L-Tyrosine, 1-[(3-chlorophenyl)sulfonyl]-3,4-didehydro-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-93-9 CAPLUS

CN Benzenebutanoic acid, .alpha.-[[[(2S)-1-[(3,5-dichlorophenyl)sulfonyl]-2-pyrrolidinyl]carbonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-94-0 CAPLUS

CN L-Tyrosine, 1-[[4-(phenylsulfonyl)-2-thienyl]sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-95-1 CAPLUS

CN L-Tyrosine, 1-[[5-[(benzoylamino)methyl]-2-thienyl]sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217451-96-2 CAPLUS

CN L-Tyrosine, 1-[[[(1E)-2-phenylethenyl]sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 217451-97-3 CAPLUS

CN L-Tyrosine, 1-[[[5-(phenylsulfonyl)-2-thienyl]sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-98-4 CAPLUS

CN L-Tyrosine, O-(1,1-dimethylethyl)-N-[[[(4R)-3-[(3-fluorophenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217451-99-5 CAPLUS

CN L-Tyrosine, 1-[(phenylmethyl)sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-01-2 CAPLUS

CN L-Tyrosine, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-02-3 CAPLUS

CN L-Tyrosine,
1-[[4-[[4-(dimethylamino)phenyl]azo]phenyl]sulfonyl]-L-prolyl-
O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




RN 217452-03-4 CAPLUS
 CN L-Tyrosine, 1-[[5-[[4-(trifluoromethyl)phenyl]sulfonyl]-2-thienyl]sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217452-04-5 CAPLUS
 CN L-Tyrosine, 1-[(3-bromophenyl)sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-06-7 CAPLUS
 CN L-Phenylalanine, 1-[[4-(methylsulfonyl)phenyl]sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman


308-4488



RN 217452-08-9 CAPLUS

CN L-Tyrosine, 1-[(4-methoxyphenyl)sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-09-0 CAPLUS

CN L-Phenylalanine, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-L-prolyl-3-fluoro-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-10-3 CAPLUS

CN L-Phenylalanine, 1-[(5-chloro-2-thienyl)sulfonyl]-L-prolyl-4-fluoro-
(9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 217452-11-4 CAPLUS

CN L-Tyrosine, N-[[(4R)-3-[(3-chlorophenyl)sulfonyl]-4-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-12-5 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-13-6 CAPLUS

CN L-Tyrosine, 1-[[[(1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-14-7 CAPLUS

CN L-Tyrosine, 1-[[[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methyl]sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-16-9 CAPLUS

CN L-Tyrosine, (4R)-1-[(3-chlorophenyl)sulfonyl]-4-hydroxy-L-prolyl-, 2-(hydrogen sulfate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



Searched by John Dantzman


308-4488

Absolute stereochemistry.




RN 217452-18-1 CAPLUS

Absolute stereochemistry.



RN 217452-19-2 CAPLUS

Absolute stereochemistry.




RN 217452-20-5 CAPLUS

CN L-Tyrosine,

(4R)-4-amino-1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-21-6 CAPLUS

CN L-Tyrosine, (4R)-4-amino-1-[(3-chlorophenyl)sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-22-7 CAPLUS

CN L-Tyrosine, 1-[(3-cyanophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-23-8 CAPLUS

CN L-Tyrosine, 1-(phenylsulfonyl)-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-24-9 CAPLUS

CN L-Tyrosine, 1-[[4-(methylsulfonyl)phenyl]sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-25-0 CAPLUS

CN L-Tyrosine, (4R)-4-amino-1-[(4,5-dichloro-2-thienyl)sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-26-1 CAPLUS

CN L-Phenylalanine, (4R)-4-amino-1-[(4,5-dichloro-2-thienyl)sulfonyl]-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-27-2 CAPLUS

CN L-Phenylalanine, 1-(phenylsulfonyl)-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-28-3 CAPLUS

CN L-Phenylalanine, 1-(octylsulfonyl)-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-29-4 CAPLUS

CN L-Phenylalanine, (5R)-1-[(3-fluorophenyl)sulfonyl]-5-phenyl-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-30-7 CAPLUS


CN L-Phenylalanine,
(3R)-1-[(3,5-dichlorophenyl)sulfonyl]-3-phenyl-L-prolyl-4-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217452-31-8 CAPLUS
 CN L-Phenylalanine,
 N-[[2-[(3,5-dichlorophenyl)sulfonyl]-1,2,3,4-tetrahydro-1-
 isoquinolinyl]carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 217452-32-9 CAPLUS
 CN L-Tyrosine, 1-[[4-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-
 [9H]xanthen]-6-yl)carbonyl]amino]phenyl]sulfonyl]-L-prolyl-O-(1,1-
 dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 217452-33-0 CAPLUS

CN L-Tyrosine, 1-[[3-(ethoxycarbonyl)phenyl]sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-34-1 CAPLUS

Searched by John Dantzman

308-4488


CN L-Phenylalanine, 1-[(4-iodophenyl)sulfonyl]-L-prolyl-4-benzoyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 217452-35-2 CAPLUS
CN L-Tyrosine, 1-[[3-[(4-benzoylbenzoyl)amino]phenyl]sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-36-3 CAPLUS
CN L-Tyrosine, 1-[[3-[[6-[[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]amino]-1-oxohexyl]amino]phenyl]sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B



RN 217452-37-4 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-(2-naphthalenyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-40-9 CAPLUS

CN L-Tryptophan, N-[[[(2S)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2-piperidinyldipeptide]-2-
piperidinyldipeptide]-2- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-41-0 CAPLUS

CN L-Norleucine, 1-[(4-nitrophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-42-1 CAPLUS

CN L-Norleucine, 1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-L-prolyl- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 217452-44-3 CAPLUS

CN L-Norleucine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-46-5 CAPLUS

CN L-Norleucine, 1-[(3-(trifluoromethyl)phenyl)sulfonyl]-L-prolyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 217452-47-6 CAPLUS

CN L-Norleucine, 1-[[4-(benzoylamino)phenyl]sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-48-7 CAPLUS

CN L-Norleucine, 1-[(4-methoxy-3,5-dinitrophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-49-8 CAPLUS

CN L-Norleucine, 1-[(3-chlorophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-50-1 CAPLUS

CN L-Alanine, 1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-51-2 CAPLUS

CN L-Norleucine, 1-[(3-nitrophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-52-3 CAPLUS

CN L-Norleucine, 1-[(3-cyanophenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-53-4 CAPLUS

CN L-Norleucine, 1-[(3-methylphenyl)sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-54-5 CAPLUS

CN L-Alanine, (3S)-1-[(3,5-dichlorophenyl)sulfonyl]-3-methyl-L-prolyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217452-55-6 CAPLUS


CN L-Alanine, 1-[(3-chlorophenyl)sulfonyl]-L-prolyl-3-(2-naphthalenyl)- (9CI)

Searched by John Dantzman

308-4488

(CA INDEX NAME)

Absolute stereochemistry.




RN 217452-56-7 CAPLUS

CN L-Alanine, 1-[(3-fluorophenyl)sulfonyl]-L-prolyl-3-(2-naphthalenyl)- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 217452-60-3 CAPLUS

CN L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-61-4 CAPLUS

CN L-Alanine, 1-(phenylsulfonyl)-L-prolyl-3-(2-naphthalenyl)- (9CI) (CA

Searched by John Dantzman 308-4488

INDEX NAME)

Absolute stereochemistry.




RN 217452-62-5 CAPLUS

CN L-Alanine,

1-[[4-[[[(phenylamino)carbonyl]amino]phenyl]sulfonyl]-L-prolyl-3-(2-naphthalenyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-63-6 CAPLUS

CN L-Alanine, 1-[(3-fluorophenyl)sulfonyl]-5,5-dimethyl-L-prolyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-64-7 CAPLUS

CN L-Alanine,

1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]sulfonyl]-L-prolyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-65-8 CAPLUS

CN L-Phenylalanine, 1-[(3-fluorophenyl)sulfonyl]-L-prolyl-4-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-66-9 CAPLUS

CN L-Alanine,

1-[[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]sulfonyl]-L-prolyl-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-69-2 CAPLUS

CN L-Phenylalanine, 1-[(3-fluorophenyl)sulfonyl]-2-methyl-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-70-5 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-72-7 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-73-8 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-5-methyl-L-prolyl-4-

Searched by John Dantzman 308-4488

fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-74-9 CAPLUS

CN L-Phenylalanine, N-[[1-[(3,5-dichlorophenyl)sulfonyl]-3-phenyl-2-azetidinyl]carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-75-0 CAPLUS

CN L-Phenylalanine,
1-[(3,5-dichlorophenyl)sulfonyl]-2-(2-propenyl)-L-prolyl-
4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-76-1 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-
(9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 217452-77-2 CAPLUS

CN L-Phenylalanine,
2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-
4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-78-3 CAPLUS

CN L-Phenylalanine,

(3R)-1-[(3,5-dichlorophenyl)sulfonyl]-3-methyl-L-prolyl-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 217452-79-4P 217452-80-7P 217452-81-8P
 217452-82-9P 217452-83-0P 217452-84-1P
 217452-85-2P 217452-86-3P 217452-87-4P
 217452-88-5P 217452-89-6P 217452-90-9P
 217452-91-0P 217452-92-1P 217452-93-2P
 217452-94-3P 217452-95-4P 217452-96-5P
 217452-97-6P 217452-98-7P 217452-99-8P
 217453-00-4P 217453-01-5P 217453-02-6P
 217453-03-7P 217453-04-8P 217453-05-9P
 217453-06-0P 217453-07-1P 217453-08-2P
 217453-09-3P 217453-10-6P 217453-11-7P
 217453-12-8P 217453-13-9P 217453-14-0P
 217453-15-1P 217453-16-2P 217453-17-3P
 217453-18-4P 217453-19-5P 217453-20-8P
 217453-21-9P 217453-22-0P 217453-23-1P
 217453-24-2P 217453-25-3P 217453-26-4P
 217453-28-6P 217453-29-7P 217453-31-1P
 217453-32-2P 217453-33-3P 217453-34-4P
 217453-35-5P 217453-36-6P 217453-37-7P
 217453-38-8P 217453-39-9P 217453-40-2P
 217453-41-3P 217453-44-6P 217458-10-1P

Searched by John Dantzman

308-4488


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic dipeptide derivs. as cell adhesion inhibitors)

RN 217452-79-4 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-cyano- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-80-7 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(aminocarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-81-8 CAPLUS


CN L-Phenylalanine, (3R)-1-[(3,5-dichlorophenyl)sulfonyl]-3-methyl-L-prolyl-4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-82-9 CAPLUS
 CN L-Phenylalanine,
 (3R)-1-[(3,5-dichlorophenyl)sulfonyl]-3-methyl-L-prolyl-4-
 (aminomethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217452-83-0 CAPLUS
 CN L-Phenylalanine,
 2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-
 4-(acetylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-84-1 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-

4-[[[(2-methylphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-85-2 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-

4-[[[(4-fluorophenyl)sulfonyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217452-86-3 CAPLUS

CN L-Phenylalanine,


2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-

4-[(ethoxycarbonyl)amino]- (9CI) (CA INDEX NAME)

Searched by John Dantzman

308-4488

Absolute stereochemistry.



RN 217452-87-4 CAPLUS

CN L-Phenylalanine,


2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-

4-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]amino]-
(9CI)


(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 217452-88-5 CAPLUS

CN L-Phenylalanine,


2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-

4-[[[4-(4-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman

308-4488




RN 217452-89-6 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-90-9 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-[(4-fluorobenzoyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217452-91-0 CAPLUS


CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-4-[[[(2-methylpropoxy)carbonyl]amino]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman

308-4488




RN 217452-92-1 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-
4-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217452-93-2 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-
4-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217452-94-3 CAPLUS


CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-
4-(1,1-dioxido-2-isothiazolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman

308-4488




RN 217452-95-4 CAPLUS

CN L-Phenylalanine,

2-methyl-1-[[3-(trifluoromethyl)phenyl]sulfonyl]-L-prolyl-
4-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-96-5 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-(4-
fluorobenzoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-97-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-(2-methoxybenzoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217452-98-7 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(4-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488

RN 217452-99-8 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-00-4 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-4-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-01-5 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-(2-nitrophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-02-6 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-03-7 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488

RN 217453-04-8 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-(2-aminophenyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-05-9 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-[2-(acetylamino)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-06-0 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-[4-(acetylamino)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-07-1 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-[2-(acetylamino)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-08-2 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-cyanophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488

RN 217453-09-3 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(4-cyanophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-10-6 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-11-7 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-methyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 217453-12-8 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-(phenylmethyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-13-9 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-butyl- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 217453-14-0 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-(cyanomethyl)-

Searched by John Dantzman 308-4488

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-15-1 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-(2-methoxyethyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-16-2 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-(2-ethoxyethyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




Searched by John Dantzman

308-4488


RN 217453-17-3 CAPLUS
 CN L-Tyrosine, 1-(phenylsulfonyl)-L-prolyl-O-(2-methoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-18-4 CAPLUS
 CN L-Tyrosine, 1-(phenylsulfonyl)-L-prolyl-O-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217453-19-5 CAPLUS
 CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-, 1-pyrrolidinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-20-8 CAPLUS
 CN L-Tyrosine, 1-(phenylsulfonyl)-L-prolyl-, 1-pyrrolidinecarboxylate (ester) (9CI) (CA INDEX NAME)

Searched by John Dantzman

308-4488


Absolute stereochemistry.



RN 217453-21-9 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-[2-(1,1-dimethylethoxy)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-22-0 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-,
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-23-1 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-(2-oxopropyl)-
(9CI) (CA INDEX NAME)

Searched by John Dantzman

308-4488


Absolute stereochemistry.



RN 217453-24-2 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-, 1-pyrrolidinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-25-3 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-[2-(1,1-dimethylethoxy)-2-oxoethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-26-4 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-28-6 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-(carboxymethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-29-7 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-O-(2-oxopropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-31-1 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-,
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-32-2 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-,
1H-pyrrole-2-carboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-33-3 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-,
Searched by John Dantzman 308-4488

methylphenylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-34-4 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-, diethylcarbamate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-35-5 CAPLUS


CN L-Tyrosine, 1-[(3-chlorophenyl)sulfonyl]-2-methyl-L-prolyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-36-6 CAPLUS
CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-,
bis(1-methylethyl)carbamate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-37-7 CAPLUS
CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-, benzoate (ester)
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 217453-38-8 CAPLUS
CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-,
cyclopentanecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-39-9 CAPLUS

CN L-Tyrosine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-O-(1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217453-40-2 CAPLUS

CN L-Histidine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217453-41-3 CAPLUS

CN L-Phenylalanine, 1-(phenylsulfonyl)-L-prolyl-.beta.-methyl-, (.beta.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by John Dantzman


308-4488



RN 217453-44-6 CAPLUS

CN L-Phenylalanine, 1-[(3,5-dichlorophenyl)sulfonyl]-2-methyl-L-prolyl-4-(1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-5-pyrimidinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217458-10-1 CAPLUS

CN L-Phenylalanine, N-[[3-[(3,5-dichlorophenyl)sulfonyl]-3-azabicyclo[3.1.0]hex-2-yl]carbonyl]-4-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





=> d bib abs hitstr 20

L8 ANSWER 20 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1998:795039 CAPLUS
 DN 130:52733
 TI Preparation of tyrosine derivatives as antiinflammatory agents
 IN Head, John Clifford; Archibald, Sarah Catherine; Warrellow, Graham John
 PA Celltech Therapeutics Limited, UK
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9854207	A1	19981203	WO 1998-GB1580	19980529
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9876674	A1	19981230	AU 1998-76674	19980529
PRAI	GB 1997-11143		19970530		
	GB 1997-22674		19971027		
	WO 1998-GB1580		19980529		
OS	MARPAT 130:52733				
GI					



AB Tyrosine derivs. I [R = R1X1, (Hal)3CSO2; R1 = optionally substituted
 Searched by John Dantzman 308-4488

alkyl or arom. group; R2, R3 = independently H, halo, alkyl, alkoxy, OH, NO2; R4 = H, Me; R5 = (CH2)_pCO2R8; R6 = H, alkyl; R7 = optionally substituted alkyl group, aryl, aralkyl; R8 = H, alkyl; Alk = alkylene chain; Hal1 = F, Cl; X1 = bond, (CH2)_n, CO, CH2CO, NHCO, CH2NHCO, SO2; X2 = CO, CO2, CONH, SO2; Y = S, S(O)_q; m = 0, 1; n = 1, 2; p = 0, 1; q = 1, 2] and the salts, solvates and hydrates thereof, are described. The compds. are able to inhibit the binding of .alpha.4 integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders. Thus, coupling of N-acetyl-D-thiopropine with L-tyrosine tert-Bu ester, followed by O-acylation with

2,6-dichlorobenzoyl

chloride and acidic deesterification, gave desired tyrosine deriv. II.

II

and related thiopropyltyrosine derivs. were tested for inhibition of .alpha.4 integrin-dependent cell adhesion, and generally have IC50 values of .ltoreq.1 .mu.M in .alpha.4.beta.1 and .alpha.4.beta.7 assays, and

IC50

values of .gtoreq. 50 .mu.M in assays of other integrins.

IT

217479-41-9P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of tyrosine derivs. as antiinflammatory agents)

RN 217479-41-9 CAPLUS

CN L-Tyrosine, N-[[(4S)-3-(methylsulfonyl)-4-thiazolidinyl]carbonyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 21

L8 ANSWER 21 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1998:568589 CAPLUS
 DN 129:175653
 TI Preparation of benzenesulfonamides as elastase inhibitors
 IN Nakae, Takahiko; Kato, Masashi; Fujita, Takehito; Kawabata, Kazuhito;
 Ohno, Hiroyuki
 PA Ono Pharmaceutical Co., Ltd., Japan
 SO U.S., 150 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5795890	A	19980818	US 1996-718722	19960924
	JP 09165365	A2	19970624	JP 1995-272058	19950927
	JP 09278742	A2	19971028	JP 1996-271341	19960924
	JP 2881688	B2	19990412		
	JP 10251218	A2	19980922	JP 1998-111630	19960924
	AU 9665837	A1	19970410	AU 1996-65837	19960925
	NO 9604045	A	19970401	NO 1996-4045	19960926
	CA 2186665	AA	19970328	CA 1996-2186665	19960927
	US 5998410	A	19991207	US 1998-31192	19980226
PRAI	JP 1995-272058		19950927		
	JP 1996-45663		19960224		
	JP 1996-271341		19960924		
	US 1996-718722		19960924		
OS	MARPAT 129:175653				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = C1-8 alkyl, C1-8 alkoxy, OH, etc.; n = 0-5; D
 = carbocyclic ring; R2, R3 = H, C1-4 alkyl, C1-4 alkoxy, etc.; R2R3 = C1-4
 alkylidene; CR2R3 = C3-7 cycloalkyl; R4 = C1-4 alkyl, C1-4 alkoxy; two of
 R4, attached to the benzene nucleus at ortho positions relative to each
 other, represent C3-5 alkylene; m = 0-4; R5, R6 = H, OH, C1-8 alkyl,
 etc.;

NR5R6 = heterocyclyl] and their salts, which have an inhibitory effect on
 elastase and therefore are useful in the prevention and/or the treatment
 of emphysema, rheumatoid arthritis, atherosclerosis, adult respiratory
 distress syndrome (ARDS), glomerular nephritis, myocardial infarction,
 idiopathic ulcerative colitis, and gingivitis, were prep'd. and
 formulated.

Thus, treatment of the ester II (prepn. described) with CF3CO2H in
 CH2Cl2/MeOPh afforded the title compd. III.HCl which showed IC50 of 0.055
 .mu.M against human polymorphonuclear elastase.

IT 190252-08-5P 190252-40-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
 Searched by John Dantzman 308-4488

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of benzenesulfonamides as elastase inhibitors)

RN 190252-08-5 CAPLUS

CN Glycine,


1-[[4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190252-40-5 CAPLUS


CN Benzeneacetic acid, .alpha.-ethyl-4-(1-pyrrolidinyl)-, 4-[[2-[[[(carboxymethyl)amino]carbonyl]-2,3-dihydro-1H-indol-1-yl]sulfonyl]phenyl ester (9CI) (CA INDEX NAME)



=> d bib abs hitstr 22

L8 ANSWER 22 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1998:424232 CAPLUS
 DN 129:95510
 TI Preparation of 2-piperazinecarboxamides as inhibitors of MMP or TNF
 IN Neya, Masahiro; Yamazaki, Hitoshi; Kayakiri, Natsuko; Sato, Kentaro; Oku, Teruo
 PA Fujisawa Pharmaceutical Co., Ltd., Japan; Neya, Masahiro; Yamazaki, Hitoshi; Kayakiri, Natsuko; Sato, Kentaro; Oku, Teruo
 SO PCT Int. Appl., 199 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827069	A1	19980625	WO 1997-JP4613	19971215
	W: AU, CA, CN, HU, IL, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	AU 9854122	A1	19980715	AU 1998-54122	19971215
	EP 948489	A1	19991013	EP 1997-947944	19971215
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI					
PRAI	AU 1996-4249		19961217		
	AU 1997-7156		19970603		
	AU 1997-8568		19970814		
	WO 1997-JP4613		19971215		
OS	MARPAT 129:95510				
GI					



AB The title compds. [I; A = SO₂, C(O); R₁ = (un)substituted aryl, heterocyclic, lower alkyl, lower alkenyl; R₂ = H, (un)substituted lower alkyl, aryl, heterocyclic; R₃ = (un)substituted lower alkyl, lower alkoxy, aryloxy, etc.; R₄ = H, (un)substituted lower alkyl, aryl, heterocyclic; R₅ = H, (un)substituted lower alkyl, aryl, heterocyclic; R₁₀ = OH, protected OH] and their pharmaceutically acceptable salts, useful for prophylactic and therapeutic treatment of MMP- or TNF.alpha.-mediated diseases, were prepd. Thus, treatment of a soln. of (2R)-1-(4-nitrobenzenesulfonyl)-4-

Searched by John Dantzman 308-4488

methanesulfonylpiperazine-2-[N-(2-tetrahydropyranyloxy)]carboxamide in MeOH with 10% HCl-MeOH afforded (2R)-I [R1 = 4-O2NC6H4SO2; R2 = R4 = R5 = H; R3 = Me; R10 = OH] which showed 95.3% inhibition of collagenase activity at 1×10^{-6} M.

IT **209591-46-8P**


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2-piperazinecarboxamides as inhibitors of MMP or TNF)

RN 209591-46-8 CAPLUS

CN Glycine, N-[[[(3R)-4-[[5-(4-fluorophenyl)-2-thienyl]sulfonyl]-3-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-1-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 24

L8 ANSWER 24 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1998:129595 CAPLUS

DN 128:140693

TI Preparation of

N-(.alpha.-carboxy-.alpha.-benothiazolylmethyl)tetrahydroquinolinesulfonamides as inhibitors of trypsin and thrombin

IN Brundish, Derek Edward; Kane, Peter Daniel; Walker, Clive Victor; Menear, Keith Allan; Le Grand, Darren Mark; Allen, Mark Christopher; Hayler, Judy D.; Herold, Peter; Butler, Paul Ian; Fullerton, Joseph Dawson; Smith, Garrick Paul; Wathey, William Bernard; Cockcroft, Xiao-Ling; Hatto, Julia Doris Ida

PA Ciba-Geigy A.-G., Switz.

SO Brit. UK Pat. Appl., 86 pp.



CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2312674	A1	19971105	GB 1996-9187	19960502
OS	MARPAT 128:140693				
GI					



AB Compds. of the general formula (I; A, B = H, a C1-5 alkyl which may be interrupted by one or more oxygen atoms, C1-5 alkenyl, alkoxyalkyl, hydroxyalkyl, alkylthioalkyl, alkylamino, dialkylamino or trialkylamino, or together form a methylene group, or together with the carbon atom to which they are attached form a C1-7 carboxylic ring; C = a group -R-X in which R is a C1-4 alkylene group optionally interrupted by oxygen or is a direct bond; X = an aminocarbonyl, carbonylamino, sulfonylamino, amino, azido or heterocyclic alkyl, or salts thereof) and their novel intermediates thereof (II; A, B, C = same as above) are prepd. They are potent and orally bioavailable inhibitors of serine protease, esp. trypsin

Searched by John Dantzman

308-4488

and thrombin, and are useful for the treatment and prophylaxis of various diseases attributed to thrombin-mediated or thrombin-assocd. actions and processes including thrombotic diseases such as myocardial infarction, stroke, pulmonary embolism, deep vein thrombosis, etc. They are also used

for decreasing the dosage of a thrombotic agent required to establish reperfusion or prevent reocclusion in a patient. Thus, 3-(1,2,3,4-tetrahydroquinolin-6-yl)propionic acid deriv. I (A = B = Me, C = CH₂CH₂CO₂H) was heated with (PhO)₂P(O)N₃ and Et₃N in toluene at 100.degree. for 2 h and the resulting oil I (A = B = Me, C = CH₂CH₂NCO) was stirred with MeNH₂ in CH₂Cl₂ at 20.degree. for 1 h to give I (A = B = Me, C = CH₂CH₂NHCONHMe). The title compds. I in vitro inhibited human thrombin with K_i values of 18-86 nM.

IT 202469-20-3P 202469-38-3P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of

N-(.alpha.-carboxy-.alpha.-benothiazolylmethyl)tetrahydroquinolinesulfonamides as inhibitors of trypsin and thrombin and antithrombotics)

RN 202469-20-3 CAPLUS

CN Glycine, N-[[8-[[[(1S)-1-(2-benzothiazolylmethyl)-2-[4-(2-fluoroethyl)-1-piperidinyl]-2-oxoethyl]amino]sulfonyl]-1,2,3,4-tetrahydro-3,3-dimethyl-6-quinolinyl]carbonyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na


RN 202469-38-3 CAPLUS

CN L-Serine,

N-[[8-[[[(1S)-1-(2-benzothiazolylmethyl)-2-[4-(2-fluoroethyl)-1-piperidinyl]-2-oxoethyl]amino]sulfonyl]-3,3-diethyl-1,2,3,4-tetrahydro-6-quinolinyl]carbonyl]- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488


Absolute stereochemistry.



=> d bib abs hitstr 25

L8 ANSWER 25 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1997:798601 CAPLUS
 DN 128:13436
 TI Preparation of tryptophan urea derivatives as tachykinin receptor antagonists
 IN Maccoss, Malcolm; Oi, Hongbo; Shah, Shrenik K.
 PA Merck and Co., Inc., USA
 SO Brit. UK Pat. Appl., 47 pp.
 CODEN: BAXXDU
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2311523	A1	19971001	GB 1997-5861	19970321
PRAI	US 1996-14003		19960325		
	GB 1996-11786		19960606		
OS	MARPAT 128:13436				
GI					



AB Substituted title azacycles I [Z = N, R = CH₂Ph, Ph, 2-MeOC₆H₄, 2-MeC₆H₄, R₁ = absent; Z = C, R = Ph, R₁ = NHOMe; R = CH₂Ph, 2-oxo-1,2,3,4-tetrahydroquinazolin-1-yl, R₁ = H; RZR₁ = spiro-fused 1-indanyl, 3-indenyl, 1-methylsulfonyl-2,3-dihydroindol-3-yl, 1-acetyl-2,3-dihydroindol-3-yl; R₂ = OCH₂Ph wherein the Ph is substituted with 0-3 groups halo, Me, or CF₃; or R₂ = NR₃-C₁-4-alkylphenyl wherein the C₁-4-alkyl may be linear or branched and the Ph may be substituted with 0-3 groups halo, Me, OMe, CF₃; R₃ = H, Me, Et] and pharmaceutically acceptable salts thereof are tachykinin receptor antagonists useful in

the treatment of inflammatory diseases, pain or migraine, and asthma. In particular, compds. I are neurokinin antagonists. Thus, amidation of 1.967 g Boc-Trp-OH (Boc = Me₃CO₂C) with 0.87 mL MeNHCH₂Ph gave 2.56 g of the corresponding amide, which underwent deprotection with CF₃CO₂H,

Searched by John Dantzman 308-4488

condensation with carbonyldiimidazole, and urea formation with spiro[1H-indene-1,4'-piperidine] hydrochloride to give title compd. II (L-743,516). I and related Trp derivs. showed IC50 values of >1000 to 1 nM for human neurokinin 1 (NK1) antagonist activity.


IT 199110-55-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of tryptophan urea derivs. as tachykinin receptor antagonists)

RN 199110-55-9 CAPLUS

CN L-Tryptophan, N-[[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indol-3,4'-piperidin]-1'-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



=> d bib abs hitstr 26

L8 ANSWER 26 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1997:390578 CAPLUS
 DN 127:5005
 TI Preparation of sulfamoylphenyl alkanoates as elastase inhibitors
 IN Nakae, Takahiko; Kato, Masashi; Fujita, Takehito; Kawabata, Kazuhito;
 Ohno, Hiroyuki
 PA Ono Pharmaceutical Co., Ltd., Japan
 SO Eur. Pat. Appl., 270 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 769498	A1	19970423	EP 1996-307048	19960927
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT,				
SE	JP 09165365	A2	19970624	JP 1995-272058	19950927
	JP 09278742	A2	19971028	JP 1996-271341	19960924
	JP 2881688	B2	19990412		
	JP 10251218	A2	19980922	JP 1998-111630	19960924
	AU 9665837	A1	19970410	AU 1996-65837	19960925
	NO 9604045	A	19970401	NO 1996-4045	19960926
	CA 2186665	AA	19970328	CA 1996-2186665	19960927
PRAI	JP 1995-272058		19950927		
	JP 1996-45663		19960224		
	JP 1996-271341		19960924		
OS	MARPAT 127:5005				
GI					



AB R1CR2R3CO2ZSO2NR5R6 [I; R1 = (un)substituted carbocyclic or heterocyclic ring; R2,R3 = H, halo, alkyl, Ph, etc.; R2R3 = alkylidene or atoms to complete a carbocyclic ring; R5,R6 = H, OH, alkyl, etc.; NR5R6 = heterocyclyl; Z = (un)substituted 1,4-phenylene] were prepd. Thus, (S)-4-(tert-butoxycarbonyl-1-pyrrolidinylsulfonyl)-2-methylphenol was esterified by 2-(4-pyrrolidinophenyl)butanoic acid (prepn. each given) to give title compd. II. Data for biol. activity of I were given.

IT 190252-08-5P 190252-40-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

Searched by John Dantzman 308-4488

(Preparation); USES (Uses)


(prepn. of sulfamoylphenyl alkanoates as elastase inhibitors)

RN 190252-08-5 CAPLUS


CN Glycine,

1-[[4-[1-oxo-2-[4-(1-pyrrolidinyl)phenyl]butoxy]phenyl]sulfonyl]-
L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 190252-40-5 CAPLUS

CN Benzeneacetic acid, .alpha.-ethyl-4-(1-pyrrolidinyl)-,
4-[[2-[[[(carboxymethyl)amino]carbonyl]-2,3-dihydro-1H-indol-1-yl]sulfonyl]phenyl ester (9CI) (CA INDEX NAME)

=> d bib abs hitstr 27

L8 ANSWER 27 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1997:346821 CAPLUS
 DN 126:317322
 TI Preparation of substituted 3-hydroxyquinoline-2-carboxamides as
 prolyl-4-hydroxylase inhibitors.
 IN Weidmann, Klaus; Baringhaus, Karl-Heinz; Tschank, Georg; Bickel, Martin
 PA Hoechst A.-G., Germany
 SO Eur. Pat. Appl., 55 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 765871	A1	19970402	EP 1996-115110	19960920
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT,				
SE	DE 19536263	A1	19970403	DE 1995-19536263	19950928
	CN 1216981	A	19990519	CN 1996-180274	19960430
	US 5719164	A	19980217	US 1996-675208	19960703
	US 5726305	A	19980310	US 1996-675155	19960703
	AU 9665838	A1	19970410	AU 1996-65838	19960926
	CN 1154365	A	19970716	CN 1996-122806	19960926
	CA 2186717	AA	19970329	CA 1996-2186717	19960927
	NO 9604093	A	19970401	NO 1996-4093	19960927
	JP 09124606	A2	19970513	JP 1996-276901	19960930
PRAI	DE 1995-19536263		19950928		
	DE 1996-19605170		19960213		
OS	MARPAT 126:317322				
GI					



AB Title compds. [I; A = (substituted) alkylene; B = (modified) carboxy, tetrazolyl, imidazolyl, 3-hydroxyisoxazolyl; R1-R5 = H, OH, halo, cyano, CF3, NO2, CO2H, alkyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkoxy, cycloalkoxyalkyl, aryl, aralkyl, aralkoxy, hydroxyalkyl, alkenyl, alkynyl, alkynyloxyalkyl, alkoxycarbonyl, alkylcarbonyloxy, arylcarbonyloxy, cinnamoyl, alkenylcarbonyl, arylcarbonyl, aralkoxycarbonyloxy, etc.; m = 0, 1], were prepd. as antifibrotics (no data). Thus, 3-benzyloxyquinoline-2-carboxylic acid (prepn. given) was coupled with glycine benzyl ester

Searched by John Dantzman 308-4488

tosylate using Et₃N/EtO₂CCl to give after hydrogenolysis
3-hydroxyquinoline-2-carboxylic acid N-(carboxymethyl)amide.


IT 189359-09-9P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted 3-hydroxyquinoline-2-carboxamides as
prolyl-4-hydroxylase inhibitors)

RN 189359-09-9 CAPLUS


CN Glycine, N-[[3-hydroxy-6-(phenylsulfonyl)-2-quinolinyl]carbonyl]- (9CI)
(CA INDEX NAME)



=> d bib abs hitstr 29

L8 ANSWER 29 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1995:777639 CAPLUS
 DN 123:198616
 TI Preparation of N-sulfonylindoline derivatives with affinity for
 vasopressin and oxytocin receptors
 IN Wagnon, Jean; de Cointet, Paul; Nisato, Dino; Plouzane, Claude;
 Sereadeil-Legal, Claudine; Tonnerre, Bernard
 PA Elf Sanofi, Fr.
 SO U.S., 50 pp. Cont.-in-part of U.S. Ser. No.737,655, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5338755	A	19940816	US 1992-923839	19920803
	FR 2665441	A1	19920207	FR 1990-9778	19900731
	FR 2665441	B1	19921204		
	IL 114934	A1	19960804	IL 1991-114934	19910730
	FR 2679903	A1	19930205	FR 1991-9908	19910802
	FR 2679903	B1	19931203		
	AU 9224758	A1	19930302	AU 1992-24758	19920731
	AU 658664	B2	19950427		
	BR 9205336	A	19931116	BR 1992-5336	19920731
	JP 06501960	T2	19940303	JP 1993-503337	19920731
	IL 117592	A1	19990411	IL 1992-117592	19920731
	NO 9301262	A	19930526	NO 1993-1262	19930401
	NO 180047	B	19961028		
	NO 180047	C	19970205		
	US 5397801	A	19950314	US 1994-240360	19940510
	US 5481005	A	19960102	US 1994-348150	19941128
	US 5578633	A	19961126	US 1995-458614	19950602
	FI 9800175	A	19980127	FI 1998-175	19980127
PRAI	FR 1990-9778		19900731		
	US 1991-737655		19910730		
	FR 1991-9908		19910802		
	IL 1991-99012		19910730		
	IL 1992-102703		19920731		
	WO 1992-FR758		19920731		
	US 1992-923839		19920803		
	FI 1993-1476		19930401		
	US 1993-923839		19930803		
	US 1994-240360		19940510		
	US 1994-348150		19941128		
OS	MARPAT 123:198616				
GI					



AB Title compds. I (R'1 = halo, C1-4 alkyl, HO, C1-4 alkoxy, PhCH2O, NC, F3C,

O2N, H2N; R'2 = C1-6 alkyl, C3-7 cycloalkyl, C5-7 cycloalkylene, (substituted) Ph, etc.; R'3 = H; R'4 = H2NCO, R'6R'7NCO wherein R'6R'7N = satd. 5-membered substituted N-heterocyclyl; R'5 = C1-4 alkyl, 1-, 2-naphthyl, (substituted) Ph, etc.; n = m = 0-2) or a salt thereof, are prepd. CH2BrCONMe2 (prepn. given) and 5-chloro-2-(tosylamino)phenyl cyclohexyl ketone were reacted to give 2-[N-tosyl-N-(dimethylcarbamoylmethyl)amino]-5-(chlorophenyl) cyclohexyl ketone which in THF was treated with Li diisopropylamide to give after workup trans-I (R'1n = 5-Cl, R'2 = cyclohexyl, R'3 = H, R'4 = Me2NCO, R'5 = 4-MeC6H4, m = 0). The IC50 of I affinity for oxytocin receptors was 10⁻⁵-10⁻⁸M.

IT **149129-32-8P 149129-46-4P 149129-47-5P**
149151-64-4P 149151-65-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonylindoline derivs. with affinity for vasopressin

and


oxytocin receptors)

RN 149129-32-8 CAPLUS

CN Glycine,

N-[[5-bromo-1-[(3,4-dimethoxyphenyl)sulfonyl]-3-(2-fluorophenyl)-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-N-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 149129-46-4 CAPLUS

CN Glycine,

N-[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-
2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-N-methyl-, cis- (9CI) (CA
INDEX NAME)

Relative stereochemistry.



RN 149129-47-5 CAPLUS

CN Glycine,


N-[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-
2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-N-methyl-, trans- (9CI)
(CA

INDEX NAME)

Searched by John Dantzman

308-4488

Relative stereochemistry.




RN 149151-64-4 CAPLUS

CN Glycine,

N-[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-
2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-N-ethyl-, cis- (9CI) (CA
INDEX NAME)

Relative stereochemistry.



RN 149151-65-5 CAPLUS


CN Glycine,

N-[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-
2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-N-propyl-, cis- (9CI) (CA

Searched by John Dantzman 308-4488

INDEX NAME)

Relative stereochemistry.




*Q5 in the claims
is not H.*


=> d bib abs hitstr 30

L8 ANSWER 30 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1994:409147 CAPLUS
 DN 121:9147
 TI Substituted azetidinones useful in the treatment of leukemia
 IN Davies, Philip; Doherty, James B.; Finke, Paul E.; Humes, John L.;
 Leudke,
 Edward S.; Maccoss, Malcolm; Mumford, Richard A.; Shah, Shrenik K.
 PA Merck and Co., Inc., USA
 SO Brit. UK Pat. Appl., 115 pp.
 CODEN: BAXXDU
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2266527	A1	19931103	GB 1993-5470	19930317
PRAI	US 1992-852870		19920317		
OS	MARPAT 121:9147				
GI					



I



III

AB Compds. I and salts for use in treatment of leukemia are claimed, wherein R is alkyl; R1 is alkyl or alkoxyalkyl; M is H, alkyl, hydroxyalkyl, haloalkyl, alkenyl, or alkoxyalkyl; X5 is H, alkyl, haloalkyl, alkenyl, alkynyl, CO2H, carboxyalkyl, etc.; X6 and X7 are independently H, alkyl, halo, CO2H, alkoxy, Ph, alkylcarbonyl, dialkylamino, PhO; or X6X7 forms 3,4-methylenedioxy or furan or thiophene ring; and X8 is H, alkyl, halo, alkoxy, or hydroxy. Also claimed are subsets of I, specific I, and antileukemic pharmaceutical compns. contg. I and selected addnl. drugs. Synthetic examples cover prepn. of several I and some related azetidinones. For example, 4-propionyloxy-3,3-diethylazetidin-2-one (prepn. given) was etherified with 4-HOC6H4CH2CO2CH2Ph via substitution of the propionate group, followed by debenzylation, resoln., and esterification with allyl bromide to give (S)-3,3-diethyl-4-[(4-allyloxycarbonylmethyl)phenoxy]azetidin-2-one (II). Reaction of II with (R)-.alpha.-allylbenzofuran-5-ylmethyl isocyanate (prepn. given) at the 1-position, followed by deprotection of the allyl ester and hydrogenation,

Searched by John Dantzman 308-4488

gave title compd. III. Kinetic results (mostly 2nd order rate consts.) for inhibition of proteinase 3 and/or elastase by both I and a large no. of other azetidinones are given.

IT 127020-97-7


RL: RCT (Reactant)

(protease-inhibiting activity of)

RN 127020-97-7 CAPLUS

CN Glycine, N-[[3-ethyl-1-[(4-methylphenyl)sulfonyl]-4-oxo-2-azetidinyl]carbonyl]-N-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> d bib abs hitstr 31


L8 ANSWER 31 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1993:539091 CAPLUS
 DN 119:139091
 TI Preparation of 1-phenylsulfonyl-3-hydroxyindoline-2-carboxamides as
 oxytocin and vasopressin antagonists
 IN Wagnon, Jean; Serradeil-Legal, Claudine; Tonnerre, Bernard; Plouzane,
 Claude; Nisato, Dino
 PA Elf Sanofi, Fr.
 SO Eur. Pat. Appl., 71 pp.
 CODEN: EPXXDW
 DT Patent
 LA French
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 526348	A1	19930203	EP 1992-402213	19920803
	EP 526348	B1	19980218		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	FR 2679903	A1	19930205	FR 1991-9908	19910802
	FR 2679903	B1	19931203		
	CA 2093221	AA	19930203	CA 1992-2093221	19920731
	CA 2093221	C	19980922		
	WO 9303013	A1	19930218	WO 1992-FR758	19920731
	W: AU, BR, CA, CS, FI, HU, JP, KR, NO, RU				
	AU 9224758	A1	19930302	AU 1992-24758	19920731
	AU 658664	B2	19950427		
	ZA 9205781	A	19930302	ZA 1992-5781	19920731
	BR 9205336	A	19931116	BR 1992-5336	19920731
	JP 06501960	T2	19940303	JP 1993-503337	19920731
	LT 3064	B	19941025	LT 1992-114	19920731
	LV 10091	B	19950420	LV 1992-87	19920731
	HU 68927	A2	19950828	HU 1993-951	19920731
	IL 102703	A1	19970318	IL 1992-102703	19920731
	JP 2633085	B2	19970723	JP 1992-503337	19920731
	IL 117592	A1	19990411	IL 1992-117592	19920731
	AT 163289	E	19980315	AT 1992-402213	19920803
	ES 2117038	T3	19980801	ES 1992-402213	19920803
	NO 9301262	A	19930526	NO 1993-1262	19930401
	NO 180047	B	19961028		
	NO 180047	C	19970205		
	US 5481005	A	19960102	US 1994-348150	19941128
	AU 9511541	A1	19950504	AU 1995-11541	19950203
	AU 691223	B2	19980514		
	FI 9800175	A	19980127	FI 1998-175	19980127
PRAI	FR 1991-9908		19910802		
	FR 1990-9778		19900731		
	US 1991-737655		19910730		
	IL 1992-102703		19920731		
	WO 1992-FR758		19920731		
	FI 1993-1476		19930401		
	US 1993-923839		19930803		
	US 1994-240360		19940510		
OS	MARPAT 119:139091				

Searched by John Dantzman

308-4488

GI



AB Title compds. [I; R¹ = OH, halo, alkyl, alkoxy, etc.; R² = (cyclo)alkyl, (nitro)phenyl, etc.; R⁵ = alkyl, (nitro)phenyl, naphthyl, etc.; R⁶ = alkyl; R⁶, R⁷ = 4-piperidinyl, 3-azetidiny, etc.; NR⁶R⁷ = (thio)morpholino, thiazolidino, piperazino, etc.; m, n = 0-2] were prepd. Thus, 2-amino-5-bromo-2'-fluorobenzophenone was amidated by 3,4-(MeO)₂C₆H₃SO₂Cl and the product N-alkylated by BrCH₂CONMeCH₂CO₂Me to give, after cyclization of the product, title compd. II. I had IC₅₀ of 10⁻⁹, and 10⁻⁵ to 10⁻⁸ M, against vasopressin and oxytocin binding, resp., in vitro.

IT 149129-32-8P 149129-46-4P 149129-47-5P

149151-64-4P 149151-65-5P


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as oxytocin and vasopressin antagonist)

RN 149129-32-8 CAPLUS

CN Glycine,

N-[[5-bromo-1-[(3,4-dimethoxyphenyl)sulfonyl]-3-(2-fluorophenyl)-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-N-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 149129-46-4 CAPLUS

CN Glycine,

N-[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-
2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-N-methyl-, cis- (9CI) (CA
INDEX NAME)

Relative stereochemistry.



RN 149129-47-5 CAPLUS


CN Glycine,

N-[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-
2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-N-methyl-, trans- (9CI)
(CA
INDEX NAME)

Searched by John Dantzman

308-4488

Relative stereochemistry.




RN 149151-64-4 CAPLUS

CN Glycine,

N-[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-
2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-N-ethyl-, cis- (9CI) (CA
INDEX NAME)

Relative stereochemistry.




RN 149151-65-5 CAPLUS

CN Glycine,

N-[[5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-
2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-N-propyl-, cis- (9CI) (CA
Searched by John Dantzman 308-4488

INDEX NAME)



Relative stereochemistry.



=> d bib abs hitstr 35

L8 ANSWER 35 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1990:478146 CAPLUS
 DN 113:78146
 TI Substituted azetidinones as anti-inflammatory and antidegenerative agents
 IN Shah, Shrenik K.; Finke, Paul E.; Doherty, James B.; Barker, Peter L.;
 Hagmann, William; Dorn, Conrad P.; Firestone, Raymond A.
 PA Merck and Co., Inc., USA
 SO Eur. Pat. Appl., 45 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 337549	A1	19891018	EP 1989-200864	19890406
	EP 337549	B1	19951004		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 128704	E	19951015	AT 1989-200864	19890406
	ES 2079373	T3	19960116	ES 1989-200864	19890406
	ZA 8902549	A	19891129	ZA 1989-2549	19890407
	CA 1337990	A1	19960123	CA 1989-595997	19890407
	AU 8932630	A1	19891012	AU 1989-32630	19890410
	AU 621865	B2	19920326		
	DK 8901705	A	19891012	DK 1989-1705	19890410
	DK 169329	B1	19941010		
	FI 8901689	A	19891012	FI 1989-1689	19890410
	NO 8901470	A	19891012	NO 1989-1470	19890410
	CN 1037144	A	19891115	CN 1989-103271	19890410
	HU 50761	A2	19900328	HU 1989-1708	19890410
	JP 02006471	A2	19900110	JP 1989-91723	19890411
	JP 2736113	B2	19980402		
	US 5229510	A	19930720	US 1992-816982	19920103
	AU 9218582	A1	19920910	AU 1992-18582	19920625
	AU 660026	B2	19950608		
	LV 11459	B	19961220	LV 1996-24	19960201
PRAI	US 1988-179688		19880411		
	US 1983-557030		19831201		
	US 1985-721811		19850410		
	US 1986-842834		19860327		
	US 1987-89797		19870827		
	US 1989-388771		19890802		
	US 1990-597617		19901015		
	US 1990-608607		19901031		
	US 1991-719653		19910612		
	US 1991-720976		19910625		
	US 1991-720977		19910625		
	US 1991-735696		19910725		
	US 1991-761191		19910920		
	US 1992-852854		19920317		
	US 1992-891614		19920601		
OS	MARPAT 113:78146				
GI					



AB The title compds. I (R, R1 = C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl; M = H, C1-6 alkyl, C2-6 alkenyl, etc.; X5 = H, C1-6 alkyl, C2-6 alkenyl, alkynyl;

X6 = H, C1-6 alkyl, halo, CO2H) were prepd. I are elastase inhibitors and

therefore are useful antiinflammatory and antidegenerative agents.

(3R,4S)-1-(Benzylaminocarbonyl)-3-ethyl-3-methyl-4-(4-carboxyphenoxy)azetidin-2-one was prepd. in 4 steps from (3R,4S)-1-tert-butyltrimethylsilyl-3-methylazetidin-2-one-4-carboxylic acid. For azetidinone II, the second order rate const. of inactivation

of

elastase is 1501.

IT **127020-97-7**


RL: RCT (Reactant)

(elastase inhibiting activity of)

RN 127020-97-7 CAPLUS


CN Glycine, N-[[3-ethyl-1-[(4-methylphenyl)sulfonyl]-4-oxo-2-azetidinyl]carbonyl]-N-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




=> d bib abs hitstr 36

L8 ANSWER 36 OF 61 CAPLUS COPYRIGHT 2000 ACS
AN 1990:191617 CAPLUS
DN 112:191617
TI Some derivatives of N-acyl derivatives of D-penicillamine: synthesis and antihypertensive effect
AU Granik, V. G.; Grizik, S. I.; Faermark, I. F.; Shvarts, G. Ya.; Solov'eva, N. P.; Chistyakov, V. V.; Mashkovskii, M. D.
CS VNKhFI, Moscow, USSR
SO Khim.-Farm. Zh. (1989), 23(11), 1320-3
CODEN: KHFZAN; ISSN: 0023-1134
DT Journal
LA Russian
GI



AB Acylation of D-penicillamine with N-tosylpyroglutamic acid chloride gave
I which was ring cleaved with N₂H₄ to give
H₂NNHCO(CH₂)₂CH(NHTs)CONHCH(CO₂H)
C(SH)Me₂.N₂H₄ (II) (where Ts = p-toluenesulfonyl). I and II showed
angiotensin I converting enzyme (kinase II) inhibiting activity in rats.
Both I and II showed antihypertensive activity, II being twice more
active than I.
IT **126794-82-9P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(prepn. and antihypertensive activity of)
RN 126794-82-9 CAPLUS
CN D-Valine, 3-mercapto-N-[1-[(4-methylphenyl)sulfonyl]-5-oxo-L-prolyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 37

L8 ANSWER 37 OF 61 CAPLUS COPYRIGHT 2000 ACS

AN 1990:118534 CAPLUS

DN 112:118534

TI Preparation of 1-sulfo-2-oxoazetidines as antibacterial agents

IN Ochiai, Michihiko; Kishimoto, Shoji; Matsuo, Taisuke

PA Takeda Chemical Industries, Ltd., Japan

SO U.S., 252 pp. Cont.-in-part of U.S. Ser. No. 326,938.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4782147	A	19881101	US 1983-499802	19830531
	WO 8201873	A1	19820610	WO 1980-JP297	19801205
	W: MC				
	WO 8203859	A1	19821111	WO 1981-JP103	19810430
	W: MC				
	WO 8300689	A1	19830303	WO 1981-JP183	19810821
	W: MC				
	WO 8301063	A1	19830331	WO 1981-JP252	19810924
	W: MC				
	US 4822788	A	19890418	US 1981-326938	19811203
	JP 58210061	A2	19831207	JP 1982-93463	19820531
	JP 04066865	B4	19921026		
	US 4572801	A	19860225	US 1983-499801	19830531
	GB 2156350	A1	19851009	GB 1985-9070	19850409
	GB 2156350	B2	19860604		
	NO 8700981	A	19831031	NO 1987-981	19870310
	FI 8801563	A	19880405	FI 1988-1563	19880405
PRAI	WO 1980-JP297		19801205		
	WO 1981-JP103		19810430		
	WO 1981-JP183		19810821		
	WO 1981-JP252		19810924		
	US 1981-326938		19811203		
	JP 1982-93463		19820531		
	WO 1981-WO103		19810430		
	WO 1981-WO183		19810821		
	WO 1981-WO252		19810924		
	JP 1982-73728		19820430		
	US 1982-405592		19820805		
	GB 1983-10520		19830419		
	FI 1983-1457		19830428		
	NO 1983-1514		19830429		
OS	MARPAT 112:118534				
GI					



AB The title compds. [I; R = H, N3, halo, NH2, acylamino, OR5, SOnR5, P(O)(OR5)2, SSR5, C-attached org. residue; R1 = (protected) NH2, acylamino; R5 = org. residue; X = H, MeO; n = 0-2] and their salts were prepd. 2-Oxoazetidine II [R1 = PhCH2O2CNH, R2 = OMe, R3 = 2,4-(MeO)2C6H3CH2] (prepn. from corresponding 3-amino deriv. given] was stirred 3 h at 90-95.degree. with K2S2O8 in aq. MeCN contg. K2HPO4 to

give

II (R1 and R2 as above, R3 = H) which was stirred 19 h in THF contg. aq. NH3 to give II (R1 as above, R2 = NH2, R3 = H). The latter was hydrogenolyzed over Pd/C and the product stirred with 4-O2NC6H4CH2O2CCMe2ON:CQCOC1 [Q = 2-(2-chloroacetamido)-4-thiazolyl]

(prepn.

given) to give II (R1 = 4-O2NC6H4CH2O2CCMe2ON:CQCONH, R2 = NH2, R3 = H) which was treated overnight at 4.degree. with SO3.DMF in DMF to give, after ion-exchange chromatog., II (R1, R2 unchanged, R3 = SO3Na). Deprotection of the latter in 2 steps gave title compd. III, which had min. inhibitory concn. of 1.56 and 0.39 .mu.g/mL against Enterobacter cloacae IFO 129537 and Klebsiella pneumoniae TN 1711, resp.

IT **84186-86-7P 84187-30-4P 84237-27-4P 84237-28-5P**


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as antibacterial agent)

RN 84186-86-7 CAPLUS

CN L-Alanine, N-[[3-[[[(2-amino-4-thiazolyl)[[1,1-dimethyl-2-[(4-nitrophenyl)methoxy]-2-oxoethoxy]imino]acetyl]amino]-4-oxo-1-sulfo-2-azetidiny]carbonyl]-, monosodium salt, [2R-[2.alpha.,3.alpha.(Z)]]-

(9CI)


(CA INDEX NAME)



● Na


RN 84187-30-4 CAPLUS

CN L-Alanine, N-[[3-[[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-4-oxo-1-sulfo-2-azetidiny]carbonyl]-, [2S-[2.alpha.,3.alpha.(Z)]]- (9CI) (CA INDEX NAME)



RN 84237-27-4 CAPLUS


CN L-Alanine, N-[[3-[[[(2-amino-4-thiazolyl)[[1,1-dimethyl-2-[(4-nitrophenyl)methoxy]-2-oxoethoxy]imino]acetyl]amino]-4-oxo-1-sulfo-2-azetidiny]carbonyl]-, monosodium salt, [2S-[2.alpha.,3.alpha.(Z)]]- (9CI) (CA INDEX NAME)



● Na

RN 84237-28-5 CAPLUS

CN L-Alanine, N-[[3-[[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-4-oxo-1-sulfo-2-azetidiny]carbonyl]-, [2R-[2.alpha.,3.alpha.(Z)]]- (9CI) (CA INDEX NAME)




=> d bib abs hitstr 38

L8 ANSWER 38 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1989:594450 CAPLUS
 DN 111:194450
 TI Preparation of 3-(acylamino)-1-sulfoazetidinones and their salts as
 antibacterial agents
 IN Sykes, Richard B.; Parker, William L.; Cimarusti, Christopher M.; Koster,
 William H.; Slusarchyk, William A.
 PA Squibb, E. R., and Sons, Inc., USA
 SO U.S., 70 pp. Cont.-in-part of U.S. Ser. No. 188,893, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4775670	A	19881004	US 1981-226562	19810119
	BE 887428	A1	19810806	BE 1981-203736	19810206
	SE 8100861	A	19810808	SE 1981-861	19810206
	SE 457954	B	19890213		
	SE 457954	C	19890713		
	FI 8100352	A	19810808	FI 1981-352	19810206
	FI 80271	B	19900131		
	FI 80271	C	19900510		
	DK 8100523	A	19810808	DK 1981-523	19810206
	DK 166280	B	19930329		
	DK 166280	C	19930830		
	NO 8100410	A	19810810	NO 1981-410	19810206
	NO 161065	B	19890320		
	NO 161065	C	19890628		
	AU 8166985	A1	19810813	AU 1981-66985	19810206
	AU 548896	B2	19860109		
	GB 2071650	A	19810923	GB 1981-3655	19810206
	GB 2071650	B2	19841205		
	DE 3104145	A1	19811217	DE 1981-3104145	19810206
	DE 3104145	C2	19990512		
	ZA 8100808	A	19820224	ZA 1981-808	19810206
	ES 499171	A1	19820601	ES 1981-499171	19810206
	DD 156180	C	19820804	DD 1981-227473	19810206
	FR 2509299	A1	19830114	FR 1981-2372	19810206
	FR 2509299	B1	19850830		
	PL 126840	B1	19830930	PL 1981-229569	19810206
	PL 128184	B1	19840131	PL 1981-234758	19810206
	AT 8100550	A	19841215	AT 1981-550	19810206
	AT 378367	B	19850725		
	RO 86528	B3	19850315	RO 1981-111297	19810206
	HU 35669	A2	19850729	HU 1981-296	19810206
	HU 191029	B	19861228		
	CH 651020	A	19850830	CH 1981-816	19810206
	CH 653993	A	19860131	CH 1981-5565	19810206
	CS 244105	B2	19860717	CS 1981-909	19810206
	IL 62082	A1	19860831	IL 1981-62082	19810206
	SU 1272981	A3	19861123	SU 1981-3248001	19810206
	JP 04027226	B4	19920511	JP 1981-17379	19810206

Searched by John Dantzman 308-4488

CA 1338670	A1	19961022	CA 1981-370320	19810206
EP 48953	A2	19820407	EP 1981-107572	19810923
EP 48953	A3	19820818		
EP 48953	B1	19880309		
R: IT				
GB 2139618	A1	19841114	GB 1983-33191	19831213
GB 2139618	B2	19850501		
AT 8402169	A	19851015	AT 1984-2169	19840705
AT 380472	B	19860526		
AT 8402168	A	19860115	AT 1984-2168	19840705
AT 381089	B	19860825		
US 4529698	A	19850716	US 1984-652694	19841105
CS 244146	B2	19860717	CS 1984-9615	19841211
AU 8545748	A1	19851107	AU 1985-45748	19850802
AU 569407	B2	19880128		
NO 8600225	A	19810810	NO 1986-225	19860122
NO 170015	B	19920525		
NO 170015	C	19920902		
SE 8602193	A	19860514	SE 1986-2193	19860514
SE 500216	C2	19940509		
SE 8602194	A	19860514	SE 1986-2194	19860514
JP 02160764	A2	19900620	JP 1989-304538	19891122
JP 06023188	B4	19940330		
JP 05086023	A2	19930406	JP 1991-121251	19910527
JP 06070006	B4	19940907		
CA 1340253	A1	19981215	CA 1996-617057	19960828
PRAI US 1980-119276		19800207		
US 1980-188893		19800929		
US 1981-226562		19810119		
US 1981-230837		19810202		
AT 1981-550		19810206		
CA 1981-370320		19810206		
CH 1981-816		19810206		
CS 1981-909		19810206		
GB 1981-3655		19810206		
OS MARPAT 111:194450				
GI				



AB The title compds. [I; M = H, cation; R1 = H, carboxylic acid-derived acyl;

R2 = H, alkoxy; R3, R4 = H, alkyl, cycloalkyl, (un)substituted Ph, or 1 of

R3, R4 = H and the other = alkoxycarbonyl, 1-alkenyl, 1-alkynyl, CH:CHPh, C.tplbond.CPh] were prepd. HOCHMeCH(NHCO2CMe3)CONHOCH2Ph (prepn. given) was stirred .apprx.16 h in THF under N with Ph3P and EtO2CN:NCO2Et to give

azetidinone II (R1 = Me3O2C, R5 = OCH2Ph) which was converted in 3 steps to II (R1 = PhCH2O2C, R5 = H). The latter was stirred 1 h with SO3 in DMF

to give, after salt formation, II (R1 = PhCH2O2C, R5 = SO3- N+Bu4) which was hydrogenolyzed over Pd/C and the product stirred .apprx.16 h with

(Z)-2-amino-.alpha.-[[1-[(diphenylmethoxy)carbonyl]-1-methylethoxy]imino]-4-thiazoleacetic acid in DMF contg. DCC and N-hydroxybenzotriazole to give, after sapon., title compd. III which had min. inhibitory concn. of <0.05 .mu.g/mL against, e.g., Klebsiella pneumoniae 9527 and Proteus mirabilis 3855.

IT 42057-23-8


RL: RCT (Reactant)

(reaction of, in prepn. of antibacterial agents)

RN 42057-23-8 CAPLUS

CN Benzeneacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]-, (R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



=> d bib abs hitstr 39

L8 ANSWER 39 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1989:172993 CAPLUS
 DN 110:172993
 TI Preparation of cephalosporins and antibiotic pharmaceutical compositions containing them
 PA Huirui Co., Panama
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 135 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 85105749	A	19861231	CN 1985-105749	19850701
GI					



AB Prepn. of cephalosporins and antibiotic pharmaceutical compns. contg. them. The title compds. [I; R = (substituted) Ph, cyclohexenyl, HOCHMe, etc.; R1 = (substituted) carbamoyl, (substituted) benzoyl, other acyl groups; R2 = CH2OAc, CH2O2CNH2, heterocyclylthiomethyl, pyrrolidinomethyl, etc.], useful as antibiotics (no data), are prepd.

via reaction of cephems II (X = alkylthio, PhS, PhCH2S) or their O-protected derivs. with HONH2, its acid addn. salts, or its O-protected derivs. in the presence of ions of Hg, Ag, Pb, Cu, or Tl. HONH2.HCl in DMF was added

to a soln. of II (X = MeS, R = Ph, R1 = 4-ethyl-2,3-dioxo-1-piperazinylcarbonyl, R2 = 1,2,3-thiadiazol-5-ylthiomethyl) tert-Bu ester in DMF contg. Hg acetate at -50.degree. and the resulting mixt. was allowed to warm to 0.degree. over 1 h to give I (R = Ph, R1 = 4-ethyl-2,3-dioxo-1-piperazinylcarbonyl, R2 = 1,2,3-thiadiazol-5-ylthiomethyl) tert-Bu ester, which was hydrolyzed to give the free acid.


IT 103587-85-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as intermediate for B-lactam antibiotics)

RN 103587-85-5 CAPLUS

CN L-Threonine, N-[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 42057-23-8


RL: RCT (Reactant)

(reaction of, in prepn. of cephem derivs.)

RN 42057-23-8 CAPLUS

CN Benzeneacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]-, (R)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



=> d bib abs hitstr 40

L8 ANSWER 40 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1988:112072 CAPLUS
 DN 108:112072
 TI 7-Hydroxyaminocephalosporin antibiotics, their preparation, and their use
 IN Greengrass, Colin W.; Hoople, David W. T.; Howarth, Thomas T.
 PA Pfizer Inc., USA
 SO U.S., 16 pp. Cont.-in-part of U.S. Ser. No. 749,915.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4684642	A	19870804	US 1986-836771	19860305
	US 4684641	A	19870804	US 1985-749915	19850627
PRAI	US 1985-749915		19850627		
	GB 1985-31202		19851218		
	GB 1984-16498		19840628		
	GB 1984-25751		19841011		
GI					




AB Cephalosporins I [Q = H, radical forming a metabolically labile ester; R
 = thiazolyl, thiadiazolyl, furyl, pyridyl; amide side chain is D or DL; R1
 = Q1; R4 = alkyl, alkylsulfonyl; n = 1, 2; R2 = CH2OAc, CH2O2CNH2, Q2 (m =
 1, 2; each R3 independently = H, alkyl), CH2SX [X = (un)substituted
 heterocyclyl]] or a pharmaceutically acceptable cationic salt thereof,
 when Q = H or R2 contains an acidic function, useful as antibiotics (no
 data), were prepd. 7.alpha.-Hydroxyamino-7.beta.-[DL-2-(2-oxo-3-
 methylsulfonylimidazolidin-1-ylcarbonylamino)-2-(thiazol-4-
 yl)acetamido]cephalosporanic acid (II) was prepd. in 4 steps from
 DL-2-amino-2-(thiazol-4-yl)acetic acid (III) and 2-oxo-3-
 methylsulfonylimidazolidin-1-ylcarbonyl chloride (IV).
 IT 112111-02-1P 112111-21-4P 112111-22-5P
 113141-73-4P

Searched by John Dantzman 308-4488

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, in synthesis of cephalosporanic antibiotic)


RN 112111-02-1 CAPLUS

CN 1,2,3-Thiadiazole-4-acetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 112111-21-4 CAPLUS

CN 3-Pyridineacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 112111-22-5 CAPLUS

CN 2-Furanacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 113141-73-4 CAPLUS


CN 4-Thiazoleacetic acid, .alpha.-[[[1-(methylsulfonyl)-2-oxo-3-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 41

L8 ANSWER 41 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1988:37505 CAPLUS
 DN 108:37505
 TI Preparation of 7.beta.-acetamido-7.alpha.-hydroxyaminocephemcarboxylic acids as antibiotics
 IN Greengrass, Colin William; Howarth, Thomas Trefor; Hoople, David William Thomas
 PA Pfizer Ltd., UK
 SO Brit. UK Pat. Appl., 17 pp.
 CODEN: BAXXD
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2184722	A1	19870701	GB 1986-29677	19861211
PRAI	GB 1985-31202	19851218			
GI					



AB The title compds. I [R = unsubstituted thiazolyl, thiadiazolyl, furyl, pyridyl; R2 = CH2OAc, CH2CONH2, Q1 (wherein R3 = H, alkyl; m = 1,2), CH2SR4 wherein R4 = (un)substituted heterocyclyl; R1 = Q2 (wherein R5 = alkyl, sulfonylalkyl; n = 1, 2), useful as antibiotics (no data), were prepd. Condensation of DL-2-(2-oxo-3-methylsulfonylimidazolidin-1-

Searched by John Dantzman 308-4488


ylcarbonylamino)-2-(thiazol-4-yl)acetic acid with benzhydryl 7.beta.-amino-7.alpha.-methylthiocephalosporanate gave the corresponding amide, which was deprotected with PhOMe/CF₃CO₂H to give cephem deriv. DL-II (R = SMe) (III). III was successively treated with Hg(OAc)₂ and NH₂OH.HCl in DMF to give the cephem antibiotic II (R = NH₂OH).

IT 112111-22-5

RL: RCT (Reactant)
(acylation of)

RN 112111-22-5 CAPLUS

CN 2-Furanacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




IT 112111-21-4

RL: RCT (Reactant)
(amidation of)

RN 112111-21-4 CAPLUS

CN 3-Pyridineacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




IT 112111-02-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and amidation of, in synthesis of cephalosporin antibiotic)

RN 112111-02-1 CAPLUS

CN 1,2,3-Thiadiazole-4-acetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




IT 112110-97-1P 112111-22-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antibiotic intermediate)


RN 112110-97-1 CAPLUS

CN 4-Thiazoleacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 112111-22-5 CAPLUS

CN 2-Furanacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 42

L8 ANSWER 42 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1987:497096 CAPLUS
 DN 107:97096
 TI Synthesis of N.alpha.-(tosylprolylglycyl)- and N.alpha.-(tosylglycylprolyl)-4-amidinophenylalanine amides as inhibitors of thrombin
 AU Voigt, B.; Wagner, G.
 CS Sekt. Biowiss., Karl-Marx-Univ., Leipzig, DDR-7010, Ger. Dem. Rep.
 SO Pharmazie (1986), 41(6), 378-81
 CODEN: PHARAT; ISSN: 0031-7144
 DT Journal
 LA German
 OS CASREACT 107:97096
 GI




AB Title compds. I (Tos = tosyl; X-X1 = Pro-Gly, Gly-DL-Pro, Gly-Pro; NRR1 = piperidino, pyrrolidino, morpholino, NHBu) were prepd. from the corresponding cyano compds. II via thioamides III and thioimidic esters IV. Tos-X-X1-OH (X-X1 = Pro-Gly, Gly-DL-Pro) were coupled with 4-NCC6H4CH2CH2CH(NH2)CO2H by active ester or mixed anhydride methods to give the corresponding tripeptides, which were amidated with the appropriate amine to give the corresponding II. Peptide V [R2 = PhCH2O2C (Z)] was Z-deblocked and then coupled with Tos-Gly-Cl to give V (R2 = Tos-Gly), which was amidated to give amides II (X-X1 = Gly-Pro; NRR1 =

Searched by John Dantzman 308-4488


same). I an be used as thrombin inhibitors.
IT **109947-74-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and peptide coupling of, with cyanophenylalanine)
RN 109947-74-2 CAPLUS
CN Glycine, N-[1-[(4-methylphenyl)sulfonyl]-L-prolyl]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




=> d bib abs hitstr 43

L8 ANSWER 43 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1987:458954 CAPLUS
 DN 107:58954
 TI Synthesis and properties of
 2H-4-hydroxy-2,5,7-trimethylpyrido[3,2-e]-1,2-
 thiazine-1,1-dioxide-3-carboxamides
 AU Zawisza, T.; Malinka, W.
 CS Dep. Chem. Drugs, Sch. Med., Wroclaw, Pol.
 SO Farmaco, Ed. Sci. (1986), 41(11), 892-8
 CODEN: FRPSAX; ISSN: 0430-0920
 DT Journal
 LA English
 GI



AB Rearrangement of pyridoisothiazolinoneacetate I with EtO⁻ gave
 pyridothiazinecarboxylate II (R = OEt). Reaction of II (R = OEt) with
 amines gave amides II (R = NH-2-pyridyl, NPh, NH-2-thiazolyl, etc.)
 (III). III show antiinflammatory and immunosuppressive activity.
 IT **109418-00-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 109418-00-0 CAPLUS
 CN Glycine, N-[(4,6-dimethyl-2-sulfo-3-pyridinyl)carbonyl]- (9CI) (CA INDEX
 NAME)



=> d bib abs hitstr 45


L8 ANSWER 45 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1987:119555 CAPLUS
 DN 106:119555
 TI Antibiotic isoxazole derivatives and their use
 IN Yoshioka, Koichi; Harada, Setsuo; Ochiai, Michihiko
 PA Takeda Chemical Industries, Ltd. , Japan
 SO Eur. Pat. Appl., 188 pp.
 CODEN: EPXXDW

DT Patent
 LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 191989	A1	19860827	EP 1985-309197	19851217
	EP 191989	B1	19920902		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	WO 8603752	A1	19860703	WO 1984-JP602	19841218
	W: MC				
	WO 8700178	A1	19870115	WO 1985-JP358	19850625
	W: MC				
	HU 41773	A2	19870528	HU 1985-4822	19851217
	HU 204266	B	19911230		
	AT 80162	E	19920915	AT 1985-309197	19851217
PRAI	WO 1984-JP602	19841218			
	WO 1985-JP358	19850625			
	JP 1985-195075	19850904			
	JP 1985-253188	19851111			
	EP 1985-309197	19851217			

GI



AB The title compds. (I; R1 = H2N, acylamino, alkenylamino, thioamino, etc.; R2 = CO2H, CO2R3, CONR4R5; R3 = alkyl, alkenyl, aryl, cycloalkyl, heterocyclyl, silyl; R4, R5 = H, alkyl, aryl, cycloalkyl, alkenyl, heterocyclyl, or NR4R5 = heterocyclyl, etc.; X = H, MeO, HCONH) and their salts, were prepd. Thus, diphenylmethyl 2-[(4S)-4-amino-3-oxo-2-isoxazolidinyl]-5-oxo-2-tetrahydrofuran carboxylate was added to a soln.

in

DMF of 2-(2-chloroacetamido-4-thiazolyl)-(Z)-methoxyiminoacetic acid, 1-hydroxybenzotriazole, and dicyclohexylcarbodiimide to give the chloroacetamido deriv., which was dechloroacetylated and deprotected to give Na

2-[(4S)-4-[2-(2-amino-4-thiazolyl)-(Z)-2-(methoxyimino)acetamido]-3-oxo-2-isoxazolidinyl]-5-oxo-2-tetrahydrofuran carboxylate (II). II had

a

min. inhibitory concn. of 1.56 .mu.g/mL against Escherichia coli. A tablet formulation contained I 300, corn starch 50, lactose 28, hydroxypropyl cellulose 20, and Mg stearate 2 mg.

IT 42057-23-8


RL: RCT (Reactant)

(amidation of, with aminofurancarboxylate deriv.)

RN 42057-23-8 CAPLUS

CN Benzeneacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



=> d bib abs hitstr 46

L8 ANSWER 46 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1986:478755 CAPLUS
 DN 105:78755
 TI Cephalosporin antibiotics
 IN Greengrass, Colin William; Hoople, David William Thomas; Howarth, Thomas
 Trefor
 PA Pfizer Ltd., UK; Pfizer Corp.
 SO Eur. Pat. Appl., 156 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 168177	A2	19860115	EP 1985-304145	19850612
	EP 168177	A3	19870401		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	FI 8502506	A	19851229	FI 1985-2506	19850625
	DD 240375	A5	19861029	DD 1985-277821	19850626
	DK 8502904	A	19851229	DK 1985-2904	19850627
	NO 8502595	A	19851230	NO 1985-2595	19850627
	AU 8544250	A1	19860102	AU 1985-44250	19850627
	AU 557205	B2	19861211		
	ZA 8504860	A	19870225	ZA 1985-4860	19850627
	ES 544640	A1	19870301	ES 1985-544640	19850627
	HU 41036	A2	19870330	HU 1985-2523	19850627
	JP 61018788	A2	19860127	JP 1985-141441	19850628
PRAI	GB 1984-16498		19840628		
	GB 1984-25751		19841011		
GI					




AB The title compds. I (R = (un)substituted Ph, cyclohexenyl, CH₃CH(OH), heterocyclyl, etc.; R₁ = CONR₄R₅, etc. R₄ = H, C1-4 alkyl; R₅ = R₄, (un)substituted heterocyclyl, etc.; R₂ = CH₂OCOMe, CH₂OCONH₂, Cl, F, OMe, etc.) and their salts were prepd. Thus, tert-Bu
 7.beta.-[D-2-(4-ethyl-2,3-dioxopiperazin-1-ylcarbonylamino)-2-phenylacetamido]-7.alpha.-(hydroxyamino)-3-[1,2,3-thiadiazol-5-yl]thiomethyl]ceph-3-em-4-carboxylate (II) prepd. in 5 steps from 7.beta.-amino-3-[1,2,3-thiadiazol-5-ylthio)methyl]ceph-3-em-4-carboxylic acid, was deprotected with CF₃CO₂H to

Searched by John Dantzman 308-4488


give the II free acid.
IT 103587-85-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and coupling of, with benzhydryl cephalosporanate deriv.)
RN 103587-85-5 CAPLUS
CN L-Threonine, N-[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 42057-23-8
RL: RCT (Reactant)
(reaction of, with cephalosporanate deriv.)
RN 42057-23-8 CAPLUS
CN Benzeneacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]-, (R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



=> d bib abs hitstr 47

L8 ANSWER 47 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1986:148624 CAPLUS
 DN 104:148624
 TI Ureido derivatives of semisynthetic penicillins
 IN Novak, Ludvik
 PA Czech.
 SO Czech., 4 pp.
 CODEN: CZXXA9
 DT Patent
 LA Czech
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 218030	B	19830225	CS 1981-6770	19810914
GI					



AB Azlocillin I (R = H) and mezlocillin I (R = SO₂Me) were prepd. by acylating 6-aminopenicillanic acid (II) with III (R = H) via active esters

III (R₁ = C₆H₅, C₆F₅). Thus, treating a chilled aq. soln. of 21.9 g D-(-)-PhCH(NH₂)CO₂H with a Et₂O soln. of 23.6 g 2-imidazolidinone-N-carbonyl chloride in the presence of Na₂CO₃ and NaOH gave 39 g D-II (R = R₁ = H) which was coupled (7.8 g) with 7.8 g C₆H₅OH in DMF in the presence of dicyclohexylcarbodiimide. The resulting D-III (R = H, R₁ = C₆H₅) (2.7 g) was added (2.2 g) to 0.93 g II in CH₂Cl₂ contg. NEt₃ to yield 1.4 g azlocillin. Similarly 0.5 g mezlocillin was obtained from 0.43 g II and 1 g D-III (R = SO₂Me, R₁ = C₆F₅).


IT 42057-23-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and esterification of, with halophenols)

RN 42057-23-8 CAPLUS


CN Benzeneacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 48

L8 ANSWER 48 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1986:130251 CAPLUS
 DN 104:130251
 TI Synthesis of some isonicotinoyl- and nicotinoyl-sulfonylamino acid derivatives and their antimicrobial activity
 AU El-Naggar, A. M.; Sammour, A. A.; Kora, F. A.; El-Nemma, E. M.
 CS Fac. Sci., Al-Azhar Univ., Cairo, Egypt
 SO Farmaco, Ed. Sci. (1985), 40(10), 786-94
 CODEN: FRPSAX; ISSN: 0430-0920
 DT Journal
 LA English
 GI



AB Title amino acid derivs. I (X = Val, Leu, Ser, Phe, Tyr; R = OH, OMe) and II (X, R = same) were prepd. by acylating the appropriate amino acids or amino acid Me esters with acid chlorides III and IV, resp. Hydrazides I (X = Val, Leu, Ser, Phe, Tyr; R = NHNH₂) and II (X = Val, R = NHNH₂) and dipeptides V (X₁ = Val, Leu, Ser, Phe, Tyr) and VI (X-X₁ = Val-Leu, Val-Phe, Ser-Ser, Ser-Tyr) were also prepd. Thirty-two of the above compds. exhibited sp. antimicrobial activities against different microorganisms.


IT 100923-33-9P 100923-35-1P 100923-37-3P
 100923-53-3P 100923-56-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. and antimicrobial activity of)

Searched by John Dantzman 308-4488


RN 100923-33-9 CAPLUS
 CN L-Valine, N-[[4-[[[(1-carboxy-2-methylpropyl)amino]carbonyl]-2-pyridinyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 100923-35-1 CAPLUS
 CN L-Serine, N-[[4-[[[(1-carboxy-2-hydroxyethyl)amino]carbonyl]-2-pyridinyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 100923-37-3 CAPLUS
 CN L-Tyrosine,
 N-[[4-[[[(1-carboxy-2-(4-hydroxyphenyl)ethyl)amino]carbonyl]-2-pyridinyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 100923-53-3 CAPLUS
 CN L-Leucine, N-[[5-[[[(1-carboxy-3-methylbutyl)amino]carbonyl]-3-pyridinyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)

Searched by John Dantzman 308-4488

pyridinyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 100923-56-6 CAPLUS

CN L-Tyrosine,

N-[[5-[[[1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-3-pyridinyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 100923-52-2P 100923-54-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and peptide coupling reaction and antimicrobial activity of)

RN 100923-52-2 CAPLUS

CN L-Valine, N-[[5-[[[1-carboxy-2-methylpropyl]amino]carbonyl]-3-pyridinyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 100923-54-4 CAPLUS

CN L-Serine, N-[[5-[[[(1-carboxy-2-hydroxyethyl)amino]carbonyl]-3-pyridinyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 100923-34-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 100923-34-0 CAPLUS

CN L-Leucine, N-[[4-[[[(1-carboxy-3-methylbutyl)amino]carbonyl]-2-pyridinyl]sulfonyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



=> d bib abs hitstr 49

L8 ANSWER 49 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1983:143181 CAPLUS
 DN 98:143181
 TI 1-Sulfo-2-oxoazetidine derivatives and their use
 IN Kishimoto, Shoji; Sendai, Michiyuki; Tomimoto, Mitsumi; Michihiko, Ochiai;
 Taisuke, Matsuo
 PA Takeda Chemical Industries, Ltd. , Japan
 SO Eur. Pat. Appl., 286 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 53816	A1	19820616	EP 1981-110155	19811204
	EP 53816	B1	19880504		
	R: AT, BE, CH, DE, FR, IT, LU, NL, SE				
	WO 8201873	A1	19820610	WO 1980-JP297	19801205
	W: MC				
	WO 8203859	A1	19821111	WO 1981-JP103	19810430
	W: MC				
	WO 8300689	A1	19830303	WO 1981-JP183	19810821
	W: MC				
	WO 8301063	A1	19830331	WO 1981-JP252	19810924
	W: MC				
	AT 33981	E	19880515	AT 1981-110155	19811204
PRAI	WO 1980-JP297		19801205		
	WO 1981-JP103		19810430		
	WO 1981-JP183		19810821		
	WO 1981-JP252		19810924		
	EP 1981-110155		19811204		
GI					



AB More than 250 2-oxoazetidine-1-sulfonic acids (I; R = NH₂, optionally acylated or protected, R₁ = H or OMe, R₂ = org. moiety) or their esters
 or
 pharmaceutically acceptable salts, which showed antimicrobial and .beta.-lactamase-inhibiting activity, were prepd. Thus, acylation of cis-3-[(benzyloxy)carboxamido]-4-carbamoyl-2-azetidinone with the appropriate acyl chloride, followed by sulfonation and deprotection, gave cis-syn-I [R = 2-(2-amino-4-thiazolyl)-2-[(1-carboxyl-1-methylethoxy)imino]acetamido, R₁ = H, R₂ = CONH₂], which had I50 1.56 and
 Searched by John Dantzman 308-4488

0.39 mcg/mL, resp., for inhibition of growth, in vitro, of *Enterobacter cloacae* IFO 12937 and *Klebsiella pneumoniae* TN 1711.


IT 84186-86-7P 84187-30-4P 84237-27-4P
84237-28-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 84186-86-7 CAPLUS

CN L-Alanine, N-[[3-[[2-amino-4-thiazolyl][1,1-dimethyl-2-[(4-nitrophenyl)methoxy]-2-oxoethoxy]imino]acetyl]amino]-4-oxo-1-sulfo-2-azetidiny]carbonyl]-, monosodium salt, [2R-[2.alpha.,3.alpha.(Z)]]-
(9CI)


(CA INDEX NAME)



● Na

RN 84187-30-4 CAPLUS

CN L-Alanine, N-[[3-[[2-amino-4-thiazolyl][(1-carboxy-1-methylethoxy)imino]acetyl]amino]-4-oxo-1-sulfo-2-azetidiny]carbonyl]-, [2S-[2.alpha.,3.alpha.(Z)]]- (9CI) (CA INDEX NAME)




RN 84237-27-4 CAPLUS

CN L-Alanine, N-[[3-[[2-amino-4-thiazolyl][1,1-dimethyl-2-[(4-

Searched by John Dantzman 308-4488


nitrophenyl)methoxy]-2-oxoethoxy]imino]acetyl]amino]-4-oxo-1-sulfo-2-azetidiny]carbonyl]-, monosodium salt, [2S-[2.alpha.,3.alpha.(Z)]]-(9CI)
(CA INDEX NAME)



● Na

RN 84237-28-5 CAPLUS

CN L-Alanine, N-[[3-[[2-amino-4-thiazolyl][(1-carboxy-1-methylethoxy)imino]acetyl]amino]-4-oxo-1-sulfo-2-azetidiny]carbonyl]-, [2R-[2.alpha.,3.alpha.(Z)]]-(9CI) (CA INDEX NAME)



=> d bib abs hitstr 50


L8 ANSWER 50 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1982:181062 CAPLUS
 DN 96:181062
 TI Antibiotic .beta.-lactams
 PA Squibb, E. R., and Sons, Inc. , USA
 SO Neth. Appl., 117 pp.
 CODEN: NAXXAN
 DT Patent
 LA Dutch
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	NL 8100571	A	19810901	NL 1981-571	19810206
	NL 192924	B	19980105		
	NL 192924	C	19980507		
	BE 887428	A1	19810806	BE 1981-203736	19810206
	SE 8100861	A	19810808	SE 1981-861	19810206
	SE 457954	B	19890213		
	SE 457954	C	19890713		
	FI 8100352	A	19810808	FI 1981-352	19810206
	FI 80271	B	19900131		
	FI 80271	C	19900510		
	DK 8100523	A	19810808	DK 1981-523	19810206
	DK 166280	B	19930329		
	DK 166280	C	19930830		
	NO 8100410	A	19810810	NO 1981-410	19810206
	NO 161065	B	19890320		
	NO 161065	C	19890628		
	AU 8166985	A1	19810813	AU 1981-66985	19810206
	AU 548896	B2	19860109		
	GB 2071650	A	19810923	GB 1981-3655	19810206
	GB 2071650	B2	19841205		
	DE 3104145	A1	19811217	DE 1981-3104145	19810206
	DE 3104145	C2	19990512		
	ZA 8100808	A	19820224	ZA 1981-808	19810206
	ES 499171	A1	19820601	ES 1981-499171	19810206
	DD 156180	C	19820804	DD 1981-227473	19810206
	FR 2509299	A1	19830114	FR 1981-2372	19810206
	FR 2509299	B1	19850830		
	PL 126840	B1	19830930	PL 1981-229569	19810206
	PL 128184	B1	19840131	PL 1981-234758	19810206
	AT 8100550	A	19841215	AT 1981-550	19810206
	AT 378367	B	19850725		
	RO 86528	B3	19850315	RO 1981-111297	19810206
	HU 35669	A2	19850729	HU 1981-296	19810206
	HU 191029	B	19861228		
	CH 651020	A	19850830	CH 1981-816	19810206
	CH 653993	A	19860131	CH 1981-5565	19810206
	CS 244105	B2	19860717	CS 1981-909	19810206
	IL 62082	A1	19860831	IL 1981-62082	19810206
	SU 1272981	A3	19861123	SU 1981-3248001	19810206
	JP 04027226	B4	19920511	JP 1981-17379	19810206
	CA 1338670	A1	19961022	CA 1981-370320	19810206

Searched by John Dantzman 308-4488

GB 2139618	A1	19841114	GB 1983-33191	19831213
GB 2139618	B2	19850501		
AT 8402169	A	19851015	AT 1984-2169	19840705
AT 380472	B	19860526		
AT 8402168	A	19860115	AT 1984-2168	19840705
AT 381089	B	19860825		
CS 244146	B2	19860717	CS 1984-9615	19841211
AU 8545748	A1	19851107	AU 1985-45748	19850802
AU 569407	B2	19880128		
NO 8600225	A	19810810	NO 1986-225	19860122
NO 170015	B	19920525		
NO 170015	C	19920902		
SE 8602193	A	19860514	SE 1986-2193	19860514
SE 500216	C2	19940509		
SE 8602194	A	19860514	SE 1986-2194	19860514
JP 02160764	A2	19900620	JP 1989-304538	19891122
JP 06023188	B4	19940330		
JP 05086023	A2	19930406	JP 1991-121251	19910527
JP 06070006	B4	19940907		
CA 1340253	A1	19981215	CA 1996-617057	19960828
PRAI US 1980-119276		19800207		
US 1980-188893		19800929		
AT 1981-550		19810206		
CA 1981-370320		19810206		
CH 1981-816		19810206		
CS 1981-909		19810206		
GB 1981-3655		19810206		

GI



AB .beta.-Lactams I (R = H, acyl; R1 = H, alkoxy; R2, R3 = H, alkyl, cycloalkyl, Ph, alkenyl, styryl, alkynyl, alkoxy, alkylthio, alkoxy carbamyl, CO2H, CH2OH, alkylsulfonylmethyl, arylsulfonylmethyl, halomethyl, CH2SH, CH2SCH2Ph, CH2SCPh3, CH2N3, CH2NH2; M = H, cation)

were

prepd. Thus Na penicillin G was dethiolated with Raney Ni to give II [R4 = CH(CO2H)CHMe2] which was oxidized to II [R4 = CH(OAc)CHMe2]. NaBH4 redn. of the latter compd. gave II (R4 = H) which was treated with pyridine-SO3 and KOH to give II (R4 = SO3K). II (R4 = SO3K) had a min.

of

inhibitory concn. against Staphylococcus aureus 1276 of 1.6 .mu.g/mL.

IT **42057-23-8**


RL: RCT (Reactant)

(acylation of aminoazetidinesulfonic acid by)

RN 42057-23-8 CAPLUS

CN Benzeneacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr 52


L8 ANSWER 52 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1982:68704 CAPLUS
 DN 96:68704
 TI Cephalosporin derivatives and pharmaceutical compositions containing them
 IN Wehrli, Hansuli; Kocsis, Karoly; Scartazzini, Riccardo
 PA Ciba-Geigy A.-G., Switz.
 SO Eur. Pat. Appl., 177 pp.
 CODEN: EPXXDW

DT Patent
 LA German.

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 31794	A2	19810708	EP 1980-810386	19801215
	EP 31794	A3	19820203		
	R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	US 4464366	A	19840807	US 1980-214155	19801208
	ES 497849	A1	19811116	ES 1980-497849	19801217
	DK 8005408	A	19810620	DK 1980-5408	19801218
	AU 8065518	A1	19810625	AU 1980-65518	19801218
	ZA 8007914	A	19820127	ZA 1980-7914	19801218
	JP 56103186	A2	19810818	JP 1980-181821	19801219
PRAI	CH 1979-11283		19791219		

GI



AB Cephalosporins I {m = 0, 1; n = 1-4; p = 1, 2; X = O, S, NH, bond; X1 = CO, CONHSO2, SO2NHCO; X2 = (un)substituted phenylene, thienylene, furylene; X3 = O, S; X4 = alkylene; R = H, alkyl, alkoxy, halo, esterified or etherified CH2OH, CH2SH, ammoniummethyl; R1 = H, OMe; R2 = H, (un)substituted alkyl, cycloalkyl, acyl} were prep'd. as bactericides (no

Searched by John Dantzman 308-4488


data). Thus II was obtained from the aminocephem by a 2-step acylation and deblocking.

IT **79532-81-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acylation of aminocephems by)

RN 79532-81-3 CAPLUS


CN Benzeneacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]-.alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 53

L8 ANSWER 53 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1980:586789 CAPLUS
 DN 93:186789
 TI .alpha.-Aminophenylacetic acid derivatives
 IN Schmidt, Gunter; Opitz, Wolfgang; Jacobi, Haireddin
 PA Bayer A.-G., Fed. Rep. Ger.
 SO Ger. Offen., 50 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2836613	A1	19800313	DE 1978-2836613	19780822
	NO 7902590	A	19800225	NO 1979-2590	19790808
	EP 11092	A1	19800528	EP 1979-103007	19790817
	EP 11092	B1	19820623		
	R: AT, BE, CH, DE, FR, GB, IT, NL, SE				
	AT 1240	E	19820715	AT 1979-103007	19790817
	FI 7902586	A	19800223	FI 1979-2586	19790820
	JP 55033476	A2	19800308	JP 1979-105126	19790820
	DK 7903495	A	19800223	DK 1979-3495	19790821
	ES 483532	A1	19800516	ES 1979-483532	19790821
PRAI	DE 1978-2836613		19780822		
GI	EP 1979-103007		19790817		



AB Phenylglycine derivs. I [R = H, alkyl, CF₃, halo, alkoxy, OH, CN, alkylmercapto; R₁ and R₂ = H, alkyl, substituted alkyl, alkenyl; R₁R₃N = 5-7-membered heterocyclic ring which can contain other hetero atoms (e.g., O, S, N); R₃ = H, alkyl, CH₂CN, CH₂CO₂Me, CH₂OMe, CH₂SMe; R₄ = H, alkyl, acyl; R₅ = OH, alkoxy, amino acid ester, NR₆R₇ (R₆ and R₇ = H, alkyl)] were prepd. as inflammation inhibitors. Thus, 4-(thiomorpholino)benzaldehyde was cyclized with NaCN and (NH₄)₂CO₃ in aq. EtOH at 60.degree. for 30 h to give 81% hydantoin II, which was hydrolyzed

Searched by John Dantzman 308-4488


by aq. NaOH for 20 h at 100.degree. to give DL-phenylglycine DL-III.
IT **75176-86-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 75176-86-2 CAPLUS
CN Benzeneacetic acid, .alpha.,4-bis[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 55

L8 ANSWER 55 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1980:146750 CAPLUS
 DN 92:146750
 TI Semi-synthetic beta-lactam antibiotics
 IN Ertel, Werner
 PA Bayer A.-G., Fed. Rep. Ger.
 SO Eur. Pat. Appl., 25 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 4938	A1	19791031	EP 1979-101110	19790411
	EP 4938	B1	19810603		
	R: BE, CH, DE, FR, GB, IT, NL, SE				
	DE 2817228	A1	19791031	DE 1978-2817228	19780420
	US 4229349	A	19801021	US 1979-27539	19790405
	IL 57084	A1	19820730	IL 1979-57084	19790417
	JP 54145693	A2	19791114	JP 1979-46801	19790418
	AT 7902901	A	19820415	AT 1979-2901	19790418
	AT 369004	B	19821125		
	ES 479732	A1	19800116	ES 1979-479732	19790419
PRAI	DE 1978-2817228		19780420		
GI					



AB .beta.-Lactam antibiotics were prepd. by the reaction of I (R = H, OMe; X = .beta.-lactam antibiotic residue) with R1CONHCHR3CO2CO2R2 (R1 = org. moiety; R2 = alkyl; R3 = optionally substituted Ph, cyclohexadienyl or heterocyclyl). Thus, D-H2NCHPhCO2H reacted with 1-(chlorocarbonyl)imidazolidinone, and the product reacted with ClCO2Et and Na 6-aminopenicillanate to give 91% II.

IT **73181-50-7P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and reaction of, with aminopenicillanic acid)
 RN 73181-50-7 CAPLUS
 CN Benzeneacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]-, monosodium salt, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

=> d bib abs hitstr 56

L8 ANSWER 56 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1980:76493 CAPLUS
 DN 92:76493
 TI .beta.-Lactam compounds
 IN Preiss, Michael; Koenig, Hans Bodo; Metzger, Karl Georg; Schmidt, Gunter
 PA Bayer A.-G., Fed. Rep. Ger.
 SO Eur. Pat. Appl., 48 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 3992	A3	19791017	EP 1979-100495	19790220
	EP 3992	A2	19790919		
	R: BE, CH, DE, FR, GB, IT, NL				
	DE 2810083	A1	19790920	DE 1978-2810083	19780308
	US 4235774	A	19801125	US 1979-11347	19790212
	JP 54122292	A2	19790921	JP 1979-25197	19790306
	ES 478387	A1	19791101	ES 1979-478387	19790307
PRAI	DE 1978-2810083		19780308		
GI					



AB The penicillanic acid derivs. I [R = H, (un)substituted aliph., cycloaliph., aryl, aralkyl, heterocyclyl, or acyl; R1 = (un)substituted heterocyclyl; R2 = H, alkoxy; X = (CH2)2, (CH2)3, o-C6H4; X1 = CO, bond] and their salts were prepd. and tested for bactericidal activity. Thus, 6-(amino-2-furylacetylamido)penicillanic acid reacted with 1-(chlorocarbonyl)-2-imidazolidinone in THF-NaOH to give I (X = CH2CH2,


X1 = bond, R = R2 = H, R1 = 2-furyl) Na salt.

IT **72699-64-0P 72699-72-0P 72712-26-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, with aminopenicillanic acid)


RN 72699-64-0 CAPLUS

CN 3-Isioxazoleacetic acid, 5-methyl-.alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 72699-72-0 CAPLUS

CN 4-Thiazoleacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]-2-[[(phenylmethoxy)carbonyl]amino]- (9CI)
(CA INDEX NAME)



RN 72712-26-6 CAPLUS

CN 2-Furanacetic acid, 5-methyl-.alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 57

L8 ANSWER 57 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1973:418697 CAPLUS
 DN 79:18697
 TI Penicillins
 IN Koenig, Hans Bodo; Schroeck, Wilfried; Metzger, Karl Georg
 PA Bayer A.-G.
 SO Ger. Offen., 97 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2152968	A	19730426	DE 1971-2152968	19711023
	SU 522802	D	19760725	SU 1972-1839116	19721012
	RO 60671	P	19761015	RO 1972-72545	19721017
	DD 106045	C	19740520	DD 1972-166351	19721019
	DD 106045	B3	19900808		
	HU 166539	P	19750428	HU 1972-BA2816	19721019
	CS 186766	P	19781229	CS 1972-7049	19721019
	FI 57108	B	19800229	FI 1972-2898	19721019
	FI 57108	C	19800610		
	NL 7214255	A	19730425	NL 1972-14255	19721020
	ZA 7207474	A	19730725	ZA 1972-7474	19721020
	AT 321462	B	19750410	AT 1972-9011	19721020
	IL 40627	A1	19760831	IL 1972-40627	19721020
	CA 1012531	A1	19770621	CA 1972-154339	19721020
	CH 591496	A	19770930	CH 1972-15319	19721020
	SE 401186	C	19780803	SE 1972-13593	19721020
	SE 401186	B	19780424		
	DK 138855	C	19790417	DK 1972-5233	19721020
	DK 138855	B	19781106		
	JP 48049788	A2	19730713	JP 1972-104903	19721021
	JP 55038955	B4	19801007		
	JP 48049911	A2	19730714	JP 1972-104904	19721021
	ES 407852	A1	19751001	ES 1972-407852	19721021
	BE 790441	A1	19730424	BE 1972-123385	19721023
	FR 2157909	A1	19730608	FR 1972-37484	19721023
	AU 7248067	A1	19740426	AU 1972-48067	19721023
	GB 1392850	A	19750430	GB 1972-48700	19721023
	NO 143908	B	19810126	NO 1972-3809	19721023
	NO 143908	C	19810506		
	US 3972869	A	19760803	US 1974-502765	19740903
	US 3972870	A	19760803	US 1974-502835	19740903
	US 3974142	A	19760810	US 1974-502956	19740903
	US 3974141	A	19760810	US 1974-502668	19740903
	US 3975375	A	19760817	US 1974-502753	19740903
	US 3978056	A	19760831	US 1974-502770	19740903
	US 3983105	A	19760928	US 1974-502662	19740903
	US 4009272	A	19770222	US 1975-605742	19750818
PRAI	DE 1971-2152967		19711023		
	DE 1971-2152968		19711023		
	US 1972-299246		19721020		

Searched by John Dantzman 308-4488

US 1972-300776 19721020


US 1974-502956 19740903

GI For diagram(s), see printed CA Issue.

AB Approx. 15 penicillins (I, R = MeSO₂, Ac, MeO₂C, EtSO₂; R₁ = Ph, p-ClC₆H₄,p-MeC₆H₄, 2-thienyl, 2,6-Cl₂C₆H₃) were prepd. from imidazolidinones II, 6-aminopenicillanic acid, and Na 2-ethylhexanoate. II were prepd. from chlorocarbonylimidazolidinones III and R₁CH(NH₂)CO₂H. 2-Imidazolidinone and RCl gave imidazolidinones IV, which, treated with Me₃SiCl and COCl₂, gave III.IT 42057-25-0P 42057-26-1P 42057-28-3P
42057-29-4PRL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 42057-25-0 CAPLUS

CN Benzeneacetic acid, 4-chloro-.alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 42057-26-1 CAPLUS


CN 2-Thiopheneacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 42057-28-3 CAPLUS


CN Benzeneacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 42057-29-4 CAPLUS

CN Benzeneacetic acid, 2,6-dichloro-.alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT 42057-23-8


RL: RCT (Reactant)

(reaction of, with 6-aminopenicillanic acid)

RN 42057-23-8 CAPLUS

CN Benzeneacetic acid, .alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 42057-51-2 42057-53-4

RL: RCT (Reactant)


(reaction of, with aminopenicillanic acids)

Searched by John Dantzman

308-4488


RN 42057-51-2 CAPLUS

CN Benzeneacetic acid, 4-chloro-.alpha.-[[[3-(ethylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 42057-53-4 CAPLUS

CN Benzeneacetic acid, 4-methyl-.alpha.-[[[3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 58


L8 ANSWER 58 OF 61 CAPLUS COPYRIGHT 2000 ACS
 AN 1972:539788 CAPLUS
 DN 77:139788
 TI Aziridine derivatives
 IN Kinutani, Seiji; Sakai, Katsunobu; Okawa, Kenji
 SO Japan., 4 pp.
 CODEN: JAXXAD
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 47030698	B4	19720809	JP 1968-91773	19681214

AB .beta.-(Substituted hydroxy)-.alpha.-amino acid derivs. were subjected to a ring closure using a basic condensation agent to give title derivs., intermediates to amino acids and peptides. E.g., 5.02 g N,O-ditosyl-L-threonine anilide in THF was warmed 5 hr at 37.degree. with NHEt₂ to give 2.15 g 1-tosyl-3-methyl-2-aziridinecarboxylic anilide. Similarly prepd. were N-(1-tosyl-2-aziridinecarbonyl)glycine Me and Et esters. N-(1-tosyl-3-methyl-2-aziridinecarbonyl)-glycine Et ester (hydrolysis of which gave the free acid), and Et 1-tosyl-3-methyl-2-aziridinecarboxylate.


IT **36935-15-6P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 36935-15-6 CAPLUS
 CN Glycine,
 N-[[3-methyl-1-[(4-methylphenyl)sulfonyl]-2-aziridinyl]carbonyl]-
 (9CI) (CA INDEX NAME)



=> d bib abs hitstr 59

L8 ANSWER 59 OF 61 CAPLUS COPYRIGHT 2000 ACS
AN 1972:419992 CAPLUS
DN 77:19992
TI Hydroxy amino acids. IV. Syntheses of several peptides containing
aziridinecarboxylic acid derived from the corresponding hydroxy amino
acid derivatives
AU Nakagawa, Yasuo; Tsuno, Takashi; Nakajima, Kiichiro; Iwai, Michio; Kawai,
Haruki; Okawa, Kenji
CS Fac. Sci., Kwansei Gakuin Univ., Nishinomiya, Japan
SO Bull. Chem. Soc. Jap. (1972), 45(4), 1162-7
CODEN: BCSJA8
DT Journal
LA English
AB The .beta.-elimination reaction of the O-tosyl .beta.-hydroxy amino acid
peptide deriv. was investigated. The N-tosyl-L-serylglycine ester and
the N-tosyl-L-threonylglycine ester gave the N-tosyl-L-
aziridinylcarbonylglycine ester and the N-tosyl-3-methyl-L-
aziridinylcarbonylglycine ester as the resulting products, resp., by the
elimination reaction. The N-carbobenzoxglycyl-L-serylglycine ester was
not converted in the aziridine peptide deriv.; only the dehydroalanine
peptide was obtained. However, the N-tosyl-L-phenylalanyl-L-threonyl-
glycine ester and the N-carbobenzoxglycyl-L-threonylglycine ester were
converted into the corresponding aziridine peptide, and the
N-tosyl-L-phenylalanyl-3-methyl-L-aziridinylcarbonyl-glycine ester and
the N-carbobenzoxglycyl-3-methyl-L-aziri-dinylcarbonylglycine ester were
obtained, resp. The peptides contg. threonine were easily converted into
the aziridine peptides and not the serine peptides by the
.beta.-elimination reaction.
IT **36935-15-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 36935-15-6 CAPLUS
CN Glycine,
N-[[3-methyl-1-[(4-methylphenyl)sulfonyl]-2-aziridinyl]carbonyl]-
(9CI) (CA INDEX NAME)



=> d all hitstr

L9 ANSWER 1 OF 9 COPYRIGHT 2000 ACS

AN CA59:19911e CAOLD


IT 114554-58-4

IT 114554-58-4

RN 114554-58-4 CAOLD

CN Glycine, N-(1-p-tolylsulfonyl-L-pyroglutamyl)- (6CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d all hitstr 2

L9 ANSWER 2 OF 9 COPYRIGHT 2000 ACS

AN CA57:13880b CAOLD

TI bacitracin F


AU Konigsberg, William; Craig, L. C.

IT 7469-24-1 38184-73-5 92906-71-3 94680-38-3 **97469-11-9**

IT **97469-11-9**

RN 97469-11-9 CAOLD

CN Glycine, N-[1,2,3,6-tetrahydro-1-(p-tolylsulfonyl)picolinoyl]- (7CI) (CA INDEX NAME)



=> d all hitstr 3

L9 ANSWER 3 OF 9 COPYRIGHT 2000 ACS

AN CA57:13878c CAOLD

TI participation of isolated double bonds in cleavage of peptides with
N-bromosuccinimide


AU Izumiya, Nobuo; Francis, J. E.; Robertson, A. V.; Witkop, B.

IT 1469-73-4 4743-91-3 88613-13-2 91392-67-5 91558-29-1 91566-58-4
91567-73-6 91642-35-2 91807-17-9 91844-39-2 91957-95-8 91958-51-9
92020-58-1 92033-98-2 92042-47-2 92108-01-5 92192-23-9 92256-57-0
92293-93-1 92502-22-2 92649-23-5 92870-69-4 93001-94-6
93045-85-3 93307-14-3 93405-00-6 93405-01-7 93405-04-0
93405-05-1 93476-74-5 93532-94-6 93538-58-0 94862-33-6 95134-30-8
95373-02-7 96078-74-9 97302-33-5

IT **93045-85-3**

RN 93045-85-3 CAOLD


CN Glycine, N-[[1-(p-tolylsulfonyl)-3-pyrrolin-2-yl]carbonyl]- (7CI) (CA
INDEX NAME)



=> d all hitstr 4

L9 ANSWER 4 OF 9 COPYRIGHT 2000 ACS
AN CA55:3452d CAOLD
TI peptides - (VI) synthesis of eisenin, (VII) synthesis of
L-pyroglutamyl-L-glutamyl-L-glutamine
AU Shiba, Tetsuo; Imai, S.
IT 4652-65-7 16874-70-7 21282-08-6 21477-57-6 21957-65-3 45171-72-0
54419-93-1 55559-26-7 100175-60-8 102873-77-8 106736-95-2 108541-02-2
108851-49-6 109067-62-1 109478-44-6 109481-23-4 109943-88-6
110032-51-4 111033-31-9 121394-88-5 122411-81-8
IT **108851-49-6**
RN 108851-49-6 CAOLD
CN Alanine, N-(1-p-tolylsulfonyl-5-pyroglutamyl)-, L- (6CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d all hitstr 5

L9 ANSWER 5 OF 9 COPYRIGHT 2000 ACS

AN CA53:243e CAOLD

TI amino acids and peptides - (IV) intermediates for the synthesis of cystine-contg. peptide sequences in insulin

AU Maclaren, J. A.; Savige, W. E.; Swan, J. M.


IT 980-49-4 1738-76-7 2491-20-5 2601-46-9 3850-42-8 4168-14-3
4561-11-9 21679-94-7 27169-91-1 28130-09-8 73995-16-1 74216-59-4
94165-94-3 96668-43-8 99986-09-1 100952-06-5 101354-63-6 101578-45-4
101719-50-0 102629-02-7 102758-76-9 102760-02-1 102957-36-8 103990-62-1
104511-11-7 104997-87-7 106952-35-6 111961-13-8 114160-77-9 114962-02-6
115293-36-2 115799-51-4 116032-96-3 116281-72-2 118633-74-2
118687-07-3 120175-28-2 120499-22-1 122242-44-8 122295-42-5
122315-76-8 122411-99-8 122724-01-0

IT **118687-07-3**

RN 118687-07-3 CAOLD

CN Alanine, 3-(benzylthio)-N-(1-p-tolylsulfonyl-L-pyroglutamyl)-, L- (6CI)
(CA INDEX NAME)


Absolute stereochemistry.



=> d all hitstr 6

L9 ANSWER 6 OF 9 COPYRIGHT 2000 ACS
AN CA52:16233h CAOLD
TI amino acids and peptides - (XXII) synthesis of glutamine
peptides-structure of eisenine
AU Rudinger, Josef; Pravda, Z.
IT 5356-36-5 5557-83-5 16194-07-3 16874-70-7 21477-57-6 23517-27-3
49761-50-4 54419-93-1 69356-49-6 102882-36-0 107328-52-9
109453-96-5 109478-44-6 110530-33-1 111438-78-9 113184-99-9
115799-47-8 115893-07-7 119598-34-4 121316-17-4 121426-62-8
IT **109453-96-5**
RN 109453-96-5 CAOLD
CN Glutamine, N2-(1-p-tolylsulfonyl-L-pyroglutamyl)-, L- (6CI) (CA INDEX
NAME)


Absolute stereochemistry.



=> d all hitstr 7

L9 ANSWER 7 OF 9 COPYRIGHT 2000 ACS
AN CA52:14540f CAOLD
TI synthesis of peptides of side chain A of insulin
AU Chillemi, Doroteo; Scarso, L.; Scoffone, E.
IT 4726-97-0 34027-65-1 34805-17-9 70328-12-0 83055-63-4 103166-48-9
103331-64-2 108369-52-4 **110153-82-7** 115759-31-4 116027-39-5
120265-78-3 132346-82-8 133132-48-6
IT **110153-82-7**
RN 110153-82-7 CAOLD
CN Leucine, N-(1-p-tolylsulfonyl-L-pyroglutamyl)-, L- (6CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d all hitstr 8

L9 ANSWER 8 OF 9 COPYRIGHT 2000 ACS

AN CA52:265d CAOLD

TI synthesis of L-glutaminyglycine and L-isoglutaminyglycine

AU Swan, J. M.

IT 2650-65-9 5693-85-6 6635-97-8 83871-04-9 92349-20-7 100451-59-0

101117-30-0 101266-14-2 102015-27-0 109504-62-3 109651-38-9 114538-70-4


114554-58-4 117044-95-8

IT **114554-58-4**

RN 114554-58-4 CAOLD

CN Glycine, N-(1-p-tolylsulfonyl-L-pyroglutamyl)- (6CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d all hitstr 9

L9 ANSWER 9 OF 9 COPYRIGHT 2000 ACS

AN CA51:17749a CAOLD

TI synthesis of eisenine

AU Kaneko, Takeo; Shiba, T.; Watarai, S.; Imai, S.; Shimada, T.; Ueno, K.

IT 16874-70-7 21477-57-6 55559-26-7 106736-95-2 **108851-49-6**

109067-62-1 111033-31-9 121394-88-5

IT **108851-49-6**

RN 108851-49-6 CAOLD

CN Alanine, N-(1-p-tolylsulfonyl-5-pyroglutamyl)-, L- (6CI) (CA INDEX NAME)

Absolute stereochemistry.

